HRP20050687A2 - Tri(ciclo) substituted amide compounds - Google Patents
Tri(ciclo) substituted amide compounds Download PDFInfo
- Publication number
- HRP20050687A2 HRP20050687A2 HR20050687A HRP20050687A HRP20050687A2 HR P20050687 A2 HRP20050687 A2 HR P20050687A2 HR 20050687 A HR20050687 A HR 20050687A HR P20050687 A HRP20050687 A HR P20050687A HR P20050687 A2 HRP20050687 A2 HR P20050687A2
- Authority
- HR
- Croatia
- Prior art keywords
- tetrahydropyran
- thiazol
- acrylamide
- ylpropionamide
- propionamide
- Prior art date
Links
- -1 amide compounds Chemical class 0.000 title claims description 105
- 150000001875 compounds Chemical class 0.000 claims abstract description 220
- 150000003839 salts Chemical class 0.000 claims abstract description 85
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 15
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 10
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 117
- 238000000034 method Methods 0.000 claims description 87
- 239000001257 hydrogen Substances 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 26
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 25
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 23
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 150000001408 amides Chemical class 0.000 claims description 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 10
- 238000009833 condensation Methods 0.000 claims description 9
- 230000005494 condensation Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 239000003472 antidiabetic agent Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- HMJAUNHXYJKDGD-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 HMJAUNHXYJKDGD-UHFFFAOYSA-N 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- NIDLAMGLZQRQLJ-HXUWFJFHSA-N (2r)-2-(4-cyclobutylsulfonylphenyl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@H](CC1CCOCC1)C=1C=CC(=CC=1)S(=O)(=O)C1CCC1)NC1=CN=CC=N1 NIDLAMGLZQRQLJ-HXUWFJFHSA-N 0.000 claims description 5
- DWIPGNHOTXSYBW-GOSISDBHSA-N (2r)-2-(4-cyclobutylsulfonylphenyl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](C=1C=CC(=CC=1)S(=O)(=O)C1CCC1)CC1CCOCC1 DWIPGNHOTXSYBW-GOSISDBHSA-N 0.000 claims description 5
- DQIITKNITDKAJZ-LJQANCHMSA-N (2r)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound O=C([C@H](CC1CCOCC1)C=1C=CC(=CC=1)S(=O)(=O)C1CC1)NC1=CN=CC=N1 DQIITKNITDKAJZ-LJQANCHMSA-N 0.000 claims description 5
- DBMFNEZMJWKKPU-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonylphenyl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](C=1C=CC(=CC=1)S(=O)(=O)C1CC1)CC1CCOCC1 DBMFNEZMJWKKPU-QGZVFWFLSA-N 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- MNNGVQPWHYBWLL-LFIBNONCSA-N (e)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoic acid Chemical compound C=1C=C(S(=O)(=O)C2CC2)C=CC=1/C(C(=O)O)=C\C1CCOCC1 MNNGVQPWHYBWLL-LFIBNONCSA-N 0.000 claims description 4
- QYBGDJMLOIMBAO-XNTDXEJSSA-N (e)-n-(5-fluoro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(=O)NC=1SC(F)=CN=1)=C/C1CCOCC1 QYBGDJMLOIMBAO-XNTDXEJSSA-N 0.000 claims description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 4
- 101100533877 Hypocrea jecorina (strain QM6a) sor8 gene Proteins 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 3
- BUUMCCCRRFQHMB-DEDYPNTBSA-N (e)-2-(4-cyclopropylsulfonylphenyl)-n-(5-fluoropyridin-2-yl)-3-(oxan-4-yl)prop-2-enamide Chemical compound N1=CC(F)=CC=C1NC(=O)C(\C=1C=CC(=CC=1)S(=O)(=O)C1CC1)=C\C1CCOCC1 BUUMCCCRRFQHMB-DEDYPNTBSA-N 0.000 claims description 3
- INXMLFBJZKIDHL-GXDHUFHOSA-N (e)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(O)=O)=C/C1CCOCC1 INXMLFBJZKIDHL-GXDHUFHOSA-N 0.000 claims description 3
- ZOKRSUIVATZNNQ-XNTDXEJSSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(thian-4-yl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(=O)NC=1SC(Cl)=CN=1)=C/C1CCSCC1 ZOKRSUIVATZNNQ-XNTDXEJSSA-N 0.000 claims description 3
- BVDIPOMNZVHUHS-UHFFFAOYSA-N 2-(3-amino-4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(N)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 BVDIPOMNZVHUHS-UHFFFAOYSA-N 0.000 claims description 3
- FDDGTVMRLFSINT-UHFFFAOYSA-N 2-(3-fluoro-4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(F)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 FDDGTVMRLFSINT-UHFFFAOYSA-N 0.000 claims description 3
- UAHDKOITUXMTEL-UHFFFAOYSA-N 2-(4-cyclobutylsulfonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C=1C=C(S(=O)(=O)C2CCC2)C=CC=1C(C(=O)O)CC1CCOCC1 UAHDKOITUXMTEL-UHFFFAOYSA-N 0.000 claims description 3
- IMDSBCGXPMSCCM-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C=1C=C(S(=O)(=O)C2CC2)C=CC=1C(C(=O)O)CC1CCOCC1 IMDSBCGXPMSCCM-UHFFFAOYSA-N 0.000 claims description 3
- BCWQXFMJAUSUJF-UHFFFAOYSA-N 2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)propanoic acid Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1C(C(O)=O)CC1CCOCC1 BCWQXFMJAUSUJF-UHFFFAOYSA-N 0.000 claims description 3
- GUSSDECQXMLCNC-UHFFFAOYSA-N 2-[4-(methoxymethylsulfanyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(SCOC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 GUSSDECQXMLCNC-UHFFFAOYSA-N 0.000 claims description 3
- JAVVGKVAMOAKJY-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-pyridin-3-ylsulfanylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(SC=2C=NC=CC=2)=CC=1)C(=O)NC1=NC=CS1 JAVVGKVAMOAKJY-UHFFFAOYSA-N 0.000 claims description 3
- OKCSLRBGVVZWTM-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(2-oxopropylsulfonyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)CC(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 OKCSLRBGVVZWTM-UHFFFAOYSA-N 0.000 claims description 3
- XRSUYPNWCZILLT-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxan-4-ylmethylsulfanyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(SCC2CCOCC2)=CC=1)C(=O)NC1=NC=CS1 XRSUYPNWCZILLT-UHFFFAOYSA-N 0.000 claims description 3
- HUUPNPWVDMNTAH-UHFFFAOYSA-N 5-fluoro-1,3-thiazol-2-amine Chemical group NC1=NC=C(F)S1 HUUPNPWVDMNTAH-UHFFFAOYSA-N 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- PMMYDURMMJDGHR-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-3-(oxan-4-yl)-2-(4-piperazin-1-ylsulfonylphenyl)propanamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(=O)(=O)N1CCNCC1)CC1CCOCC1 PMMYDURMMJDGHR-UHFFFAOYSA-N 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- UAHDKOITUXMTEL-QGZVFWFLSA-N (2r)-2-(4-cyclobutylsulfonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)C=1C=CC(=CC=1)S(=O)(=O)C1CCC1)C1CCOCC1 UAHDKOITUXMTEL-QGZVFWFLSA-N 0.000 claims description 2
- IMDSBCGXPMSCCM-MRXNPFEDSA-N (2r)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)C=1C=CC(=CC=1)S(=O)(=O)C1CC1)C1CCOCC1 IMDSBCGXPMSCCM-MRXNPFEDSA-N 0.000 claims description 2
- BCWQXFMJAUSUJF-OAHLLOKOSA-N (2r)-2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)propanoic acid Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1[C@H](C(O)=O)CC1CCOCC1 BCWQXFMJAUSUJF-OAHLLOKOSA-N 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- GXVGHWZNUFYRSW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)C(C=1C=C(Cl)C(Cl)=CC=1)CC1CCOCC1 GXVGHWZNUFYRSW-UHFFFAOYSA-N 0.000 claims description 2
- FHGVMYOILIXKJQ-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 FHGVMYOILIXKJQ-UHFFFAOYSA-N 0.000 claims description 2
- CVZAVSHUQGUQMQ-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 CVZAVSHUQGUQMQ-UHFFFAOYSA-N 0.000 claims description 2
- NFBYFHVUKFKSNZ-UHFFFAOYSA-N 2-(3-fluoro-4-methylsulfanylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(F)C(SC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 NFBYFHVUKFKSNZ-UHFFFAOYSA-N 0.000 claims description 2
- CDDVTCOOFCKRPF-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylphenyl)-n-(5-formyl-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(C=O)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(=O)(=O)C1CC1)CC1CCOCC1 CDDVTCOOFCKRPF-UHFFFAOYSA-N 0.000 claims description 2
- DQKIMAIVKMWANO-UHFFFAOYSA-N 2-(4-methylsulfanyl-3-nitrophenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C([N+]([O-])=O)C(SC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 DQKIMAIVKMWANO-UHFFFAOYSA-N 0.000 claims description 2
- TYLADYPAZCBXPE-UHFFFAOYSA-N 2-(4-morpholin-4-ylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)N1CCOCC1)C(=O)NC1=NC=CS1 TYLADYPAZCBXPE-UHFFFAOYSA-N 0.000 claims description 2
- SGRSALQZAPHSAM-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxan-4-ylmethylsulfonyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)CC1CCOCC1)C(=O)NC1=NC=CS1 SGRSALQZAPHSAM-UHFFFAOYSA-N 0.000 claims description 2
- DOCFYJACCBDKEG-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxetan-3-ylsulfonyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C1COC1)C(=O)NC1=NC=CS1 DOCFYJACCBDKEG-UHFFFAOYSA-N 0.000 claims description 2
- 101100134927 Gallus gallus COR8 gene Proteins 0.000 claims description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- UKRSGIMTXRJUHR-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(Br)=CN=1)CC1CCOCC1 UKRSGIMTXRJUHR-UHFFFAOYSA-N 0.000 claims description 2
- RQTGSHWPCRNTKL-UHFFFAOYSA-N n-ethyl-4-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 RQTGSHWPCRNTKL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- GJQQHYNZZYZIKE-UHFFFAOYSA-N n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C=CC(=O)NC1=NC=CS1 GJQQHYNZZYZIKE-UHFFFAOYSA-N 0.000 claims 11
- OGNHGQOTYHQMQC-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)propanamide Chemical compound NC(=O)C(C)C1=NC=CS1 OGNHGQOTYHQMQC-UHFFFAOYSA-N 0.000 claims 8
- HFGHLEDHAXUTTP-GZTJUZNOSA-N (e)-2-(4-cyclopropylsulfonylphenyl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)prop-2-enamide Chemical compound S1C(F)=CN=C1NC(=O)C(\C=1C=CC(=CC=1)S(=O)(=O)C1CC1)=C\C1CCOCC1 HFGHLEDHAXUTTP-GZTJUZNOSA-N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- WZDVMMXSSQLTNJ-LJQANCHMSA-N (2r)-2-(4-cyclobutylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,2-oxazol-3-yl)propanamide Chemical compound O=C([C@H](CC1CCOCC1)C=1C=CC(=CC=1)S(=O)(=O)C1CCC1)NC=1C=CON=1 WZDVMMXSSQLTNJ-LJQANCHMSA-N 0.000 claims 2
- BPXNPIJGKLIHBF-HXUWFJFHSA-N (2r)-2-(4-cyclobutylsulfonylphenyl)-3-(oxan-4-yl)-n-pyrimidin-4-ylpropanamide Chemical compound O=C([C@H](CC1CCOCC1)C=1C=CC(=CC=1)S(=O)(=O)C1CCC1)NC1=CC=NC=N1 BPXNPIJGKLIHBF-HXUWFJFHSA-N 0.000 claims 2
- ZUWSRHRGHHWFPG-HXUWFJFHSA-N (2r)-2-(4-cyclobutylsulfonylphenyl)-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound CN1C=CC(NC(=O)[C@H](CC2CCOCC2)C=2C=CC(=CC=2)S(=O)(=O)C2CCC2)=N1 ZUWSRHRGHHWFPG-HXUWFJFHSA-N 0.000 claims 2
- REZAQEOMRWZPEJ-QGZVFWFLSA-N (2r)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,2,4-thiadiazol-5-yl)propanamide Chemical compound O=C([C@H](CC1CCOCC1)C=1C=CC(=CC=1)S(=O)(=O)C1CC1)NC1=NC=NS1 REZAQEOMRWZPEJ-QGZVFWFLSA-N 0.000 claims 2
- XXQUXRVEFJGEPM-GOSISDBHSA-N (2r)-2-(4-cyclopropylsulfonylphenyl)-n-(3-methyl-1,2,4-thiadiazol-5-yl)-3-(oxan-4-yl)propanamide Chemical compound CC1=NSC(NC(=O)[C@H](CC2CCOCC2)C=2C=CC(=CC=2)S(=O)(=O)C2CC2)=N1 XXQUXRVEFJGEPM-GOSISDBHSA-N 0.000 claims 2
- UXSQKWUEYZCYMX-GOSISDBHSA-N (2r)-2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1[C@H](C(=O)NC=1N=CC=NC=1)CC1CCOCC1 UXSQKWUEYZCYMX-GOSISDBHSA-N 0.000 claims 2
- BAMQXRCGGLVHNQ-LJQANCHMSA-N (2r)-2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-pyridin-2-ylpropanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1[C@H](C(=O)NC=1N=CC=CC=1)CC1CCOCC1 BAMQXRCGGLVHNQ-LJQANCHMSA-N 0.000 claims 2
- XFOFEZSUWFRWHI-GOSISDBHSA-N (2r)-2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-pyrimidin-4-ylpropanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1[C@H](C(=O)NC=1N=CN=CC=1)CC1CCOCC1 XFOFEZSUWFRWHI-GOSISDBHSA-N 0.000 claims 2
- VXRCLIPPCBRTJM-GOSISDBHSA-N (2r)-2-[4-(ethylsulfamoyl)phenyl]-n-(1-methylpyrazol-3-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1[C@H](C(=O)NC1=NN(C)C=C1)CC1CCOCC1 VXRCLIPPCBRTJM-GOSISDBHSA-N 0.000 claims 2
- LQZQXINXHUUTEV-QGZVFWFLSA-N (2r)-2-[4-(ethylsulfamoyl)phenyl]-n-(3-methyl-1,2,4-thiadiazol-5-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1[C@H](C(=O)NC=1SN=C(C)N=1)CC1CCOCC1 LQZQXINXHUUTEV-QGZVFWFLSA-N 0.000 claims 2
- VMOWTQMIQLQNHR-GOSISDBHSA-N (2r)-2-[4-(ethylsulfamoyl)phenyl]-n-(6-methoxypyrimidin-4-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1[C@H](C(=O)NC=1N=CN=C(OC)C=1)CC1CCOCC1 VMOWTQMIQLQNHR-GOSISDBHSA-N 0.000 claims 2
- YMJKYTOZNSBULD-QGOAFFKASA-N (e)-2-(4-ethylsulfonylphenyl)-3-(oxan-4-yl)-n-pyrimidin-4-ylprop-2-enamide Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C(\C(=O)NC=1N=CN=CC=1)=C/C1CCOCC1 YMJKYTOZNSBULD-QGOAFFKASA-N 0.000 claims 2
- CAUIQZMSJLZRDB-XNTDXEJSSA-N (e)-n-(5-bromo-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(=O)NC=1SC(Br)=CN=1)=C/C1CCOCC1 CAUIQZMSJLZRDB-XNTDXEJSSA-N 0.000 claims 2
- XZJCBYGJKKADFU-GZTJUZNOSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfinylphenyl)-3-(oxan-4-yl)prop-2-enamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(\C=1C=CC(=CC=1)S(=O)C1CC1)=C\C1CCOCC1 XZJCBYGJKKADFU-GZTJUZNOSA-N 0.000 claims 2
- IWFIHTHSDUIGSP-XNTDXEJSSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfanylphenyl)-3-(oxan-4-yl)prop-2-enamide Chemical compound C1=CC(SC)=CC=C1C(\C(=O)NC=1SC(Cl)=CN=1)=C/C1CCOCC1 IWFIHTHSDUIGSP-XNTDXEJSSA-N 0.000 claims 2
- IWONKESQUNTQFN-XNTDXEJSSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfinylphenyl)-3-(thian-4-yl)prop-2-enamide Chemical compound C1=CC(S(=O)C)=CC=C1C(\C(=O)NC=1SC(Cl)=CN=1)=C/C1CCSCC1 IWONKESQUNTQFN-XNTDXEJSSA-N 0.000 claims 2
- PWTXOSVKVNVJJK-XNTDXEJSSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(=O)NC=1SC(Cl)=CN=1)=C/C1CCOCC1 PWTXOSVKVNVJJK-XNTDXEJSSA-N 0.000 claims 2
- JXOYSGUHHCUWRC-NTEUORMPSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-nitrophenyl)-3-(oxan-4-yl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(\C(=O)NC=1SC(Cl)=CN=1)=C/C1CCOCC1 JXOYSGUHHCUWRC-NTEUORMPSA-N 0.000 claims 2
- SLNHJGGMIWLPSD-UHFFFAOYSA-N 2-(4-cyclobutylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C1CCC1)C(=O)NC1=NC=CS1 SLNHJGGMIWLPSD-UHFFFAOYSA-N 0.000 claims 2
- REZAQEOMRWZPEJ-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,2,4-thiadiazol-5-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C1CC1)C(=O)NC1=NC=NS1 REZAQEOMRWZPEJ-UHFFFAOYSA-N 0.000 claims 2
- VYLRVLPTTGJPMN-UHFFFAOYSA-N 2-(4-imidazol-1-ylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)N1C=NC=C1)C(=O)NC1=NC=CS1 VYLRVLPTTGJPMN-UHFFFAOYSA-N 0.000 claims 2
- PJXJCNQJHGXCDE-UHFFFAOYSA-N 2-[4-(1,3-dioxolan-2-ylmethylsulfonyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)CC1OCCO1)C(=O)NC1=NC=CS1 PJXJCNQJHGXCDE-UHFFFAOYSA-N 0.000 claims 2
- KEFRRBHRUFXXAD-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C(CC2CCOCC2)C(=O)NC=2SC=CN=2)C=C1 KEFRRBHRUFXXAD-UHFFFAOYSA-N 0.000 claims 2
- PTIHVGVDARHUAE-UHFFFAOYSA-N 2-[4-(azetidin-1-ylsulfonyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)N1CCC1)C(=O)NC1=NC=CS1 PTIHVGVDARHUAE-UHFFFAOYSA-N 0.000 claims 2
- JKRCQEKRSDZPOH-UHFFFAOYSA-N 2-[4-(cyclopropylmethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NCC1CC1)C(=O)NC1=NC=CS1 JKRCQEKRSDZPOH-UHFFFAOYSA-N 0.000 claims 2
- ATZDKIUTEGSRCR-UHFFFAOYSA-N 2-[4-(cyclopropylmethylsulfonyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)CC1CC1)C(=O)NC1=NC=CS1 ATZDKIUTEGSRCR-UHFFFAOYSA-N 0.000 claims 2
- LLAWDJRAYDVHRO-UHFFFAOYSA-N 2-[4-(cyclopropylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NC1CC1)C(=O)NC1=NC=CS1 LLAWDJRAYDVHRO-UHFFFAOYSA-N 0.000 claims 2
- VLBRSHOHSRUCDN-UHFFFAOYSA-N 2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 VLBRSHOHSRUCDN-UHFFFAOYSA-N 0.000 claims 2
- GCIDOAHMBFCACF-UHFFFAOYSA-N 2-[4-(methoxymethylsulfonyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)COC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 GCIDOAHMBFCACF-UHFFFAOYSA-N 0.000 claims 2
- XVDBWOBWURIKDJ-UHFFFAOYSA-N 2-[4-(methylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 XVDBWOBWURIKDJ-UHFFFAOYSA-N 0.000 claims 2
- HYSINOPDLMFMLN-UHFFFAOYSA-N 2-[4-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1CN(C)CCCN1S(=O)(=O)C1=CC=C(C(CC2CCOCC2)C(=O)NC=2SC=CN=2)C=C1 HYSINOPDLMFMLN-UHFFFAOYSA-N 0.000 claims 2
- NNEKRCSAASOGBL-IJXZTRCJSA-N 2-[4-[[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]sulfonyl]phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2S(=O)(=O)C(C=C1)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 NNEKRCSAASOGBL-IJXZTRCJSA-N 0.000 claims 2
- LRBLCZPWURLPGQ-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-pyridin-3-ylsulfonylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C=1C=NC=CC=1)C(=O)NC1=NC=CS1 LRBLCZPWURLPGQ-UHFFFAOYSA-N 0.000 claims 2
- VOABPSXEVMBGJS-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxan-4-ylsulfonyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C1CCOCC1)C(=O)NC1=NC=CS1 VOABPSXEVMBGJS-UHFFFAOYSA-N 0.000 claims 2
- GPNIHLYUXVYYMU-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(pyridin-2-ylmethylsulfamoyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NCC=1N=CC=CC=1)C(=O)NC1=NC=CS1 GPNIHLYUXVYYMU-UHFFFAOYSA-N 0.000 claims 2
- CEBFOXWFJYYIHR-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(pyridin-3-ylmethylsulfamoyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NCC=1C=NC=CC=1)C(=O)NC1=NC=CS1 CEBFOXWFJYYIHR-UHFFFAOYSA-N 0.000 claims 2
- UQELQAOGACYKKG-MRTLOADZSA-N 3-(oxan-4-yl)-2-[4-[(3r)-oxolan-3-yl]sulfonylphenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)[C@H]1COCC1)C(=O)NC1=NC=CS1 UQELQAOGACYKKG-MRTLOADZSA-N 0.000 claims 2
- UQELQAOGACYKKG-OYKVQYDMSA-N 3-(oxan-4-yl)-2-[4-[(3s)-oxolan-3-yl]sulfonylphenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)[C@@H]1COCC1)C(=O)NC1=NC=CS1 UQELQAOGACYKKG-OYKVQYDMSA-N 0.000 claims 2
- CRCCQJLTZVWUSO-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)CC1CCOCC1 CRCCQJLTZVWUSO-UHFFFAOYSA-N 0.000 claims 2
- DOTNXOZFPLAGNY-GOSISDBHSA-N (2r)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound O=C([C@H](CC1CCOCC1)C=1C=CC(=CC=1)S(=O)(=O)C1CC1)NC1=NC=CS1 DOTNXOZFPLAGNY-GOSISDBHSA-N 0.000 claims 1
- CILQAVQRGKBESP-HXUWFJFHSA-N (2r)-2-(4-cyclopropylsulfonylphenyl)-n-(5-fluoropyridin-2-yl)-3-(oxan-4-yl)propanamide Chemical compound N1=CC(F)=CC=C1NC(=O)[C@@H](C=1C=CC(=CC=1)S(=O)(=O)C1CC1)CC1CCOCC1 CILQAVQRGKBESP-HXUWFJFHSA-N 0.000 claims 1
- JIKOFDJUFCPMRR-OAHLLOKOSA-N (2r)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1SC(Cl)=CN=1)CC1CCOCC1 JIKOFDJUFCPMRR-OAHLLOKOSA-N 0.000 claims 1
- IERGAZGAANLJJZ-OAHLLOKOSA-N (2r)-n-(5-fluoro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 IERGAZGAANLJJZ-OAHLLOKOSA-N 0.000 claims 1
- MFXVKZCXRYWRCI-GOSISDBHSA-N (2r)-n-(5-fluoropyridin-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1N=CC(F)=CC=1)CC1CCOCC1 MFXVKZCXRYWRCI-GOSISDBHSA-N 0.000 claims 1
- GMIDEGNGAWBEPP-OQLLNIDSSA-N (e)-2-(4-bromophenyl)-3-(furan-2-yl)-n-(5-methyl-1,3-thiazol-2-yl)prop-2-enamide Chemical compound S1C(C)=CN=C1NC(=O)C(\C=1C=CC(Br)=CC=1)=C\C1=CC=CO1 GMIDEGNGAWBEPP-OQLLNIDSSA-N 0.000 claims 1
- RFAJVDOTBIPOJX-RVDMUPIBSA-N (e)-2-(4-ethylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C(\C(O)=O)=C/C1CCOCC1 RFAJVDOTBIPOJX-RVDMUPIBSA-N 0.000 claims 1
- TXNZVVSGEICVLV-MHWRWJLKSA-N (e)-3-(furan-2-yl)-2-(4-methoxyphenyl)-n-(5-methyl-1,3-thiazol-2-yl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(\C(=O)NC=1SC(C)=CN=1)=C/C1=CC=CO1 TXNZVVSGEICVLV-MHWRWJLKSA-N 0.000 claims 1
- GZLORFGQDOGCAA-FOWTUZBSSA-N (e)-3-(oxan-4-yl)-2-(4-propylsulfonylphenyl)prop-2-enoic acid Chemical compound C1=CC(S(=O)(=O)CCC)=CC=C1C(\C(O)=O)=C/C1CCOCC1 GZLORFGQDOGCAA-FOWTUZBSSA-N 0.000 claims 1
- ZHVMEASEGQJUNT-GZTJUZNOSA-N (e)-3-(thian-4-yl)-n-(1,3-thiazol-2-yl)-2-[4-(1,2,4-triazol-1-yl)phenyl]prop-2-enamide Chemical compound C1CSCCC1/C=C(\C=1C=CC(=CC=1)N1N=CN=C1)C(=O)NC1=NC=CS1 ZHVMEASEGQJUNT-GZTJUZNOSA-N 0.000 claims 1
- YKJKMEAMHKAJKF-MHWRWJLKSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-cyanophenyl)-3-phenylprop-2-enamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(\C=1C=CC(=CC=1)C#N)=C\C1=CC=CC=C1 YKJKMEAMHKAJKF-MHWRWJLKSA-N 0.000 claims 1
- ZDLBJHWDWABECS-LFIBNONCSA-N (e)-n-(5-chloro-4-methyl-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(thian-4-yl)prop-2-enamide Chemical compound S1C(Cl)=C(C)N=C1NC(=O)C(\C=1C=CC(=CC=1)S(C)(=O)=O)=C\C1CCSCC1 ZDLBJHWDWABECS-LFIBNONCSA-N 0.000 claims 1
- PNSBAFUCSCHAJR-UHFFFAOYSA-N 2-(1,3,4-thiadiazol-2-yl)propanamide Chemical compound S1C(=NN=C1)C(C(=O)N)C PNSBAFUCSCHAJR-UHFFFAOYSA-N 0.000 claims 1
- OMBIGEHGDWRGKI-UHFFFAOYSA-N 2-(3-bromo-4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(Br)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 OMBIGEHGDWRGKI-UHFFFAOYSA-N 0.000 claims 1
- YBQQVSWTMHNSQB-UHFFFAOYSA-N 2-(3-fluoro-4-methylsulfinylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(F)C(S(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 YBQQVSWTMHNSQB-UHFFFAOYSA-N 0.000 claims 1
- BHFMCZUKFNGETM-UHFFFAOYSA-N 2-(3-fluoro-4-methylsulfonylphenyl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=C(F)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 BHFMCZUKFNGETM-UHFFFAOYSA-N 0.000 claims 1
- KELUOWBFLOEYIN-UHFFFAOYSA-N 2-(3-methylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound CS(=O)(=O)C1=CC=CC(C(CC2CCOCC2)C(=O)NC=2SC=CN=2)=C1 KELUOWBFLOEYIN-UHFFFAOYSA-N 0.000 claims 1
- DQIITKNITDKAJZ-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C1CC1)C(=O)NC1=CN=CC=N1 DQIITKNITDKAJZ-UHFFFAOYSA-N 0.000 claims 1
- XXQUXRVEFJGEPM-UHFFFAOYSA-N 2-(4-cyclopropylsulfonylphenyl)-n-(3-methyl-1,2,4-thiadiazol-5-yl)-3-(oxan-4-yl)propanamide Chemical compound CC1=NSC(NC(=O)C(CC2CCOCC2)C=2C=CC(=CC=2)S(=O)(=O)C2CC2)=N1 XXQUXRVEFJGEPM-UHFFFAOYSA-N 0.000 claims 1
- WLSHTBZBHRVNMF-UHFFFAOYSA-N 2-(4-ethylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 WLSHTBZBHRVNMF-UHFFFAOYSA-N 0.000 claims 1
- PZSHPLYDZZAPSV-UHFFFAOYSA-N 2-(4-ethylsulfonylphenyl)-n-(3-methyl-1,2,4-thiadiazol-5-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C(C(=O)NC=1SN=C(C)N=1)CC1CCOCC1 PZSHPLYDZZAPSV-UHFFFAOYSA-N 0.000 claims 1
- SMSKOXZUNGMFPW-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=CC=NC=1)CC1CCOCC1 SMSKOXZUNGMFPW-UHFFFAOYSA-N 0.000 claims 1
- OMQGHWIRIGBPOL-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-pyrimidin-4-ylpropanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=CN=CC=1)CC1CCOCC1 OMQGHWIRIGBPOL-UHFFFAOYSA-N 0.000 claims 1
- BDABPUQLRHDWNV-UHFFFAOYSA-N 2-[4-(1,2,4-oxadiazol-3-ylmethylsulfonyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)CC1=NOC=N1)C(=O)NC1=NC=CS1 BDABPUQLRHDWNV-UHFFFAOYSA-N 0.000 claims 1
- HXGGIKMNFTVTKL-UHFFFAOYSA-N 2-[4-(2-aminoethylsulfamoyl)phenyl]-n-(5-chloro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NCCN)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)CC1CCOCC1 HXGGIKMNFTVTKL-UHFFFAOYSA-N 0.000 claims 1
- SWEWOJLLUPCTMO-UHFFFAOYSA-N 2-[4-(cyanomethylsulfonyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)CC#N)C(=O)NC1=NC=CS1 SWEWOJLLUPCTMO-UHFFFAOYSA-N 0.000 claims 1
- OCJLJLUBBRJZBS-UHFFFAOYSA-N 2-[4-(dimethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 OCJLJLUBBRJZBS-UHFFFAOYSA-N 0.000 claims 1
- UXSQKWUEYZCYMX-UHFFFAOYSA-N 2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-pyrazin-2-ylpropanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1C(C(=O)NC=1N=CC=NC=1)CC1CCOCC1 UXSQKWUEYZCYMX-UHFFFAOYSA-N 0.000 claims 1
- XFOFEZSUWFRWHI-UHFFFAOYSA-N 2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)-n-pyrimidin-4-ylpropanamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1C(C(=O)NC=1N=CN=CC=1)CC1CCOCC1 XFOFEZSUWFRWHI-UHFFFAOYSA-N 0.000 claims 1
- TYQTXQXCTOBCQN-YMBRHYMPSA-N 2-[4-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonylphenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound COC[C@H]1CCCN1S(=O)(=O)C1=CC=C(C(CC2CCOCC2)C(=O)NC=2SC=CN=2)C=C1 TYQTXQXCTOBCQN-YMBRHYMPSA-N 0.000 claims 1
- ISLZSMBUZCGCMH-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-propan-2-ylsulfonylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C(C)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 ISLZSMBUZCGCMH-UHFFFAOYSA-N 0.000 claims 1
- XOMCNVOBYVHLBX-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-propylsulfonylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)CCC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 XOMCNVOBYVHLBX-UHFFFAOYSA-N 0.000 claims 1
- XOQWTJLJAGPTOH-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-pyrazin-2-ylsulfinylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)C=1N=CC=NC=1)C(=O)NC1=NC=CS1 XOQWTJLJAGPTOH-UHFFFAOYSA-N 0.000 claims 1
- FHKPPNBKMQJOIJ-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-pyrazin-2-ylsulfonylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C=1N=CC=NC=1)C(=O)NC1=NC=CS1 FHKPPNBKMQJOIJ-UHFFFAOYSA-N 0.000 claims 1
- ZHKNAVIDQRBIIX-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-pyridin-2-ylsulfinylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)C=1N=CC=CC=1)C(=O)NC1=NC=CS1 ZHKNAVIDQRBIIX-UHFFFAOYSA-N 0.000 claims 1
- UDQJDKUSHVEGSG-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-pyridin-2-ylsulfonylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C=1N=CC=CC=1)C(=O)NC1=NC=CS1 UDQJDKUSHVEGSG-UHFFFAOYSA-N 0.000 claims 1
- OMEWXJDQBILXTE-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-pyrimidin-5-ylsulfonylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C=1C=NC=NC=1)C(=O)NC1=NC=CS1 OMEWXJDQBILXTE-UHFFFAOYSA-N 0.000 claims 1
- LTUKKORWWXPSCD-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-sulfamoylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 LTUKKORWWXPSCD-UHFFFAOYSA-N 0.000 claims 1
- PIOMOLJSRSOAOH-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(1,4-oxazepan-4-ylsulfonyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)N1CCOCCC1)C(=O)NC1=NC=CS1 PIOMOLJSRSOAOH-UHFFFAOYSA-N 0.000 claims 1
- SLGNOFGUMAIYRQ-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxan-4-ylmethylsulfamoyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NCC1CCOCC1)C(=O)NC1=NC=CS1 SLGNOFGUMAIYRQ-UHFFFAOYSA-N 0.000 claims 1
- RFAZWUSNBQCXCJ-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxan-4-ylsulfamoyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NC1CCOCC1)C(=O)NC1=NC=CS1 RFAZWUSNBQCXCJ-UHFFFAOYSA-N 0.000 claims 1
- NPUUSHQLGRDTGF-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxan-4-ylsulfanyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(SC2CCOCC2)=CC=1)C(=O)NC1=NC=CS1 NPUUSHQLGRDTGF-UHFFFAOYSA-N 0.000 claims 1
- LXTNVVADLJXEEP-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxolan-2-ylmethylsulfamoyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NCC1OCCC1)C(=O)NC1=NC=CS1 LXTNVVADLJXEEP-UHFFFAOYSA-N 0.000 claims 1
- QHWMGKSTWGVXSI-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(pyridin-3-ylmethylsulfonyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)CC=1C=NC=CC=1)C(=O)NC1=NC=CS1 QHWMGKSTWGVXSI-UHFFFAOYSA-N 0.000 claims 1
- JLGDEWZFAXEKGX-UHFFFAOYSA-N 3-(oxan-4-yl)-2-pyrazin-2-ylpropanamide Chemical compound N1=C(C=NC=C1)C(C(=O)N)CC1CCOCC1 JLGDEWZFAXEKGX-UHFFFAOYSA-N 0.000 claims 1
- GRWCEIZCJMDULH-UHFFFAOYSA-N 3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)-2-(4-thiomorpholin-4-ylsulfonylphenyl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)N1CCSCC1)C(=O)NC1=NC=CS1 GRWCEIZCJMDULH-UHFFFAOYSA-N 0.000 claims 1
- TUYFFHKCECQCCI-UHFFFAOYSA-N 3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)-2-[4-(thiophen-2-ylmethylsulfamoyl)phenyl]propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)NCC=1SC=CC=1)C(=O)NC1=NC=CS1 TUYFFHKCECQCCI-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 claims 1
- MQXODHZCDUSFIL-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC=CN=1)CC1CCOCC1 MQXODHZCDUSFIL-UHFFFAOYSA-N 0.000 claims 1
- JIKOFDJUFCPMRR-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)CC1CCOCC1 JIKOFDJUFCPMRR-UHFFFAOYSA-N 0.000 claims 1
- IZRBOTVWDARTGD-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-thiophen-2-ylpropanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)CC1=CC=CS1 IZRBOTVWDARTGD-UHFFFAOYSA-N 0.000 claims 1
- NFGYKOXQTHEXNL-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-[4-(3-hydroxyazetidin-1-yl)sulfonylphenyl]-3-(oxan-4-yl)propanamide Chemical compound C1C(O)CN1S(=O)(=O)C1=CC=C(C(CC2CCOCC2)C(=O)NC=2SC(Cl)=CN=2)C=C1 NFGYKOXQTHEXNL-UHFFFAOYSA-N 0.000 claims 1
- FQCNQCVBXBHOAU-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-3-(oxan-4-yl)propanamide Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C(CC2CCOCC2)C(=O)NC=2SC(Cl)=CN=2)C=C1 FQCNQCVBXBHOAU-UHFFFAOYSA-N 0.000 claims 1
- CMUSTWSZVDZQIT-ATNAJCNCSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-[4-[(3s)-3-hydroxypyrrolidin-1-yl]sulfonylphenyl]-3-(oxan-4-yl)propanamide Chemical compound C1[C@@H](O)CCN1S(=O)(=O)C1=CC=C(C(CC2CCOCC2)C(=O)NC=2SC(Cl)=CN=2)C=C1 CMUSTWSZVDZQIT-ATNAJCNCSA-N 0.000 claims 1
- QIWSMPQURZDALW-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-[4-[2-(dimethylamino)ethylsulfamoyl]phenyl]-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NCCN(C)C)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)CC1CCOCC1 QIWSMPQURZDALW-UHFFFAOYSA-N 0.000 claims 1
- YINFNOHVBJTSBS-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-[4-[2-(methylamino)ethylsulfamoyl]phenyl]-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)NCCNC)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)CC1CCOCC1 YINFNOHVBJTSBS-UHFFFAOYSA-N 0.000 claims 1
- UZWGJQIRYCWYDP-UHFFFAOYSA-N n-(5-chloro-4-methyl-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound S1C(Cl)=C(C)N=C1NC(=O)C(C=1C=CC(=CC=1)S(C)(=O)=O)CC1CCOCC1 UZWGJQIRYCWYDP-UHFFFAOYSA-N 0.000 claims 1
- MFXVKZCXRYWRCI-UHFFFAOYSA-N n-(5-fluoropyridin-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=CC(F)=CC=1)CC1CCOCC1 MFXVKZCXRYWRCI-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 113
- 238000002360 preparation method Methods 0.000 description 107
- 239000000203 mixture Substances 0.000 description 93
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 82
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 73
- 102000030595 Glucokinase Human genes 0.000 description 63
- 108010021582 Glucokinase Proteins 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 238000003756 stirring Methods 0.000 description 42
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 239000002904 solvent Substances 0.000 description 38
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- 239000012190 activator Substances 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 30
- 238000001914 filtration Methods 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 27
- 235000019341 magnesium sulphate Nutrition 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 239000000460 chlorine Substances 0.000 description 20
- 150000002148 esters Chemical class 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 description 17
- 235000017550 sodium carbonate Nutrition 0.000 description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- 238000001704 evaporation Methods 0.000 description 16
- 230000008020 evaporation Effects 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 238000000935 solvent evaporation Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 14
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- GIXPKCTZHPNNJS-UHFFFAOYSA-N 3-(oxan-4-yl)-2-(4-sulfanylphenyl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 GIXPKCTZHPNNJS-UHFFFAOYSA-N 0.000 description 7
- MQLFSPBSNWUXSO-UHFFFAOYSA-N 4-(iodomethyl)oxane Chemical compound ICC1CCOCC1 MQLFSPBSNWUXSO-UHFFFAOYSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 5
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229960001456 adenosine triphosphate Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- FRPKQSPLXRXUJF-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(O)=O)CC1CCOCC1 FRPKQSPLXRXUJF-UHFFFAOYSA-N 0.000 description 4
- HGGWOSYNRVOQJH-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)acetic acid Chemical compound CS(=O)(=O)C1=CC=C(CC(O)=O)C=C1 HGGWOSYNRVOQJH-UHFFFAOYSA-N 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 150000001253 acrylic acids Chemical class 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- VSQDDIXLPKYJPG-UHFFFAOYSA-N ethyl 2-(4-sulfanylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(S)C=C1 VSQDDIXLPKYJPG-UHFFFAOYSA-N 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- CXLGNJCMPWUZKM-UHFFFAOYSA-N oxane-4-carbaldehyde Chemical compound O=CC1CCOCC1 CXLGNJCMPWUZKM-UHFFFAOYSA-N 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 150000003568 thioethers Chemical class 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 3
- OXXXRRRLXQNIQC-UHFFFAOYSA-N 2-[[2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]amino]-1,3-thiazole-5-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(=CN=1)C(O)=O)CC1CCOCC1 OXXXRRRLXQNIQC-UHFFFAOYSA-N 0.000 description 3
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- VEWGNRQQCZDLRY-UHFFFAOYSA-N 4-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 VEWGNRQQCZDLRY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 3
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 3
- OOGJEXQCBINWSB-UHFFFAOYSA-N ethyl 2-(4-methylsulfonylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(S(C)(=O)=O)C=C1 OOGJEXQCBINWSB-UHFFFAOYSA-N 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
- LFRXBSFJOBAAMC-UHFFFAOYSA-N ethylbenzene;heptane;oxolane Chemical compound C1CCOC1.CCCCCCC.CCC1=CC=CC=C1 LFRXBSFJOBAAMC-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- IGMBKNUVZFAHJM-UHFFFAOYSA-I hydrogen sulfate;oxido hydrogen sulfate;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-].CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC IGMBKNUVZFAHJM-UHFFFAOYSA-I 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- FNHCGDCKHYKQIY-UHFFFAOYSA-N n-(5-formyl-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(C=O)=CN=1)CC1CCOCC1 FNHCGDCKHYKQIY-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000006340 racemization Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 3
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FRPKQSPLXRXUJF-CQSZACIVSA-N (2r)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(O)=O)CC1CCOCC1 FRPKQSPLXRXUJF-CQSZACIVSA-N 0.000 description 2
- PBCYQPBAGFJYMO-FYYLOGMGSA-N (4r)-4-benzyl-3-[(2r)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)N1C(OC[C@H]1CC=1C=CC=CC=1)=O)CC1CCOCC1 PBCYQPBAGFJYMO-FYYLOGMGSA-N 0.000 description 2
- XTPLROXCZBGTGW-XYOKQWHBSA-N (e)-2-(4-bromophenyl)-3-(furan-2-yl)prop-2-enoic acid Chemical compound C=1C=C(Br)C=CC=1/C(C(=O)O)=C\C1=CC=CO1 XTPLROXCZBGTGW-XYOKQWHBSA-N 0.000 description 2
- AJUBFYFOYCVINH-MDWZMJQESA-N (e)-2-(4-methylsulfonylphenyl)-3-thiophen-3-ylprop-2-enoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(O)=O)=C/C1=CSC=C1 AJUBFYFOYCVINH-MDWZMJQESA-N 0.000 description 2
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XVAHBBIJHVCBKG-UHFFFAOYSA-N 2-(3-fluoro-4-methylsulfanylphenyl)acetic acid Chemical compound CSC1=CC=C(CC(O)=O)C=C1F XVAHBBIJHVCBKG-UHFFFAOYSA-N 0.000 description 2
- DYJAVQZXHJOPDZ-UHFFFAOYSA-N 2-(4-aminophenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(N)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 DYJAVQZXHJOPDZ-UHFFFAOYSA-N 0.000 description 2
- VXJJWBOWJONFNY-UHFFFAOYSA-N 2-(4-nitrophenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(C(=O)O)CC1CCOCC1 VXJJWBOWJONFNY-UHFFFAOYSA-N 0.000 description 2
- FUOHKPSBGLXIRL-UHFFFAOYSA-N 2-(chloromethyl)thiophene Chemical compound ClCC1=CC=CS1 FUOHKPSBGLXIRL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- JDMCKJTWYFQOHD-UHFFFAOYSA-N 2-[4-(methylsulfanylmethyl)phenyl]acetic acid Chemical compound CSCC1=CC=C(CC(O)=O)C=C1 JDMCKJTWYFQOHD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 2
- UGJUAUVUDNSBSS-UHFFFAOYSA-N 4-[1-[(5-chloro-1,3-thiazol-2-yl)amino]-3-(oxan-4-yl)-1-oxopropan-2-yl]benzenesulfonyl chloride Chemical compound S1C(Cl)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(Cl)(=O)=O)CC1CCOCC1 UGJUAUVUDNSBSS-UHFFFAOYSA-N 0.000 description 2
- UABYWBRQHJZUIE-UHFFFAOYSA-N 4-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 UABYWBRQHJZUIE-UHFFFAOYSA-N 0.000 description 2
- JTRNQTFTRDPITG-UHFFFAOYSA-N 4-iodooxane Chemical compound IC1CCOCC1 JTRNQTFTRDPITG-UHFFFAOYSA-N 0.000 description 2
- GTMGFQYVLSQTKP-UHFFFAOYSA-N 5-chloro-1,3-thiazol-3-ium-2-amine;chloride Chemical compound Cl.NC1=NC=C(Cl)S1 GTMGFQYVLSQTKP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 2
- WSHDLDNMLDZRHC-UHFFFAOYSA-N ethyl 2-(4-cyclopropylsulfanylphenyl)-2-oxoacetate Chemical compound C1=CC(C(=O)C(=O)OCC)=CC=C1SC1CC1 WSHDLDNMLDZRHC-UHFFFAOYSA-N 0.000 description 2
- SQXLMYSNUBXULN-UHFFFAOYSA-N ethyl 2-(4-cyclopropylsulfanylphenyl)-3-(oxan-4-yl)prop-2-enoate Chemical compound C=1C=C(SC2CC2)C=CC=1C(C(=O)OCC)=CC1CCOCC1 SQXLMYSNUBXULN-UHFFFAOYSA-N 0.000 description 2
- SCKYAGXIZMMYCX-UHFFFAOYSA-N ethyl 2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoate Chemical compound C=1C=C(S(=O)(=O)C2CC2)C=CC=1C(C(=O)OCC)=CC1CCOCC1 SCKYAGXIZMMYCX-UHFFFAOYSA-N 0.000 description 2
- OGLLDHZSZLXZJT-UHFFFAOYSA-N ethyl 2-(4-propylsulfanylphenyl)acetate Chemical compound CCCSC1=CC=C(CC(=O)OCC)C=C1 OGLLDHZSZLXZJT-UHFFFAOYSA-N 0.000 description 2
- UGSQXFDDOGHFEM-UHFFFAOYSA-N ethyl 2-[4-(triazol-1-yl)phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1N1N=NC=C1 UGSQXFDDOGHFEM-UHFFFAOYSA-N 0.000 description 2
- UXKULBPQQXTAQT-UHFFFAOYSA-N ethyl 2-[[2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]amino]-1,3-thiazole-5-carboxylate Chemical compound S1C(C(=O)OCC)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(C)(=O)=O)CC1CCOCC1 UXKULBPQQXTAQT-UHFFFAOYSA-N 0.000 description 2
- VNZXERIGKZNEKB-UHFFFAOYSA-N ethyl 2-amino-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(N)S1 VNZXERIGKZNEKB-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- XJEMHAHSQBWRGG-UHFFFAOYSA-M oxan-4-ylmethyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1CCOCC1 XJEMHAHSQBWRGG-UHFFFAOYSA-M 0.000 description 2
- UMFWNFVHKAJOSE-UHFFFAOYSA-N oxetan-3-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1COC1 UMFWNFVHKAJOSE-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940049953 phenylacetate Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000307 polymer substrate Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- HMJAUNHXYJKDGD-MRXNPFEDSA-N (2r)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@H](C(=O)NC=1SC=CN=1)CC1CCOCC1 HMJAUNHXYJKDGD-MRXNPFEDSA-N 0.000 description 1
- PBCYQPBAGFJYMO-GGAORHGYSA-N (4r)-4-benzyl-3-[(2s)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1[C@@H](C(=O)N1C(OC[C@H]1CC=1C=CC=CC=1)=O)CC1CCOCC1 PBCYQPBAGFJYMO-GGAORHGYSA-N 0.000 description 1
- NUSVDASTCPBUIP-UHFFFAOYSA-N (5-bromo-1,3-thiazol-2-yl)azanium;bromide Chemical compound [Br-].BrC1=C[NH2+]C(=N)S1 NUSVDASTCPBUIP-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- XHBQVEJWVYXFGI-LFIBNONCSA-N (e)-2-(4-cyclopropylsulfinylphenyl)-3-(oxan-4-yl)prop-2-enoic acid Chemical compound C=1C=C(S(=O)C2CC2)C=CC=1/C(C(=O)O)=C\C1CCOCC1 XHBQVEJWVYXFGI-LFIBNONCSA-N 0.000 description 1
- HEUPPXFMOYKQFN-RQZCQDPDSA-N (e)-2-(4-formylphenyl)-n-(5-formyl-1,3-thiazol-2-yl)-3-(oxan-4-yl)prop-2-enamide Chemical compound S1C(C=O)=CN=C1NC(=O)C(\C=1C=CC(C=O)=CC=1)=C\C1CCOCC1 HEUPPXFMOYKQFN-RQZCQDPDSA-N 0.000 description 1
- UQTYHTOKAQHAFD-UKTHLTGXSA-N (e)-2-(4-methylsulfonylphenyl)-3-thiophen-2-ylprop-2-enoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(O)=O)=C/C1=CC=CS1 UQTYHTOKAQHAFD-UKTHLTGXSA-N 0.000 description 1
- YWTATITWHQRQBK-FMIVXFBMSA-N (e)-2-phenyl-3-thiophen-2-ylprop-2-enoic acid Chemical compound C=1C=CC=CC=1/C(C(=O)O)=C\C1=CC=CS1 YWTATITWHQRQBK-FMIVXFBMSA-N 0.000 description 1
- BJSQSXPJXQYYKV-RVDMUPIBSA-N (e)-3-(oxan-4-yl)-2-[4-(triazol-1-yl)phenyl]prop-2-enoic acid Chemical compound C=1C=C(N2N=NC=C2)C=CC=1/C(C(=O)O)=C\C1CCOCC1 BJSQSXPJXQYYKV-RVDMUPIBSA-N 0.000 description 1
- KDCYKVAOHCVHCU-GHRIWEEISA-N (e)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]-2-(4-methylsulfonylphenyl)prop-2-enoic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1\C=C(\C(O)=O)C1=CC=C(S(C)(=O)=O)C=C1 KDCYKVAOHCVHCU-GHRIWEEISA-N 0.000 description 1
- IVADKJANLNXBEW-XNTDXEJSSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(1-oxothian-4-yl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(=O)NC=1SC(Cl)=CN=1)=C/C1CCS(=O)CC1 IVADKJANLNXBEW-XNTDXEJSSA-N 0.000 description 1
- LWLMVHJWWDBVLQ-XNTDXEJSSA-N (e)-n-(5-chloro-1,3-thiazol-2-yl)-3-(1,1-dioxothian-4-yl)-2-(4-methylsulfonylphenyl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(=O)NC=1SC(Cl)=CN=1)=C/C1CCS(=O)(=O)CC1 LWLMVHJWWDBVLQ-XNTDXEJSSA-N 0.000 description 1
- BKCXYOBHAPUILK-MHWRWJLKSA-N (e)-n-(5-formyl-1,3-thiazol-2-yl)-3-(oxan-4-yl)-2-phenylprop-2-enamide Chemical compound S1C(C=O)=CN=C1NC(=O)C(\C=1C=CC=CC=1)=C\C1CCOCC1 BKCXYOBHAPUILK-MHWRWJLKSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KTRCRNUZEIZGGW-UHFFFAOYSA-N 2,2,2-trifluoro-n-(5-fluoro-1,3-thiazol-2-yl)acetamide Chemical compound FC1=CN=C(NC(=O)C(F)(F)F)S1 KTRCRNUZEIZGGW-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FPDMXZGFHBWBGN-UHFFFAOYSA-N 2-(3-bromophenyl)-n-(1,3-thiazol-2-yl)-3-thiophen-2-ylprop-2-enamide Chemical compound BrC1=CC=CC(C(=CC=2SC=CC=2)C(=O)NC=2SC=CN=2)=C1 FPDMXZGFHBWBGN-UHFFFAOYSA-N 0.000 description 1
- VUEDTZVCBMTNEP-UHFFFAOYSA-N 2-(3-bromophenyl)-n-(5-chloro-1,3-thiazol-2-yl)-3-thiophen-2-ylprop-2-enamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(C=1C=C(Br)C=CC=1)=CC1=CC=CS1 VUEDTZVCBMTNEP-UHFFFAOYSA-N 0.000 description 1
- AUIJDNIPLFXNKQ-UHFFFAOYSA-N 2-(3-fluoro-4-methylsulfanylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C1=C(F)C(SC)=CC=C1C(C(O)=O)CC1CCOCC1 AUIJDNIPLFXNKQ-UHFFFAOYSA-N 0.000 description 1
- WUSXHQOKBNWCJJ-UHFFFAOYSA-N 2-(3-fluoro-4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C1=C(F)C(S(=O)(=O)C)=CC=C1C(C(O)=O)CC1CCOCC1 WUSXHQOKBNWCJJ-UHFFFAOYSA-N 0.000 description 1
- GVBCPCLYBSESTF-UHFFFAOYSA-N 2-(3-methylsulfanylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound CSC1=CC=CC(C(CC2CCOCC2)C(O)=O)=C1 GVBCPCLYBSESTF-UHFFFAOYSA-N 0.000 description 1
- PFWLOCVFZAGDDU-UHFFFAOYSA-N 2-(4-acetamidophenyl)-n-(5-chloro-1,3-thiazol-2-yl)-3-(oxan-4-yl)prop-2-enamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)=CC1CCOCC1 PFWLOCVFZAGDDU-UHFFFAOYSA-N 0.000 description 1
- HGOKUNMVNJNIPV-UHFFFAOYSA-N 2-(4-aminophenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C1=CC(N)=CC=C1C(C(=O)NC=1SC=CN=1)=CC1CCOCC1 HGOKUNMVNJNIPV-UHFFFAOYSA-N 0.000 description 1
- LCPYAEYVEDLUML-UHFFFAOYSA-N 2-(4-aminophenyl)-n-(5-chloro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(N)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)CC1CCOCC1 LCPYAEYVEDLUML-UHFFFAOYSA-N 0.000 description 1
- NCGJIYJUFGKDPQ-UHFFFAOYSA-N 2-(4-bromophenyl)-3-(furan-2-yl)-n-(1,3,4-thiadiazol-2-yl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1C(C(=O)NC=1SC=NN=1)=CC1=CC=CO1 NCGJIYJUFGKDPQ-UHFFFAOYSA-N 0.000 description 1
- KLWLBPOSHBZOOD-UHFFFAOYSA-N 2-(4-bromophenyl)-3-(furan-2-yl)prop-2-enoyl chloride Chemical compound C=1C=C(Br)C=CC=1C(C(=O)Cl)=CC1=CC=CO1 KLWLBPOSHBZOOD-UHFFFAOYSA-N 0.000 description 1
- QMTPOGUJXPAMPR-UHFFFAOYSA-N 2-(4-bromophenyl)-3-thiophen-2-yl-n-[4-(trifluoromethyl)-1,3-thiazol-2-yl]prop-2-enamide Chemical compound FC(F)(F)C1=CSC(NC(=O)C(=CC=2SC=CC=2)C=2C=CC(Br)=CC=2)=N1 QMTPOGUJXPAMPR-UHFFFAOYSA-N 0.000 description 1
- TZPYJCLBIYKSMZ-UHFFFAOYSA-N 2-(4-bromophenyl)-n-(4,5-dimethyl-1,3-thiazol-2-yl)-3-thiophen-2-ylprop-2-enamide Chemical compound S1C(C)=C(C)N=C1NC(=O)C(C=1C=CC(Br)=CC=1)=CC1=CC=CS1 TZPYJCLBIYKSMZ-UHFFFAOYSA-N 0.000 description 1
- LRDZIUDIGIZNHT-UHFFFAOYSA-N 2-(4-bromophenyl)-n-(5-bromopyridin-2-yl)-3-(furan-2-yl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1C(C(=O)NC=1N=CC(Br)=CC=1)=CC1=CC=CO1 LRDZIUDIGIZNHT-UHFFFAOYSA-N 0.000 description 1
- LSVHOHCFLNEVRO-UHFFFAOYSA-N 2-(4-bromophenyl)-n-(5-bromopyridin-2-yl)-3-thiophen-2-ylprop-2-enamide Chemical class C1=CC(Br)=CC=C1C(C(=O)NC=1N=CC(Br)=CC=1)=CC1=CC=CS1 LSVHOHCFLNEVRO-UHFFFAOYSA-N 0.000 description 1
- YTLSNRMMMVPIPK-UHFFFAOYSA-N 2-(4-bromophenyl)-n-pyrazin-2-yl-3-thiophen-2-ylprop-2-enamide Chemical compound C1=CC(Br)=CC=C1C(C(=O)NC=1N=CC=NC=1)=CC1=CC=CS1 YTLSNRMMMVPIPK-UHFFFAOYSA-N 0.000 description 1
- DQPVDHKLUJHWPI-UHFFFAOYSA-N 2-(4-bromophenyl)-n-pyridin-2-yl-3-thiophen-2-ylprop-2-enamide Chemical compound C1=CC(Br)=CC=C1C(C(=O)NC=1N=CC=CC=1)=CC1=CC=CS1 DQPVDHKLUJHWPI-UHFFFAOYSA-N 0.000 description 1
- BDNQEPDMTXDELY-UHFFFAOYSA-N 2-(4-bromophenyl)-n-pyrimidin-4-yl-3-thiophen-2-ylprop-2-enamide Chemical compound C1=CC(Br)=CC=C1C(C(=O)NC=1N=CN=CC=1)=CC1=CC=CS1 BDNQEPDMTXDELY-UHFFFAOYSA-N 0.000 description 1
- SOQPWGXPPBNIQX-UHFFFAOYSA-N 2-(4-cyanophenyl)-3-(furan-2-yl)-n-(1,3,4-thiadiazol-2-yl)prop-2-enamide Chemical compound C=1C=COC=1C=C(C=1C=CC(=CC=1)C#N)C(=O)NC1=NN=CS1 SOQPWGXPPBNIQX-UHFFFAOYSA-N 0.000 description 1
- QAHGWJJCLHDPBT-UHFFFAOYSA-N 2-(4-cyanophenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)C#N)C(=O)NC1=NC=CS1 QAHGWJJCLHDPBT-UHFFFAOYSA-N 0.000 description 1
- SLOPMYOSWZSXPZ-UHFFFAOYSA-N 2-(4-cyanophenyl)-3-phenyl-n-(1,3,4-thiadiazol-2-yl)prop-2-enamide Chemical compound C=1C=CC=CC=1C=C(C=1C=CC(=CC=1)C#N)C(=O)NC1=NN=CS1 SLOPMYOSWZSXPZ-UHFFFAOYSA-N 0.000 description 1
- MHDCYLGWOLXYJI-UHFFFAOYSA-N 2-(4-cyanophenyl)-3-phenyl-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C=1C=CC=CC=1C=C(C=1C=CC(=CC=1)C#N)C(=O)NC1=NC=CS1 MHDCYLGWOLXYJI-UHFFFAOYSA-N 0.000 description 1
- RBFXHJSQGABQRB-UHFFFAOYSA-N 2-(4-methoxycarbonylphenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C1=CC(C(=O)OC)=CC=C1C(C(O)=O)CC1CCOCC1 RBFXHJSQGABQRB-UHFFFAOYSA-N 0.000 description 1
- ZOBVECUFYIXDEH-UHFFFAOYSA-N 2-(4-methylsulfanyl-3-nitrophenyl)-3-(oxan-4-yl)propanoic acid Chemical compound C1=C([N+]([O-])=O)C(SC)=CC=C1C(C(O)=O)CC1CCOCC1 ZOBVECUFYIXDEH-UHFFFAOYSA-N 0.000 description 1
- NIJZPUPHLPEMPR-UHFFFAOYSA-N 2-(4-methylsulfonyl-3-nitrophenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C([N+]([O-])=O)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 NIJZPUPHLPEMPR-UHFFFAOYSA-N 0.000 description 1
- YDOTUORMFNGEJM-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-(3-methylthiophen-2-yl)-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C1=CSC(C=C(C(=O)NC=2SC=CN=2)C=2C=CC(=CC=2)S(C)(=O)=O)=C1C YDOTUORMFNGEJM-UHFFFAOYSA-N 0.000 description 1
- GSUQCSMXBOIACQ-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)-n-[5-(trifluoromethyl)-1,3-thiazol-2-yl]propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(=CN=1)C(F)(F)F)CC1CCOCC1 GSUQCSMXBOIACQ-UHFFFAOYSA-N 0.000 description 1
- REDAUCXETSNECY-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-piperidin-1-yl-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CN1CCCCC1 REDAUCXETSNECY-UHFFFAOYSA-N 0.000 description 1
- LSKFJWBOXCJNEJ-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-piperidin-4-yl-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)=CC1CCNCC1 LSKFJWBOXCJNEJ-UHFFFAOYSA-N 0.000 description 1
- AGYCPEXHKHNHPI-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-pyridin-3-yl-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)=CC1=CC=CN=C1 AGYCPEXHKHNHPI-UHFFFAOYSA-N 0.000 description 1
- CPYUSCAQYPXMOX-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-thiophen-2-ylpropanoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(O)=O)CC1=CC=CS1 CPYUSCAQYPXMOX-UHFFFAOYSA-N 0.000 description 1
- UADSFVSGABRBFM-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-4-(oxan-4-yl)-n-(1,3-thiazol-2-yl)but-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)=CCC1CCOCC1 UADSFVSGABRBFM-UHFFFAOYSA-N 0.000 description 1
- UOEXIPIKIGLLEB-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-4-(oxan-4-yl)-n-(1,3-thiazol-2-yl)butanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CCC1CCOCC1 UOEXIPIKIGLLEB-UHFFFAOYSA-N 0.000 description 1
- WDAZGRYMBCILRV-UHFFFAOYSA-N 2-(4-nitrophenyl)-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 WDAZGRYMBCILRV-UHFFFAOYSA-N 0.000 description 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DNFSRFWBPUDHPC-UHFFFAOYSA-N 2-[3-(cyclopropylsulfonylamino)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=C(NS(=O)(=O)C2CC2)C=CC=1)C(=O)NC1=NC=CS1 DNFSRFWBPUDHPC-UHFFFAOYSA-N 0.000 description 1
- CAJIFEZDZLGVQM-UHFFFAOYSA-N 2-[3-(methanesulfonamido)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound CS(=O)(=O)NC1=CC=CC(C(CC2CCOCC2)C(=O)NC=2SC=CN=2)=C1 CAJIFEZDZLGVQM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BSBSUJIHGLGFTD-UHFFFAOYSA-N 2-[4-(methylaminomethyl)phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C1=CC(CNC)=CC=C1C(C(=O)NC=1SC=CN=1)=CC1CCOCC1 BSBSUJIHGLGFTD-UHFFFAOYSA-N 0.000 description 1
- WKVNKOKNOAJWOI-UHFFFAOYSA-N 2-[4-[(dimethylamino)methyl]phenyl]-3-(oxan-4-yl)-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound C1=CC(CN(C)C)=CC=C1C(C(=O)NC=1SC=CN=1)=CC1CCOCC1 WKVNKOKNOAJWOI-UHFFFAOYSA-N 0.000 description 1
- NMHFLBLIADKSPE-XNTDXEJSSA-N 2-[[(e)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoyl]amino]-1,3-thiazole-5-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(\C(=O)NC=1SC(=CN=1)C(O)=O)=C/C1CCOCC1 NMHFLBLIADKSPE-XNTDXEJSSA-N 0.000 description 1
- ZDBAIAMNQZUKES-UHFFFAOYSA-N 2-[[2-(4-carboxyphenyl)-3-(oxan-4-yl)prop-2-enoyl]amino]-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(=O)O)=CN=C1NC(=O)C(C=1C=CC(=CC=1)C(O)=O)=CC1CCOCC1 ZDBAIAMNQZUKES-UHFFFAOYSA-N 0.000 description 1
- AOHOYANXBBYBKM-UHFFFAOYSA-N 2-[[2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]amino]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=C(N=1)C(O)=O)CC1CCOCC1 AOHOYANXBBYBKM-UHFFFAOYSA-N 0.000 description 1
- HZKMBJCDAXLMDN-UHFFFAOYSA-N 2-amino-1,3-thiazole-5-carbaldehyde Chemical compound NC1=NC=C(C=O)S1 HZKMBJCDAXLMDN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical class NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GNVXHIOZTZBMNU-UHFFFAOYSA-N 3-(furan-2-yl)-2-(3-methoxyphenyl)-n-(1,3-thiazol-2-yl)prop-2-enamide Chemical compound COC1=CC=CC(C(=CC=2OC=CC=2)C(=O)NC=2SC=CN=2)=C1 GNVXHIOZTZBMNU-UHFFFAOYSA-N 0.000 description 1
- YXBNAVQJNQWGEM-UHFFFAOYSA-N 3-(furan-2-yl)-2-(3-methoxyphenyl)-n-pyridin-2-ylprop-2-enamide Chemical compound COC1=CC=CC(C(=CC=2OC=CC=2)C(=O)NC=2N=CC=CC=2)=C1 YXBNAVQJNQWGEM-UHFFFAOYSA-N 0.000 description 1
- AFGZWQZADKOTBG-UHFFFAOYSA-N 3-(furan-2-yl)-2-(4-methoxyphenyl)-n-(1,3,4-thiadiazol-2-yl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1SC=NN=1)=CC1=CC=CO1 AFGZWQZADKOTBG-UHFFFAOYSA-N 0.000 description 1
- BDAYVJJTSROLOC-UHFFFAOYSA-N 3-(furan-2-yl)-2-(4-methoxyphenyl)-n-[4-(trifluoromethyl)-1,3-thiazol-2-yl]prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1SC=C(N=1)C(F)(F)F)=CC1=CC=CO1 BDAYVJJTSROLOC-UHFFFAOYSA-N 0.000 description 1
- OPGWVSWXZSYDHM-UHFFFAOYSA-N 3-(furan-2-yl)-2-(4-methoxyphenyl)-n-pyrimidin-4-ylprop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1N=CN=CC=1)=CC1=CC=CO1 OPGWVSWXZSYDHM-UHFFFAOYSA-N 0.000 description 1
- BAZGZQRQSNYIDO-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(2-oxopropylsulfanyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=CC(SCC(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 BAZGZQRQSNYIDO-UHFFFAOYSA-N 0.000 description 1
- WONFARLFVMATMW-UHFFFAOYSA-N 3-(oxan-4-yl)-2-[4-(oxetan-3-ylsulfanyl)phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(SC2COC2)=CC=1)C(=O)NC1=NC=CS1 WONFARLFVMATMW-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- JHXZOPJPGIZXFX-UHFFFAOYSA-N 3-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]-n-(1,3-thiazol-2-yl)benzamide Chemical compound C1COCCC1CC(C=1C=C(C=CC=1)C(=O)NC=1SC=CN=1)C(=O)NC1=NC=CS1 JHXZOPJPGIZXFX-UHFFFAOYSA-N 0.000 description 1
- ZYHAKEQMINKBGZ-UHFFFAOYSA-N 3-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C(CC2CCOCC2)C(=O)NC=2SC=CN=2)=C1 ZYHAKEQMINKBGZ-UHFFFAOYSA-N 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
- XDELKSRGBLWMBA-UHFFFAOYSA-N 3-iodopyridine Chemical compound IC1=CC=CN=C1 XDELKSRGBLWMBA-UHFFFAOYSA-N 0.000 description 1
- WUXCECMNMNJYSC-UHFFFAOYSA-N 37777-68-7 Chemical compound OC(=O)CC1=CC=C(Cl)C([N+]([O-])=O)=C1 WUXCECMNMNJYSC-UHFFFAOYSA-N 0.000 description 1
- QOWSWEBLNVACCL-UHFFFAOYSA-N 4-Bromophenyl acetate Chemical compound OC(=O)CC1=CC=C(Br)C=C1 QOWSWEBLNVACCL-UHFFFAOYSA-N 0.000 description 1
- NBTPTICIRPGYIQ-UHFFFAOYSA-N 4-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 NBTPTICIRPGYIQ-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- WUTUCTHNAXSTGJ-UHFFFAOYSA-N 5-chloro-4-methyl-1,3-thiazol-2-amine Chemical compound CC=1N=C(N)SC=1Cl WUTUCTHNAXSTGJ-UHFFFAOYSA-N 0.000 description 1
- HUXNGTYNEWXYDM-UHFFFAOYSA-N 5-fluoro-1,3-thiazol-2-amine;hydrochloride Chemical compound Cl.NC1=NC=C(F)S1 HUXNGTYNEWXYDM-UHFFFAOYSA-N 0.000 description 1
- YJTXQLYMECWULH-UHFFFAOYSA-N 5-fluoropyridin-2-amine Chemical compound NC1=CC=C(F)C=N1 YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQOXQRCZOLPYPM-UHFFFAOYSA-N Dimethyl disulfide Natural products CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150109586 Gk gene Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101001133924 Homo sapiens Gamma-glutamyl phosphate reductase Proteins 0.000 description 1
- 101000905392 Homo sapiens Glycerol kinase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910004879 Na2S2O5 Inorganic materials 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 238000003684 Perkin reaction Methods 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Tetrahydrothiophene-1,1-dioxide, Natural products O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WWCNXHYRAKUQDB-SNVBAGLBSA-N [(3r)-oxolan-3-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1COCC1 WWCNXHYRAKUQDB-SNVBAGLBSA-N 0.000 description 1
- WWCNXHYRAKUQDB-JTQLQIEISA-N [(3s)-oxolan-3-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@@H]1COCC1 WWCNXHYRAKUQDB-JTQLQIEISA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YIBKCPJOFAUAKY-UHFFFAOYSA-N cyclopropylsulfanylbenzene Chemical compound C1CC1SC1=CC=CC=C1 YIBKCPJOFAUAKY-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000005610 enamide group Chemical group 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- OLCZVCWNOGDQFZ-FOWTUZBSSA-N ethyl (e)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoate Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1/C(C(=O)OCC)=C\C1CCOCC1 OLCZVCWNOGDQFZ-FOWTUZBSSA-N 0.000 description 1
- OEUJTMHRUVTMHO-UHFFFAOYSA-N ethyl 2-(3-fluoro-4-methylsulfanylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(SC)C(F)=C1 OEUJTMHRUVTMHO-UHFFFAOYSA-N 0.000 description 1
- JFGXDPCDOFKEQM-UHFFFAOYSA-N ethyl 2-(3-nitrophenyl)-3-(oxan-4-yl)prop-2-enoate Chemical compound C=1C=CC([N+]([O-])=O)=CC=1C(C(=O)OCC)=CC1CCOCC1 JFGXDPCDOFKEQM-UHFFFAOYSA-N 0.000 description 1
- GVSTWFAYXHCBTH-UHFFFAOYSA-N ethyl 2-(3-nitrophenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC([N+]([O-])=O)=C1 GVSTWFAYXHCBTH-UHFFFAOYSA-N 0.000 description 1
- FGVWGMBEACNSAS-UHFFFAOYSA-N ethyl 2-(4-chloro-3-nitrophenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(Cl)C([N+]([O-])=O)=C1 FGVWGMBEACNSAS-UHFFFAOYSA-N 0.000 description 1
- GFFNJDBLUUWICZ-UHFFFAOYSA-N ethyl 2-(4-chlorosulfonylphenyl)-3-(oxan-4-yl)propanoate Chemical compound C=1C=C(S(Cl)(=O)=O)C=CC=1C(C(=O)OCC)CC1CCOCC1 GFFNJDBLUUWICZ-UHFFFAOYSA-N 0.000 description 1
- KWLKPEYJDYHDSO-UHFFFAOYSA-N ethyl 2-(4-cyclobutylsulfanylphenyl)acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1SC1CCC1 KWLKPEYJDYHDSO-UHFFFAOYSA-N 0.000 description 1
- UPLRFFVIDBHNOQ-UHFFFAOYSA-N ethyl 2-(4-cyclobutylsulfonylphenyl)acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1S(=O)(=O)C1CCC1 UPLRFFVIDBHNOQ-UHFFFAOYSA-N 0.000 description 1
- IMLQSIZGYLSBKE-UHFFFAOYSA-N ethyl 2-(4-cyclopropylsulfinylphenyl)-3-(oxan-4-yl)prop-2-enoate Chemical compound C=1C=C(S(=O)C2CC2)C=CC=1C(C(=O)OCC)=CC1CCOCC1 IMLQSIZGYLSBKE-UHFFFAOYSA-N 0.000 description 1
- RGNBBURLJAKHQF-UHFFFAOYSA-N ethyl 2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)propanoate Chemical compound C=1C=C(S(=O)(=O)C2CC2)C=CC=1C(C(=O)OCC)CC1CCOCC1 RGNBBURLJAKHQF-UHFFFAOYSA-N 0.000 description 1
- GLFFKIVJNHWDNB-UHFFFAOYSA-N ethyl 2-(4-ethylsulfanylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(SCC)C=C1 GLFFKIVJNHWDNB-UHFFFAOYSA-N 0.000 description 1
- BPVFNVADDRBUAL-UHFFFAOYSA-N ethyl 2-(4-ethylsulfonylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(S(=O)(=O)CC)C=C1 BPVFNVADDRBUAL-UHFFFAOYSA-N 0.000 description 1
- ZLQPAONBGBXGFN-UHFFFAOYSA-N ethyl 2-(4-methylsulfanylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(SC)C=C1 ZLQPAONBGBXGFN-UHFFFAOYSA-N 0.000 description 1
- ALNTXCANFNFJKZ-UHFFFAOYSA-N ethyl 2-(4-methylsulfinylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(S(C)=O)C=C1 ALNTXCANFNFJKZ-UHFFFAOYSA-N 0.000 description 1
- UJZAWQLROYYPMF-UHFFFAOYSA-N ethyl 2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoate Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(C(=O)OCC)CC1CCOCC1 UJZAWQLROYYPMF-UHFFFAOYSA-N 0.000 description 1
- BKUQQATYJFTRTB-UHFFFAOYSA-N ethyl 2-(4-nitrophenyl)-3-(oxan-4-yl)propanoate Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(C(=O)OCC)CC1CCOCC1 BKUQQATYJFTRTB-UHFFFAOYSA-N 0.000 description 1
- DWDRNKYLWMKWTH-UHFFFAOYSA-N ethyl 2-(4-nitrophenyl)acetate Chemical compound CCOC(=O)CC1=CC=C([N+]([O-])=O)C=C1 DWDRNKYLWMKWTH-UHFFFAOYSA-N 0.000 description 1
- UZCYWJZCIYOJJD-UHFFFAOYSA-N ethyl 2-(4-propylsulfonylphenyl)acetate Chemical compound CCCS(=O)(=O)C1=CC=C(CC(=O)OCC)C=C1 UZCYWJZCIYOJJD-UHFFFAOYSA-N 0.000 description 1
- WRYXNACJTXUJEA-UHFFFAOYSA-N ethyl 2-[4-(ethylsulfamoyl)phenyl]-3-(oxan-4-yl)propanoate Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1C(C(=O)OCC)CC1CCOCC1 WRYXNACJTXUJEA-UHFFFAOYSA-N 0.000 description 1
- ZWRLNHFTISWEFV-UHFFFAOYSA-N ethyl 2-[4-(methoxymethylsulfanyl)phenyl]acetate Chemical compound CCOC(=O)CC1=CC=C(SCOC)C=C1 ZWRLNHFTISWEFV-UHFFFAOYSA-N 0.000 description 1
- IQGNFEJENLHEQB-UHFFFAOYSA-N ethyl 2-[4-(methylsulfanylmethyl)phenyl]acetate Chemical compound CCOC(=O)CC1=CC=C(CSC)C=C1 IQGNFEJENLHEQB-UHFFFAOYSA-N 0.000 description 1
- IJPMFNZPZQSXDQ-UHFFFAOYSA-N ethyl 2-[4-(oxan-4-ylsulfanyl)phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1SC1CCOCC1 IJPMFNZPZQSXDQ-UHFFFAOYSA-N 0.000 description 1
- XLAVFKGRQIROFX-SFQUDFHCSA-N ethyl 2-[[(e)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoyl]amino]-1,3-thiazole-5-carboxylate Chemical compound S1C(C(=O)OCC)=CN=C1NC(=O)C(\C=1C=CC(=CC=1)S(C)(=O)=O)=C\C1CCOCC1 XLAVFKGRQIROFX-SFQUDFHCSA-N 0.000 description 1
- JXOCLXSBXOLSOP-UHFFFAOYSA-N ethyl 2-[[2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]amino]-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(NC(=O)C(CC2CCOCC2)C=2C=CC(=CC=2)S(C)(=O)=O)=N1 JXOCLXSBXOLSOP-UHFFFAOYSA-N 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- BSVMBOPKPXFRFB-UHFFFAOYSA-N ethyl 3-(oxan-4-yl)-2-[4-(triazol-1-yl)phenyl]prop-2-enoate Chemical compound C=1C=C(N2N=NC=C2)C=CC=1C(C(=O)OCC)=CC1CCOCC1 BSVMBOPKPXFRFB-UHFFFAOYSA-N 0.000 description 1
- 125000005744 ethylethenyl group Chemical group [H]\C(*)=C(/[H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- RIGBPMDIGYBTBJ-UHFFFAOYSA-N glycyclamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 RIGBPMDIGYBTBJ-UHFFFAOYSA-N 0.000 description 1
- 229950005514 glycyclamide Drugs 0.000 description 1
- NFRPNQDSKJJQGV-UHFFFAOYSA-N glyhexamide Chemical compound C=1C=C2CCCC2=CC=1S(=O)(=O)NC(=O)NC1CCCCC1 NFRPNQDSKJJQGV-UHFFFAOYSA-N 0.000 description 1
- 229950008290 glyhexamide Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000033066 hyperinsulinemic hypoglycemia Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- CODDZYQOZMBBQT-UHFFFAOYSA-N methyl 2-(3-bromo-4-methylsulfanylphenyl)acetate Chemical compound COC(=O)CC1=CC=C(SC)C(Br)=C1 CODDZYQOZMBBQT-UHFFFAOYSA-N 0.000 description 1
- JOSRNNDWRFFBRL-UHFFFAOYSA-N methyl 3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]benzoate Chemical compound COC(=O)C1=CC=CC(CC(=O)OC(C)(C)C)=C1 JOSRNNDWRFFBRL-UHFFFAOYSA-N 0.000 description 1
- WULFSBSYPNVERD-UHFFFAOYSA-N methyl 3-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C(CC2CCOCC2)C(=O)NC=2SC=CN=2)=C1 WULFSBSYPNVERD-UHFFFAOYSA-N 0.000 description 1
- ADBSDOVEMIPANG-UHFFFAOYSA-N methyl 4-[1-[(2-methylpropan-2-yl)oxy]-3-(oxan-4-yl)-1-oxopropan-2-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C(=O)OC(C)(C)C)CC1CCOCC1 ADBSDOVEMIPANG-UHFFFAOYSA-N 0.000 description 1
- RGRJTJQQFNMOMP-UHFFFAOYSA-N methyl 4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]benzoate Chemical compound COC(=O)C1=CC=C(CC(=O)OC(C)(C)C)C=C1 RGRJTJQQFNMOMP-UHFFFAOYSA-N 0.000 description 1
- MPJUDAORRJHECX-UHFFFAOYSA-N methyl 4-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 MPJUDAORRJHECX-UHFFFAOYSA-N 0.000 description 1
- RADLKEGLJGXBJX-UHFFFAOYSA-N methyl n-[[2-[[2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]amino]-1,3-thiazol-5-yl]methyl]carbamate Chemical compound S1C(CNC(=O)OC)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(C)(=O)=O)CC1CCOCC1 RADLKEGLJGXBJX-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- UFYUUXRNWMAZHL-UHFFFAOYSA-N n,n-dimethyl-4-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 UFYUUXRNWMAZHL-UHFFFAOYSA-N 0.000 description 1
- JSRPLUUDKRRWGT-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-(4-bromophenyl)-3-thiophen-2-ylprop-2-enamide Chemical class C1=CC(Br)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)=CC1=CC=CS1 JSRPLUUDKRRWGT-UHFFFAOYSA-N 0.000 description 1
- QQBWNHVNTXORLZ-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-3-(furan-2-yl)-2-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1SC2=CC=CC=C2N=1)=CC1=CC=CO1 QQBWNHVNTXORLZ-UHFFFAOYSA-N 0.000 description 1
- NEJVPWRFWIVWRF-UHFFFAOYSA-N n-(1-methylbenzimidazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound N=1C2=CC=CC=C2N(C)C=1NC(=O)C(C=1C=CC(=CC=1)S(C)(=O)=O)CC1CCOCC1 NEJVPWRFWIVWRF-UHFFFAOYSA-N 0.000 description 1
- MSHRHUYSBZPSQD-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1NC2=CC=CC=C2N=1)CC1CCOCC1 MSHRHUYSBZPSQD-UHFFFAOYSA-N 0.000 description 1
- XOOGNFYAZPSEBH-UHFFFAOYSA-N n-(4,5-dimethyl-1,3-thiazol-2-yl)-2-phenyl-3-thiophen-2-ylprop-2-enamide Chemical compound S1C(C)=C(C)N=C1NC(=O)C(C=1C=CC=CC=1)=CC1=CC=CS1 XOOGNFYAZPSEBH-UHFFFAOYSA-N 0.000 description 1
- AHEBUBZMUJNQIT-UHFFFAOYSA-N n-(4,5-dimethyl-1,3-thiazol-2-yl)-3-(furan-2-yl)-2-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1SC(C)=C(C)N=1)=CC1=CC=CO1 AHEBUBZMUJNQIT-UHFFFAOYSA-N 0.000 description 1
- MZBBHMNHUOVRQO-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NC1=NC=C(Br)S1 MZBBHMNHUOVRQO-UHFFFAOYSA-N 0.000 description 1
- VSBOMIVZBOZKBM-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-2-(4-cyanophenyl)-3-phenylprop-2-enamide Chemical compound S1C(Br)=CN=C1NC(=O)C(C=1C=CC(=CC=1)C#N)=CC1=CC=CC=C1 VSBOMIVZBOZKBM-UHFFFAOYSA-N 0.000 description 1
- OHCWKVFKLIXQPQ-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-3-(furan-2-yl)-2-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(C(=CC=2OC=CC=2)C(=O)NC=2SC(Br)=CN=2)=C1 OHCWKVFKLIXQPQ-UHFFFAOYSA-N 0.000 description 1
- XQDOBVIUORSYLJ-UHFFFAOYSA-N n-(5-bromo-1,3-thiazol-2-yl)-3-(furan-2-yl)-2-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1SC(Br)=CN=1)=CC1=CC=CO1 XQDOBVIUORSYLJ-UHFFFAOYSA-N 0.000 description 1
- FYLLCDMWVZYHKX-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(furan-2-yl)-2-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1N=CC(Br)=CC=1)=CC1=CC=CO1 FYLLCDMWVZYHKX-UHFFFAOYSA-N 0.000 description 1
- PFTNBNKKQKHXPN-UHFFFAOYSA-N n-(5-chloro-1,3-benzoxazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1OC2=CC=C(Cl)C=C2N=1)CC1CCOCC1 PFTNBNKKQKHXPN-UHFFFAOYSA-N 0.000 description 1
- GBJDBCLKFZWYPS-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-piperidin-4-ylprop-2-enamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)=CC1CCNCC1 GBJDBCLKFZWYPS-UHFFFAOYSA-N 0.000 description 1
- LDDAWJRVMZPYDP-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-2-phenyl-3-thiophen-2-ylprop-2-enamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(C=1C=CC=CC=1)=CC1=CC=CS1 LDDAWJRVMZPYDP-UHFFFAOYSA-N 0.000 description 1
- VIVIIQRNRONZBM-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-3-(furan-2-yl)-2-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(C(=CC=2OC=CC=2)C(=O)NC=2SC(Cl)=CN=2)=C1 VIVIIQRNRONZBM-UHFFFAOYSA-N 0.000 description 1
- USWFLVVWJVPZTF-UHFFFAOYSA-N n-(5-chloro-1,3-thiazol-2-yl)-3-(furan-2-yl)-2-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1C(C(=O)NC=1SC(Cl)=CN=1)=CC1=CC=CO1 USWFLVVWJVPZTF-UHFFFAOYSA-N 0.000 description 1
- BTODLWXNRHXXEE-UHFFFAOYSA-N n-(5-cyano-1,3-thiazol-2-yl)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1COCCC1CC(C=1C=CC(=CC=1)S(=O)(=O)C1CC1)C(=O)NC1=NC=C(C#N)S1 BTODLWXNRHXXEE-UHFFFAOYSA-N 0.000 description 1
- HQHIZCTVRPKGLF-UHFFFAOYSA-N n-(5-cyano-1,3-thiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(=CN=1)C#N)CC1CCOCC1 HQHIZCTVRPKGLF-UHFFFAOYSA-N 0.000 description 1
- VEVCBZYXMCYYGQ-UHFFFAOYSA-N n-(5-methyl-1,3-thiazol-2-yl)-2-phenyl-3-thiophen-2-ylprop-2-enamide Chemical compound S1C(C)=CN=C1NC(=O)C(C=1C=CC=CC=1)=CC1=CC=CS1 VEVCBZYXMCYYGQ-UHFFFAOYSA-N 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- JHNALENIJRVUPL-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-[[3-(oxan-4-yl)-2-phenylprop-2-enoyl]amino]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCN(C)C)=CN=C1NC(=O)C(C=1C=CC=CC=1)=CC1CCOCC1 JHNALENIJRVUPL-UHFFFAOYSA-N 0.000 description 1
- DBLFQAIJLGKQSQ-UHFFFAOYSA-N n-[5-(4-ethylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]-3-(oxan-4-yl)-2-phenylprop-2-enamide Chemical compound C1CN(CC)CCN1C(=O)C(S1)=CN=C1NC(=O)C(C=1C=CC=CC=1)=CC1CCOCC1 DBLFQAIJLGKQSQ-UHFFFAOYSA-N 0.000 description 1
- AFPMIPIGFKCHAS-UHFFFAOYSA-N n-[5-(4-methylpiperazine-1-carbonyl)-1,3-thiazol-2-yl]-3-(oxan-4-yl)-2-phenylprop-2-enamide Chemical compound C1CN(C)CCN1C(=O)C(S1)=CN=C1NC(=O)C(C=1C=CC=CC=1)=CC1CCOCC1 AFPMIPIGFKCHAS-UHFFFAOYSA-N 0.000 description 1
- CQZIUDRFNAPILO-UHFFFAOYSA-N n-[5-(hydroxymethyl)-1,3-thiazol-2-yl]-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC(CO)=CN=1)CC1CCOCC1 CQZIUDRFNAPILO-UHFFFAOYSA-N 0.000 description 1
- YXDGDMQWAVMTTO-UHFFFAOYSA-N n-[5-[(dimethylamino)methyl]-1,3-thiazol-2-yl]-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound S1C(CN(C)C)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(C)(=O)=O)CC1CCOCC1 YXDGDMQWAVMTTO-UHFFFAOYSA-N 0.000 description 1
- LMZSZRZWHUWWQA-UHFFFAOYSA-N n-isoquinolin-1-yl-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1C2=CC=CC=C2C=CN=1)CC1CCOCC1 LMZSZRZWHUWWQA-UHFFFAOYSA-N 0.000 description 1
- YZSRHTOCBWUYMP-UHFFFAOYSA-N n-isoquinolin-3-yl-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=O)NC=1N=CC2=CC=CC=C2C=1)CC1CCOCC1 YZSRHTOCBWUYMP-UHFFFAOYSA-N 0.000 description 1
- DYZJDUAUOJFJBV-UHFFFAOYSA-N n-methoxy-n-methyl-2-[[2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]amino]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)N(C)OC)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(C)(=O)=O)CC1CCOCC1 DYZJDUAUOJFJBV-UHFFFAOYSA-N 0.000 description 1
- TUEFJBUYCDTOSH-LFIBNONCSA-N n-methyl-2-[[(e)-2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)prop-2-enoyl]amino]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NC)=CN=C1NC(=O)C(\C=1C=CC(=CC=1)S(C)(=O)=O)=C\C1CCOCC1 TUEFJBUYCDTOSH-LFIBNONCSA-N 0.000 description 1
- RVGZUJLRHUHOBT-UHFFFAOYSA-N n-methyl-2-[[2-(4-methylsulfonylphenyl)-3-(oxan-4-yl)propanoyl]amino]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NC)=CN=C1NC(=O)C(C=1C=CC(=CC=1)S(C)(=O)=O)CC1CCOCC1 RVGZUJLRHUHOBT-UHFFFAOYSA-N 0.000 description 1
- POCVXQZQQIYCLC-UHFFFAOYSA-N n-methyl-4-[3-(oxan-4-yl)-1-oxo-1-(1,3-thiazol-2-ylamino)propan-2-yl]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C(C(=O)NC=1SC=CN=1)CC1CCOCC1 POCVXQZQQIYCLC-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- HZIVRQOIUMAXID-UHFFFAOYSA-N oxocane Chemical compound C1CCCOCCC1 HZIVRQOIUMAXID-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- AFOGBLYPWJJVAL-UHFFFAOYSA-N phenbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AFOGBLYPWJJVAL-UHFFFAOYSA-N 0.000 description 1
- 229950008557 phenbutamide Drugs 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DHHKPEUQJIEKOA-UHFFFAOYSA-N tert-butyl 2-[6-(nitromethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetate Chemical compound C1C=CC2C(CC(=O)OC(C)(C)C)(C[N+]([O-])=O)CC21 DHHKPEUQJIEKOA-UHFFFAOYSA-N 0.000 description 1
- GSFHMVIECSQBLV-UHFFFAOYSA-N tert-butyl 4-[4-[1-[(5-chloro-1,3-thiazol-2-yl)amino]-3-(oxan-4-yl)-1-oxopropan-2-yl]phenyl]sulfonylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(C(CC2CCOCC2)C(=O)NC=2SC(Cl)=CN=2)C=C1 GSFHMVIECSQBLV-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 1
- NNLBRYQGMOYARS-UHFFFAOYSA-N thiane 1-oxide Chemical compound O=S1CCCCC1 NNLBRYQGMOYARS-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- AMIGYDGSJCJWSD-UHFFFAOYSA-N thiocane Chemical compound C1CCCSCCC1 AMIGYDGSJCJWSD-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 150000007934 α,β-unsaturated carboxylic acids Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Spojevi formule (I) ili njihove farmaceutski prihvatljive soli korisni su u profilaktičkom ili terapijskom tretmanu hiperglikemije i dijabetesa.
Description
Pozadina izuma
Ovaj se izum odnosi na tri(ciklo)-supstituirane amidne spojeve. Specifično, ovaj izum usmjeren je prema amidnim spojevima supstituiranima i) na karbonilnom ugljiku etilnom/etenilnom grupom vezanom na fenilni prsten i arilni/heteroarilni/heterociklički prsten, i ii) na amino-grupi, s dušikom koji nosi heteroarilni prsten, a koji su modulatori glukokinaze i korisni su u profilaksi ili terapeutskom tretmanu hiperglikemije i dijabetesa tipa II.
Glukokinaza ("GK") se smatra važnom u regulaciji razine glukoze u plazmi.GK, koja se nalazi uglavnom u jetri i gušterači, jedna je od četiri heksokinaze koja katalizira početni metabolizam glukoze. GK put zasićen je pri višim razinama glukoze u odnosu na druge heksokinazne puteve (v. R.L.Printz i sur., Annu. Rev. Nutr., 13:463-496 (1993)). GK je kritična za održavanje ravnoteže glukoze u sisavaca. Životinje koje ne eksprimiraju GK umiru ubrzo nakon rođenja s dijabetesom, dok životinje koje prekomjerno eksprimiraju GK imaju poboljšanu toleranciju na glukozu. Aktivacija GK može dovesti do hiperinzulinemičke hipoglikemije. (V., na primjer, H.B.T. Christesen i sur., Diabetes, 51:1240-1246 (2002)). Nadalje, dijabetes tipa II u mladih uzrokovan je mutacijama s gubitkom funkcije u genu za GK, što upućuje da GK djeluje kao senzor glukoze u ljudi. (Y. Liang i sur., Biochem. J. 309:167-173 (1995)). Tako spojevi koji aktiviraju GK povećavaju osjetljivost GK senzornog sustava i bili bi korisni u liječenju hiperglikemije - naročito hiperglikemije povezane s dijabetesom tipa II. Prema tome, poželjno je stvoriti nove spojeve koji aktiviraju GK da bi se liječio dijabetes.
Međunarodna patentna publikacija br. WO 2001/044216 i U.S. patent br. 6 353 111 opisuju (E)-2,3-disupstituirane-N-heteroarilakrilamide kao aktivatore GK. Međunarodna patentna publikacija br. WO 2002/014312 i U.S. patenti br. 6 369 232, 6 388 088 i 6 441 180 opisuju tetrazolilfenilacetamidne aktivatore GK. Međunarodna patentna publikacija br. WO 2000/058293, Europska patentna prijava br. EP 1169312 i U.S. patent br. 6 320 050 opisuju aricikloalkilpropionamidne aktivatore GK. Međunarodna patentna publikacija br. 2002/008209 i U.S. patent br. 6 486 184 opisuju alfa-acil i alfa-heteroatom-supstituirane benzen-acetamidne aktivatore GK kao antidijabetička sredstva. Međunarodna patentna publikacija br. WO 2001/083478 opisuje aktivatore GK koji sadrže hidantoin. Međunarodna patentna publikacija br. WO 2001/083465 i U.S. patent br. 6 388 071 opisuju alkilfenilne heteroaromatske aktivatore GK. Međunarodna patentna publikacija br. WO 2001/085707 i U.S. patent br. 6 489 485 opisuju para-amin-supstituirane fenilamidne aktivatore GK. Međunarodna patentna publikacija br. WO 2002/048106 i U.S. patent br. 6 482 951 opisuju izoindolin-1-onske aktivatore GK. Međunarodna patentna publikacija br. WO 2001/085706 opisuje supstituirane fenilacetamidne aktivatore GK za liječenje dijabetesa tipa II. U.S. patent br. 6 384 220 opisuje para-aril ili heteroaril-supstituirane fenilne aktivatore GK. Francuski patent br. 2 834 295 opisuje postupke za pročišćavanje i kristalnu strukturu ljudske GK. Međunarodna patentna publikacija br. WO 2003/095438, objavljena nakon prioritetnog datuma ove prijave, opisuje N-heteroarilne fenilacetamide i srodne spojeve kao aktivatore GK za liječenje dijabetesa tipa II. U.S. patent br. 6 610 846 opisuje pripremu cikloalkilheteroarilnih propionamida kao aktivatora GK. Međunarodna patentna publikacija br. WO 2003/000262 opusuje vinil-fenilne aktivatore GK. Međunarodna patentna publikacija br. WO 2003/000267 opisuje aminonikotinatne derivate kao modulatore GK. Međunarodna patentna publikacija br. WO 2003/015774, objavljena nakon prioritetnog datuma ove prijave, opisje spojeve kao modulatore GK. Međunarodna patentna publikacija br. WO 2003/047626, objavljena nakon prioritetnog datuma ove prijave, opisuje uporabu aktivatora GK u kombinaciji s antagonistom glukagona za liječenje dijabetesa tipa II. Međunarodna patentna publikacija br. WO 2003/055482, objavljena nakon prioritetnog datuma ove prijave, opisuje amidne derivate kao aktivatore GK. Međunarodna patentna publikacija br. WO 2003/080585, objavljena nakon prioritetnog datuma ove prijave, opisuje aminobenzamidne derivate s aktivnošću GK za liječenje dijabetesa i gojaznosti. Međunarodna patentna publikacija br. WO 2003/097824, objavljena nakon prioritetnog datuma ove prijave, opisuje kristale GK iz ljudske jetre i njihovu upotrebu za dizajn lijekova na osnovi strukture. Međunarodna patentna publikacija br. WO 2004/002481, objavljena nakon prioritetnog datuma ove prijave, objavljuje arilkarbonilne derivate kao aktivatore GK.
Bit izuma
Spojevi predstavljeni formulom (I):
[image]
ili njihove farmaceutski prihvatljive soli korisni su u profilaksi ili terapijskom tretmanu hiperglikemije i dijabetesa tipa II.
Detaljan opis izuma
Ovaj izum usmjeren je prema spoju formule (I):
[image]
ili njegovim farmaceutski prihvatljivim solima, gdje:
Q je aril, 5- ili 6-člani heteroaril ili 4-8 člani heterociklički prsten;
T, zajedno s -N=C- na koji je vezan, tvori heteroarilni prsten, ili heterociklički prsten, gdje je N=C veza jedino nezasićeno mjesto;
R1 i R2 su, neovisno jedan o drugome, vodik, hidroksi, halogen, cijano, nitro, vinil, etinil, metoksi, OCFnH3-n, -N(C0-4 alkil)(C0-4 alkil), CHO, ili C1-2 alkil po želji supstituiran s 1-5 neovisnih halogenih, hidroksi, cijano, metoksi, -N(C0-2 alkil)(C0-2 alkil), SOCH3 ili SO2CH3 supstituenata; ili R1 i R2 zajedno tvore karbociklički ili heterociklički prsten; ili R1 i R2 mogu zajedno predstavljati kisikov atom vezan na prsten dvostrukom vezom;
R3 i R4 su, neovisno jedan o drugome, vodik, halogen, OCFnH3-n, metoksi, CO2R77, cijano, nitro, CHO, CONR99R100, CON(OCH3)CH3, ili C1-2 alkil, heteroaril, ili C3-7 cikloalkil, po želji supstituiran s 1-5 neovisnih halogenih, hidroksi, cijano, metoksi, -NHCO2CH3 ili -N(C0-2 alkil)(C0-2 alkil) supstituenata; ili R3 i R4 zajedno tvore 5-8-člani aromatski, heteroaromatski, karbociklički ili heterociklički prsten;
R5 i R6 su, neovisno jedan o drugome, vodik, hidroksi, halogen, cijano, nitro, CO2R7, CHO, COR8, C(OH)R7R8, C(=NOR7)R8, CONR9R10, SR7, SOR8, SO2R8, SO2NR9R10, CH2NR9R10, NR9R10, N(C0-4 alkil)SO2R8, NHCOR7, ili C1-4 alkilna grupa, C2-4 alkenilna grupa, C2-4 alkinilna grupa, C1-4 alkoksi grupa, arilna grupa ili heteroarilna grupa, gdje je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, CFnH3-n, aril, heteroaril, -COC1-2 alkil, -CON(C0-2 alkil)(C0-2 alkil), SCH3, SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata; ili R5 i R6 zajedno tvore 5-8-člani karbociklički ili heterociklički prsten;
R7 i R77 su, neovisno jedan o drugome, vodik, ili C1-4 alkilna grupa, C2-4 alkenilna grupa, C2-4 alkinilna grupa, C3-7 cikloalkilna grupa, arilna grupa, heteroarilna grupa, ili 4-7 člana heterociklička grupa, pri čemu je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, C3-7 cikloalkil, 4-7-članih heterocikličkih prstenova, CFnH3-n, arila, heteroarila, CO2H, -COC1-2 alkila, -CON(C0-2 alkil)(C0-2 alkil), SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata;
R8 je C1-4 alkilna grupa, C2-4 alkenilna grupa, C2-4 alkinilna grupa, C3-7 cikloalkilna grupa, arilna grupa, heteroarilna grupa, ili 4-7 člana heterociklička grupa, pri čemu je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, C3-7 cikloalkil, 4-7-članih heterocikličkih prstenova, CFnH3-n, arila, heteroarila, CO2H, -COC1-2 alkila, -CON(C0-2 alkil)(C0-2 alkil), SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata;
R9, R10, R99 i R100 su, neovisno jedan o drugome, vodik, ili C1-4 alkilna grupa, C3-7 cikloalkilna grupa, arilna grupa, heteroarilna grupa, ili 4-7 člana heterociklička grupa, pri čemu je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, C3-7 cikloalkil, 4-7 članih heterocikličkih prstenova, CFnH3-n, arila, heteroarila, -COC1-2 alkila, -CON(C0-2 alkil)(C0-2 alkil), SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata; ili R9 i R10 ili R99 i R100 zajedno tvore 6-8-člani heterobiciklički prstenasti sustav ili 4-8-člani heterociklički prsten koji je po želji supstituiran s 1-2 neovisna C1-2 alkila, CH2OCH3, COC0-2 alkila, hidroksi ili SO2CH3 supstituenta;
n je 1, 2 ili 3;
m je 0 ili 1; a
iscrtkana linija zajedno s punom linijom tvori eventualnu dvostruku vezu, a Δ znači da dvostruka veza ima (E)-konfiguraciju.
Ukoliko iscrtkana linija zajedno s punom linijom tvori jednostruku vezu, ugljikov atom koji povezuje arilni prsten i bočni ogranak koji nosi Q-grupu, s karbonilnim atomom, predstavlja kiralni centar. U skladu s time, spoj može biti prisutan bilo kao racemat, bilo kao pojedinačni enantiomer u (R)- ili (S)-konfiguraciji. Poželjniji su (R)-enantiomeri.
Posebna grupa spojeva koju treba spomenuti su spojevi formule (I), ili njihove farmaceutski prihvatljive soli, u kojima je Q nesupstituirani 5- ili 6-člani heterociklički prsten koji sadrži jedan heteroatom izabran između O, S i S=O;
T zatvara 5- ili 6-člani heteroarilni prsten koji je nesupstituiran ili monosupstituiran halogenom, metoksi, CO2-C0-4 alkilom, cijano, nitro, CONH2, CONH-C1-4 alkilom, perfluoroC1-2 alkilom, ili C1-2 alkilom, eventualno monosupstituiranim metoksi ili -NH(C0-2)alkilom;
R5 i R6 su, neovisno jedan o drugome, vodik, hidroksi, halogen, cijano, nitro, CO2-C1-4 alkil, S-C1-4 alkil, S-perfluoroC1-4 alkil, SO-C1-4 alkil, SO2-C1-4 alkil, SO2-perfluoroC1-4 alkil, SO2NH2, NH2, C1-4 alkil, perfluoroC1-4 alkil, C1-4 alkoksi ili perfluoroC1-4 alkoksi; a
m je 0;
a iscrtkana linija, zajedno s punom linijom, mora činiti dvostruku vezu.
U prvom aspektu, ovaj izum usmjeren je na spoj predstavljen formulom (Ia):
[image]
ili njegovu farmaceutski prihvatljivu sol, pri čemu su Q, T, R1-R6, m i Δ kako je definirano ranije za formulu (I).
U jednom ostvarenju prvog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ia) ili njegovu farmaceutski prihvatljivu sol, gdje je Q aril.
U drugom ostvarenju prvog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ia) ili njegovu farmaceutski prihvatljivu sol, gdje je Q 5- ili 6-člani heteroarilni prsten.
U još jednom ostvarenju prvog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ia) ili njegovu farmaceutski prihvatljivu sol, gdje je Q tienilni, furilni, tiazolilni ili piridilni prsten.
U još jednom ostvarenju prvog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ia) ili njegovu farmaceutski prihvatljivu sol, gdje je Q 4-8-člani heterociklički prsten.
U još jednom ostvarenju prvog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ia) ili njegovu farmaceutski prihvatljivu sol, gdje je Q tetrahidropiranil, piperidinil, tetrahidrotiopiranil, 1-okso-tetrahidrotiopiranil ili 1,1-diokso-tetrahidrotiopiranil.
U drugom aspektu, ovaj izum usmjeren je na spoj predstavljen formulom (Ib):
[image]
ili njegovu farmaceutski prihvatljivu sol, pri čemu su Q, T, R1-R6, m i Δ kako je definirano ranije za formulu (I).
U jednom ostvarenju drugog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ib) ili njegovu farmaceutski prihvatljivu sol, gdje je Q 5- ili 6-člani heteroarilni prsten.
U drugom ostvarenju drugog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ib) ili njegovu farmaceutski prihvatljivu sol, gdje je Q tienilni, furilni, tiazolilni ili piridilni prsten.
U još jednom ostvarenju drugog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ib) ili njegovu farmaceutski prihvatljivu sol, gdje je Q 4-8-člani heterociklički prsten.
U još jednom ostvarenju drugog aspekta, ovaj izum usmjeren je na spoj predstavljen formulom (Ib) ili njegovu farmaceutski prihvatljivu sol, gdje je Q tetrahidropiranil, piperidinil, tetrahidrotiopiranil, 1-okso-tetrahidrotiopiranil ili 1,1-diokso-tetrahidrotiopiranil.
Molekulska masa spojeva formule (I) poželjno je manja od 800, još bolje manja od 600, a najbolje manja od 500.
U ovom izumu, poželjno je da je Q 2-furil, 2-tienil, tetrahidropiranil, tetrahidrotiopiranil, 1-okso-tetrahidrotiopiranil ili 1,1-diokso-tetrahidrotiopiranil; bolje 4-tetrahidropiranil ili 4-tetrahidrotiopiranil, a najbolje 4-tetrahidropiranil.
Kad je Q heteroaril ili heterociklička grupa, poželjno je da je vezan na (CH2)m-grupu preko ugljikovog atoma.
Kad je Q heteroarilna grupa, poželjno je da nema supstituent R1 ili R2 koji bi bio različit od vodika, na položaju susjednom od točke vezanja na -(CH2)m-grupu.
U ovom izumu, poželjno je da je grupa formule
[image]
monociklička heteroarilna grupa. Bolje je da je to tiazolil, tiadiazolil, oksazolil, izoksazolil, pirimidinil, pirazinil ili piridil; još bolje 2-tiazolil, 5-[1,2,4]tiadiazolil, 2-[1,3,4]tiadiazolil, 4-pirimidinil, 2-pirazinil, 3-izoksazolil ili 2-piridil; još su bolji 2-tiazolil, 5-[1,2,4]tiadiazolil, 4-pirimidinil, 2-pirazinil ili 2-piridil; najbolje 2-tiazolil, 2-pirazinil ili 2-piridil.
Bolje je da je grupa formule
[image]
2-tiazolil ili 2-pirazinil.
Najbolje je da je grupa formule
[image]
2-tiazolil, R3 je 5-fluoro, a R4 je vodik; ili 2-pirazinil, pri čemu su R3 i R4 vodik; naročito je poželjan 2-tiazolil dok je R3 5-fluoro, a R4 je vodik.
U ovom izumu, poželjno je da su R1 i R2 vodik.
U ovom izumu, poželjno je da su R3 i R4 neovisno izabrani između vodika, halogena i metila, a još je bolje da su R3 i R4 neovisno izabrani između vodika, fluora i metila.
U ovom izumu, poželjno je da je R3 vodik ili halogen; poželjnije je da je vodik, fluor, klor ili brom; još je bolje da je vodik, fluor ili klor; najbolje vodik ili fluor.
U ovom izumu, poželjno je da je R4 vodik, halogen ili metil; bolje da je vodik ili metil.
U ovom izumu poželjno je da R5 i R6 nisu oba vodik.
U ovom izumu, poželjno je da je R5 CF3, SOR8, SO2R8, SO2NR9R10, NHSO2R8 ili triazolil; bolje da je SOR8, SO2R8 ili SO2NR9R10; najbolje SO2R8 ili SO2NR9R10; naročito SO2R8.
Naročito je R5 SO2C3-4cikloalkil, naročito SO2ciklopropil.
U ovom izumu, poželjno je da je R6 vodik, klor, fluor ili trifluorometil; najbolje vodik.
U ovom izumu, poželjno je da su R7, R77 i R8 C1-4 alkil, C3-7 cikloalkil, heteroaril, ili 4-7-člana heterociklička grupa; bolje C1-3 alkil, 4-6-člana heterociklilčka grupa ili C3-5 cikloalkil; najbolje metil, etil, n-propil, ciklopropil, ciklobutil, oksetanil ili tetrahidrofuril, a naročito metil, etil, n-propil, ciklopropil ili ciklobutil.
Kad iscrtkana linija zajedno s punom linijom tvori dvostruku vezu, poželjno je da je R8 C1-3 alkil ili C3-4 cikloalkil.
Kad iscrtkana linija zajedno s punom linijom tvori jednostruku vezu, poželjno je da je R8 C3-4cikloalkil, naročito ciklopropil.
Kad je R5 i/ili R6 CO2R7 ili SR7, poželjno je da R7 nije vodik.
U ovom izumu, poželjno je da su R9 i R10 neovisno jedan o drugome C0-4 alkil, npr. jedan od R9 i R10 je vodik, a drugi je etil, ili su spojeni i tvore 4-8-člani heterociklički prsten. Bolje je da R9 i R10 nisu istovremeno oba vodik.
U ovom izumu, poželjno je da su R99 i R100 C0-4 alkil.
U ovom izumu, poželjno je da je m 0.
U ovom izumu, poželjno je da je n 2 ili 3.
Poželjna grupa spojeva su spojevi formule (I) ili njihove farmaceutski prihvatljive soli, gdje:
Q je 4-tetrahidropiranil;
T, zajedno s -N=C- na koji je vezan tvori 2-pirazinilni ili 2-tiazolilni prsten.
R1 i R2 su vodik;
R3 i R4 su, neovisno jedan o drugome, vodik ili fluor;
R5 je SO2R8 ili SO2NR9R10;
R6 je vodik;
R8 je C3-5 cikloalkilna grupa ili 4-6-člana heterociklička grupa, a kad iscrtkana linija zajedno s punom linijom tvori dvostruku vezu, R8 može biti C1-3 alkilna grupa.
R9 i R10 su, neovisno jedan o drugome, C0-4 alkil, uz uvjet da R9 i R10 nisu istovremeno oba vodik;
m je 0, a
iscrtkana linija, zajedno s punom linijom tvori eventualnu dvostruku vezu, a Δ upućuje da dvostruka veza ima (E)-konfiguraciju.
Još poželjnija grupa spojeva su spojevi formule (I), ili njihove farmaceutski prihvatljive soli, gdje:
Q je 4-tetrahidropiranil;
T, zajedno s -N=C- na koji je vezan tvori 2-pirazinilni ili 2-tiazolilni prsten.
R1 i R2 su vodik;
R3 i R4 su, neovisno jedan o drugome, vodik ili fluor;
R5 je SO2R8;
R6 je vodik;
R8 je C3-5 cikloalkilna grupa, a kad iscrtkana linija zajedno s punom linijom tvori dvostruku vezu, R8 može biti C1-3 alkilna grupa.
m je 0, a
iscrtkana linija, zajedno s punom linijom tvori eventualnu dvostruku vezu, a Δ upućuje da dvostruka veza ima (E)-konfiguraciju.
Specifični spojevi ovog izuma koji se mogu spomenuti su oni opisani u Primjerima, naročito u Primjerima 1 do 201, kao i njihove farmaceutski prihvatljive soli.
Specifični spojevi ovog izuma koji se mogu spomenuti su:
(2R)-2-(4-ciklopropansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid; i
(E)-N-(5-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
ili njihove farmaceutski prihvatljive soli.
Naročito su poželjni spojevi:
(2R)-2-(4-ciklopropansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid; i
(E)-N-(5-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
ili njihove farmaceutski prihvatljive soli.
Dok su poželjne grupe za svaku varijablu općenito navedene ranije, odvojeno za svaku varijablu, poželjni spojevi ovog izuma uključuju one u kojima su neke ili svaka od varijabli u formuli (I) izabrane između poželjnih, poželjnijih ili najpoželjnijih, posebno i naročito nabrojanih grupa za svaku varijablu. Prema tome, ovaj izum uključuje sve kombinacije poželjnih, poželjnijih ili najpoželjnijih, posebno i naročito nabrojanih grupa.
Kako je ovdje korišteno, ukoliko nije drukčije naznačeno, "alkil", kao i ostale grupe s prefiksom "alk", kao, na primjer, alkoksi, alkanil, alkenil, alkinil i slično, označava lanac ugljika koji može biti linearan ili razgranat ili njihove kombinacije. Primjeri alkilnih grupa uključuju metil, etil, propil, izopropil, butil, sec- i terc-butil, pentil, heksil, heptil i slično. "Alkenil", "alkinil" i drugi slični izrazi uključuju ugljikove lance s bar jednom nezasićenom ugljik-ugljik vezom.
Kako je ovdje korišteno, na primjer, "C0-4 alkil" označava alkil s 0 do 4 ugljikova atoma, to jest, 0, 1, 2, 3 ili 4 ugljika u ravnoj ili razgranatoj konfiguraciji. Alkil koji nema ugljika je vodik, kad je alkil terminalna grupa. Alkil bez ugljika je direktna veza kad je alkil premošćujuća (povezna) grupa.
Izrazi "cikloalkil" i "karbociklički prsten" označavaju karbocikle koji ne sadrže heteroatome, a uključuju mono-, bi- i tricikličke zasićene karbocikle, kao i spojene sustave i sustave s mostom. Takvi spojeni prstenasti sustavi mogu uključivati jedan prsten koji je djelomično ili potpuno nezasićen, kao što je benzenski prsten, koji tvori spojeni prstenasti sustav, kao što su benzofuzionirani karbocikli. Cikloalkil uključuje takve spojene prstenaste sustave kao spiro-prstenaste spojeve. Primjeri cikloalkila i karbocikličkih prstenova uključuju C3-8 cikloalkile, kao što su ciklopropil, ciklobutil, ciklopentil, cikloheksil i dekahidronaftalen, adamantan, indanil, 1,2,3,4-tetrahidronaftalen i slično.
Izraz "halogen" uključuje atome fluora, klora, broma i joda.
Izraz "aril" uključuje, na primjer, fenil i naftil.
Ukoliko nije drukčije naznačeno, izraz "heterociklički prsten" uključuje 4-8-člane zasićene prstenove koji sadrže jedan ili dva heteroatoma izabrana između kisika, sumpora i dušika. Heteroatomi nisu direktno međusobno povezani. Primjeri heterocikličkih prstenova uključuju oksetan, tetrahidrofuran, tetrahidropiran, oksepan, oksokan, tietan, tetrahidrotiofen, tetrahidrotiopiran, tiepan, tiokan, azetidin, pirolidin, piperidin, azepan, azokan, [1,3]dioksan, oksazolidin, piperazin i slično. Ostali primjeri heterocikličkih prstenova uključuju oksidirane oblike prstenova koji sadrže sumpor. Tako se za tetrahidrotiofen-1-oksid, tetrahidrotiofen-1,1-dioksid, tetrahidrotiopiran-1-oksid i tetrahidrotiopiran-1,1-dioksid također smatra da su heterociklički prstenovi.
Ukoliko nije drukčije naznačeno, izraz "heteroaril" uključuje 5- ili 6-člane heteroarilne prstenove koji sadrže 1-4 heteroatoma izabrana između kisika, sumpora i dušika. Primjeri takvih heteroarilnih prstenova su furil, tienil, pirolil, pirazolil, imidazolil, oksazolil, izoksazolil, tiazolil, izotiazolil, triazolil, oksadiazolil, tiadiazolil, tetrazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil.
Gornje formule prikazane su bez konačne stereokemije na nekim položajima. Ovaj izum uključuje sve stereoizomere (npr. geometrijske izomere, optičke izomere, dijastereoizomere itd.) i njihove farmaceutski prihvatljive soli, osim kad je specifično navedeno ili nacrtano drugačije. Nadalje, također su uključene smjese stereoizomera, kao i izolirani specifični stereoizomeri, osim kad je specifično navedeno ili nacrtano drugačije. Tijekom sintetskih postupaka korištenih za pripremu takvih spojeva, ili postupaka racemizacije ili epimerizacije, koji su poznati stručnjacima područja, produkti takvih postupaka mogu biti smjesa stereoizomera. Kad postoji tautomer spoja gornjih formula, ovaj izum uključuje bilo koji mogući tautomer i njegove farmaceutski prihvatljive soli, kao i njihove smjese, osim kad je specifično navedeno ili nacrtano drugačije. Kad spoj gornjih formula i njihove farmaceutski prihvatljive soli postoje u obliku solvata ili polimorfnih oblika, ovaj izum uključuje sve moguće solvate i polimorfne oblike. Vrsta otapala koja tvori solvat nije naročito ograničena, sve dok je otapalo farmakološki prihvatljivo. Na primjer, mogu se koristiti voda, etanol, propanol, aceton ili slično.
Budući da su spojevi formule (I) namijenjeni za farmaceutsku primjenu, poželjno je da su pripremljeni u čistom obliku, na primjer, najmanje 60% čistoće, još bolje najmanje 75% čistoće, a naročito najmanje 98% čistoće (% se temelji na masi).
Izum također obuhvaća farmaceutski pripravak koji sadrži spoj formule (I) ili njegovu farmaceutski prihvatljivu sol u kombinaciji s farmaceutski prihvatljivim nosačem.
Poželjno je da pripravak sadrži farmaceutski prihvatljiv nosač i netoksičnu, terapijski učinkovitu količinu spoja formule (I) kako je ranije opisano, ili njegove farmaceutski prihvatljive soli.
Nadalje, unutar tog poželjnog ostvarenja, izum obuhvaća farmaceutski pripravak za profilaksu ili liječenje hiperglikemije i dijabetesa aktivacijom GK, koji sadrži farmaceutski prihvatljiv nosač i netoksičnu, terapijski učinkovitu količinu spoja formule (I) kako je ranije opisano, ili njegove farmaceutski prihvatljive soli.
Izum također daje upotrebu spoja formule (I) ili njegove farmaceutski prihvatljive soli, kao farmaceutika.
Spojevi i pripravci ovog izuma učinkoviti su u liječenju hiperglikemije u sisavaca, kao što su, na primjer, ljudi.
Izum također daje postupak profilaktičkog ili terapijskog tretmana stanja u kojem je poželjna aktivacija GK, što obuhvaća korak primjene učinkovite količine spoja formule (I) ili njegove farmaceutski prihvatljive soli.
Izum također daje postupak prevencije dijabetesa u čovjeka koji pokazuje predijabetičku hiperglikemiju ili smanjenu toleranciju glukoze, što obuhvaća korak primjene profilaktički učinkovite količine spoja formule (I) ili njegove farmaceutski prihvatljive soli.
Izum također daje upotrebu spoja formule (I) ili njegove farmaceutski prihvatljive soli kao aktivatora GK.
Izum također daje upotrebu spoja formule (I) ili njegove farmaceutski prihvatljive soli za profilaktički ili terapijski tretman hiperglikemije ili dijabetesa.
Izum također daje upotrebu spoja formule (I) ili njegove farmaceutski prihvatljive soli u prevenciji dijabetesa u čovjeka koji pokazuje predijabetičku hiperglikemiju ili smanjenu toleranciju glukoze.
Izum također daje upotrebu spoja formule (I) ili njegove farmaceutski prihvatljive soli u proizvodnji lijeka za aktivaciju GK.
Izum također daje upotrebu spoja formule (I) ili njegove farmaceutski prihvatljive soli u proizvodnji lijeka za profilaktički ili terapijski tretman hiperglikemije ili dijabetesa.
Izum također daje upotrebu spoja formule (I) ili njegove farmaceutski prihvatljive soli u proizvodnji lijeka za prevenciju dijabetesa u čovjeka koji pokazuje predijabetičku hiperglikemiju ili smanjenu toleranciju glukoze.
Spojevi i pripravci ovog izuma mogu se po želji upotrijebiti u kombinaciji s jednim ili više drugih antidijabetičkih ili antihiperglikemičkih sredstava, koji uključuju, na primjer, sulfonilureje (npr. gliburid, glimepirid, glipirid, glipizid, klorpropamid, gliklazid, glizoksepid, acetoheksamid, glibornurid, tolbutamid, tolazamid, karbutamid, glikvidon, gliheksamid, fenbutamid, tolciklamid, itd.), bigvanide (npr. metformin, fenformin, buformin, itd.), antagoniste glukagona (npr. peptidni ili nepeptidni antagonist glukagona), inhibitore glukozidaze (npr. akarboza, miglitol, itd.), sekretagoge inzulina, senzitizatore inzulina (npr. troglitazon, roziglitazon, pioglitazon, itd.) i slično, ili sredstva protiv gojaznosti (npr. sibutramin, orlistat, itd.) i slično. Spojevi i pripravci ovog izuma i druga antidijabetička ili antihiperglikemička sredstva mogu se primijeniti istovremeno, uzastopce ili odvojeno.
Izraz "farmaceutski prihvatljive soli" odnosi se na soli pripremljene iz farmaceutski prihvatljivih, netoksičnih baza ili kiselina. Kad je spoj ovog izuma kiseli, njegova odgovarajuća sol može se uobičajeno pripremiti iz farmaceutski prihvatljivih, netoksičnih baza, uključujući anorganske i organske baze. Soli dobivene iz takvih anorganskih baza uključuju aluminijeve, amonijeve, kalcijeve, bakrene, željezne, litijeve, magnezijeve, manganove, kalijeve, natrijeve, cinkove i slične soli. Naročito su poželjne amonijeve, kalcijeve, magnezijeve, kalijeve i natrijeve soli. Soli dobivene iz farmaceutski prihvatljivih organskih netoksičnih baza uključuju soli primarnih, sekundarnih i tercijarnih amina, kao i cikličkih amina te supstituiranih amina, kao što su prirodni i sintetski amini. Ostale farmaceutski prihvatljive organske netoksične baze koje su pogodne za dobivanje soli uključuju, na primjer, arginin, betain, kafein, kolin, N',N'-dibenziletilendiamin, dietilamin, 2-dietilaminoetanol, 2-dimetilaminoetanol, etanolamin, etilendiamin, N-etilmorfolin, N-etilpiperidin, glukamin, glukozamin, histidin, izopropilamin, lizin, metilglukamin, morfolin, piperazin, piperidin, poliaminske smole, prokain, purine, teobromin, trietilamin, trimetilamin, tripropilamin, trometamin i slično.
Kad je spoj ovog izuma bazičan, njegova odgovarajuća sol može se uobičajeno pripremiti iz farmaceutski prihvatljivih, netoksičnih kiselina, uključujući anorganske i organske kiseline. Takve kiseline uključuju, na primjer, octenu, benzensulfonsku, benzojevu, kamforsulfonsku, limunsku, etansulfonsku, fumarnu, glukonsku, glutaminsku, bromovodičnu, klorovodičnu, izetionsku, mliječnu, maleinsku, maličnu, mandeličnu, metansulfonsku, mucičnu, dušičnu, pamoičnu, pantotensku, fosfornu, sukcinsku, sumpornu, tartarnu, p-toluensulfonsku kiselinu i slično. Naročito su poželjne limunska, bromovodična, klorovodična, maleinska, fosforna, sumporna, metansulfonska i tartarna kiselina.
Farmaceutski pripravci ovog izuma obuhvaćaju spoj formule (I), ili njegovu farmaceutski prihvatljivu sol, kao aktivni sastojak, farmaceutski prihvatljiv nosač i eventualno druge terapijske sastojke ili dodatke. Pripravci uključuju sastave prikladne za oralnu, rektalnu, topikalnu i parenteralnu (uključujući supkutanu, intramuskularnu i intravensku) primjenu, kao i primjenu putem inhaliranja, iako najprikladniji put u svakom pojedinom slučaju ovisi o domaćinu, prirodi i težini stanja za koje se aktivni sastojak primjenjuje. Farmaceutski pripravci mogu se uobičajeno davati u jedinici doziranja, a pripremaju se postupcima dobro poznatima farmaceutskoj struci.
Poželjno je da su farmaceutski pripravci u skladu s ovim izumom prilagođeni oralnoj primjeni.
U praksi, spojevi formule (I) ovog izuma ili njihove farmaceutski prihvatljive soli, mogu se kombinirati kao aktivni sastojak u smjesi s farmaceutskim nosačem u skladu s uobičajenim farmaceutskim tehnikama. Nosač može imati razne oblike, ovisno o željenom obliku pripravka koji se primjenjuje, npr. za oralnu ili parenteralnu (uključujući intravensku) primjenu. Tako farmaceutski pripravci ovog izuma mogu biti prisutni kao diskretne jedinice prikladne za oralnu primjenu, kao što su kapsule, sašete ili tablete, pri čemu svaka od njih sadrži predodređenu količinu aktivnog sastojka. Nadalje, pripravci mogu biti prisutni kao prah, kao granule, kao otopina, kao suspenzija u vodenoj tekućini, kao bezvodna tekućina, kao emulzija ulja u vodi, ili kao tekuća emulzija vode u ulju. Osim navedenih uobičajenih oblika doziranja, spoj predstavljen formulom (I), ili njegova farmaceutski prihvatljiva sol, mogu također biti primijenjeni putem sredstava za kontrolirano otpuštanje/doziranje. Pripravci mogu biti pripremljeni bilo kojim farmaceutskim postupkom. Općenito, takvi postupci uključuju korak povezivanja aktivnog sastojka s nosačem, kojeg čini jedan ili više potrebnih sastojaka. Općenito, pripravci se pripremaju uniformnim miješanjem aktivnog sastojka s tekućim nosačim ili fino razdijeljenim krutim nosačima, ili oboje. Produkt se zatim može oblikovati u željeni oblik prezentacije na uobičajeni način.
Tako farmaceutski pripravci ovog izuma mogu uključivati farmaceutski prihvatljiv nosač i spoj formule (I), ili njegovu farmaceutski prihvatljivu sol. Spojevi formule (I), ili njihove farmaceutski prihvatljive soli mogu također biti uključene u farmaceutske pripravke u kombinaciji s jednim ili više drugih terapijski aktivnih spojeva.
Farmaceutski pripravci ovog izuma uključuju farmaceutski prihvatljivu liposomalnu formulaciju koja sadrži spoj formule (I) ili njegovu farmaceutski prihvatljivu sol.
Upotrijebljeni farmaceutski nosač može biti, na primjer, krutina, tekućina ili plin. Primjeri krutih nosača su laktoza, terra alba, saharoza, talk, želatina, agar, pektin, akakija, magnezijev stearat i sterinska kiselina. Primjeri tekućih nosača su šećerni sirup, ulje kikirikija, maslinovo ulje i voda. Primjeri plinovitih nosača uključuju ugljični dioksid i dušik.
U pripremi pripravaka za oralno doziranje može se upotrijebiti bilo koji uobičajeni farmaceutski medij. Na primjer, moguće je koristiti vodu, glikole, ulja, alkohole, sredstva za dodavanje okusa, konzervanse, boje i slično za dobivanje oralnih tekućih pripravaka kao što su suspenzije, eliksiri i otopine; dok se nosači kao što su škrobovi, šećeri, mikrokristalna celuloza, diluenti, sredstva za granulaciju, lubrikanti, veziva, dezintegrirajuća sredstva i slično mogu koristiti za pripremu oralnih krutih pripravaka, kao što su prašci, kapsule i tablete, Zbog lakoće primjene, tablete i kapsule su poželjne jedinice za oralno doziranje kad se koriste kruti farmaceutski nosači. Tablete po želji mogu biti obložene uobičajenim vodenim ili bezvodnim postupcima.
Tableta koja sadrži pripravak ovog izuma može se pripremiti komprimiranjem ili oblikovanjem u kalupu, po želji uz jedan ili više dodatnih sastojaka ili primjesa. Komprimirane tablete mogu se pripremiti kompresijom u prikladnom stroju, pri čemu se aktivni sastojak, u slobodno lebdećem obliku, kao što su prašak ili granule, miješa s vezivom, lubrikantom, inertnim diluentom, aktivnim površinskim sredstvom ili sredstvom za disperziju ili sličnim ekscipijentom. Ti ekscipijenti mogu biti, na primjer, inertni diluenti, kao što su kalcijev karbonat, natrijev karbonat, laktoza, kalcijev fosfat ili natrijev fosfat; sredstva za granulaciju i dezintegraciju, na primjer, kukuruzni škrob ili alginska kiselina; sredstva za vezivanje, na primjer, škrob, želatina ili akakija; te sredstva za vlaženje, na primjer, magnezijev stearat, stearinska kiselina ili talk. Tablete mogu biti neobložene ili mogu biti obložene poznatim tehnikama da bi se odgodila dezintegracija i apsorpcija u gastrointestinalnom traktu, čime se dobiva produljeno djelovanje tijekom vremena. Na primjer, može se koristiti materijal kao što je gliceril-monostearat ili gliceril-distearat.
U kapsulama od tvrde želatine, aktivni sastojak miješa se s inertnim punilom za razrjeđivanje, na primjer, kalcijevim karbonatom, kalcijevim fosfatom ili kaolinom. U kapsulama od meke želatine, aktivni sastojak miješa se s vodenim ili uljnim medijem, na primjer, uljem kikirikija, tekućim parafinom ili maslinovim uljem. Oblikovane tablete mogu se proizvesti oblikovanjem u prikladnom stroju, pri čemu se smjesa spoja u prahu vlaži s inertnim tekućim diluentom. Poželjno je da svaka tableta sadrži od oko 0,05 mg do oko 5 g aktivnog sastojka, a svaka sašeta ili kapsula sadrži od oko 0,05 mg do oko 5 g aktivnog sastojka.
Na primjer, formulacija namijenjena oralnoj primjeni u ljudi može sadržati od oko 0,05 mg do oko 5 g aktivnog sredstva, spojenog s odgovarajućom i uobičajenom količinom nosivog materijala, koja može varirati od oko 5 do oko 95 posto ukupnog pripravka. Oblici jediničnog doziranja općenito sadrže između oko 1 mg do oko 2 g aktivnog sastojka, tipično 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg ili 1000 mg.
Farmaceutski pripravci ovog izuma prikladni za parenteralnu primjenu mogu se pripremiti kao otopine ili supsenzije aktivnih spojeva u vodi. Moguće je uključiti prikladni surfaktant, kao što je, na primjer, hidroksipropilceluloza. Disperzije se mogu pripremiti i u glicerolu, tekućim polietilen-glikolima i njihovim smjesama u ulju. Nadalje, može se dodati i konzervans da bi se spriječio štetan rast mikroorganizama.
Farmaceutski pripravci ovog izuma prikladni za injektabilnu primjenu uključuju sterilne vodene otopine ili disperzije. Nadalje, pripravci mogu biti u obliku sterilnih prašaka za improviziranu pripremu takvih sterilnih injektabilnih otopina ili disperzija. U svim slučajevima, konačni injektabilni oblik mora biti sterilan i efektivno tekuć, za lako uštrcavanje. Farmaceutski pripravci moraju biti stabilni u uvjetima proizvodnje i pohrane; tako je poželjno da su očuvani od kontaminirajućeg djelovanja mikroorganizama, kao što su bakterije i gljivice. Nosač može biti otapalo ili medij za disperziju koji sadrži, na primjer, vodu, etanol, poliol (npr. glicerol, propilen-glikol i tekući polietilen-glikol), biljna ulja i njihove prikladne smjese.
Farmaceutski pripravci ovog izuma mogu biti u obliku prikladnom za topikalnu primjenu, kao što su, na primjer, aerosol, krema, mast, losion, prašak ili slično. Nadalje, pripravci mogu biti u obliku prikladnom za upotrebu pomoću transdermalnih sredstava. Takve formulacije mogu se pripremiti, uz korištenje spoja formule (I) ili njegove farmaceutski prihvatljive soli, putem uobičajenih postupaka. Kao primjer, krema ili mast priprema se miješanjem hidrofilnog materijala i vode zajedno sa spojem u ukupnom udjelu od oko 5% do oko 10% mase, da bi se dobila krema ili mast željene konzistencije.
Farmaceutski pripravci ovog izuma mogu biti u obliku prikladnom za rektalnu primjenu kad je nosač krutina. Poželjno je da su jedinice doziranja smjese čepići. Prikladni nosači uključuju kakaov maslac i druge uobičajeno korištene materijale. Čepići se mogu uobičajeno pripremiti miješanjem pripravka s omekšanim ili rastaljenim nosačem (nosačima), nakon čega slijedi hlađenje i oblikovanje u kalupu.
Farmaceutski pripravci ovog izuma mogu biti u obliku prikladnom za inhalacionu primjenu. Takva primjena može biti u oblicima i uz korištenje nosača opisanih u, na primjer, 1) Particulate Interactions in Dry Powder Formulations for Inhalation, Xian Zeng i sur., 2000, Taylor and Francis; 2) Pharmaceutical Inhalation Aerosol Technology, Anthony Hickey, 1992, Marcel Dekker; 3) Respiratory Drug Delivery, 1990, ur.: P.R. Byron, CRC Press.
Osim prethodno spomenutih sastojaka koji služe kao nosači, opisani farmaceutski pripravci mogu sadržati, kao prikladno, jedan ili više dodataka kao što su diluenti, puferi, sredstva za poboljšanje okusa, veziva, površinski aktivna sredstva, sredstva za zadebljanje, lubrikanti, konzervansi (uključujući antioksidanse) i slično. Nadalje, mogu se uključiti i drugi dodaci koji formulaciju čine izotoničnom s krvlju primatelja. Pripravci koji sadrže spoj formule (I) ili njegove farmaceutski prihvatljive soli mogu se također pripremiti u koncentriranom obliku kao prah ili tekućina.
Općenito, razine doziranja reda veličine od oko 0,01 mg/kg do oko 150 mg/kg tjelesne težine dnevno korisne su u liječenju gore navedenih stanja, ili alternativno, oko 0,5 mg do oko 10 g po pacijentu dnevno. Na primjer, dijabetes se učinkovito može liječiti primjenom od oko 0,01 do 100 mg spoja po kilogramu tjelesne težine dnevno, ili alternativno oko 0,5 mg do oko 7 g po pacijentu dnevno.
Razumije se, međutim, da će specifična razina doziranja za svakog pojedinog pacijenta ovisiti o raznim faktorima, uključujući dob, tjelesnu težinu, općenito zdravstveno stanje, spol, način prehrane, vrijeme i način primjene, brzinu izlučivanja, kombinacije lijekova i težinu bolesti određenog dijabetičkog pacijenta koji kreće u terapiju. Nadalje, razumije se da se spojevi i njihove soli ovog izuma mogu primijeniti i u subterapijskim razinama profilaktički, kad postoji mogućnost hiperglikemičkog stanja.
Spojevi formule (I) pokazuju poboljšana svojstva u usporedbi s poznatim aktivatorima glukokinaze, npr. kako je ilustrirano u ovdje opisanim pokusima. Naročito, spojevi ovog izuma pokazuju poboljšane vrijednosti za Km, Vmax, EC50, maksimalnu aktivaciju (koncentracija glukoze = 5 mM) i/ili maksimalnu redukciju glukoze u krvi pri bazalnim razinama glukoze u krvi (npr, u C57BL/6J miševa), ili druga poboljšana farmakološka svojstva, u usporedbi s poznatim aktivatorima GK.
Eksperimentalni dio
U skladu s ovim izumom, spojevi formule (Ia) mogu se pripremiti slijedeći protokol prikazan na Shemi 1 u nastavku:
[image]
gdje su Q, T, R1-R6, m i Δ kao što je opisano ranije, a R11 je C0-4 alkil.
Aldehidi II i feniloctene kiseline ili esteri III komercijalno su dostupni ili se lako pripremaju poznatim postupcima. Kad Q predstavlja aromatski ili heteroaromatski prsten, IV se može pripremiti Perkinovom reakcijom (G. Karminski-Zamola i sur., Tetrahedron 1982, 38, 1329-1335). U toj reakciji, II se kondenzira s feniloctenom kiselinom III (R11 = C0 alkil) u prisutnosti anhidrida karboksilne kiseline, npr. acetatnog anhidrida, i tercijarne aminske baze, npr. trietilamina, pri refluksu, da bi se dobila akrilna kiselina IV. Alternativno, IV se može pripremiti kondenzacijom II i III (R11 = C0 alkil) pod djelovanjem aminske baze, kao što je piperidin, u toluenu pri refluksu (D. Deschenes i sur., WO 01/46151). Kad je Q heterociklički prsten, α-karbanion feniloctenog estera III (R11 = C1-4 alkil), dobiven pri -78°C u, na primjer, tetrahidrofuranu, djelovanjem jake baze, npr. litijevog diizopropilamida, može se kondenzirati s II da bi se dobio α,β-nezasićeni ester (T. Severin i sur., Chem. Ber. 1985, 118, 4760-4773) koji se može saponificirati uz upotrebu, na primjer, natrijevog hidroksida (W.L. Corbett i sur., WO 01/44216), a da bi se dobio IV.
α,β-nezasićene karboksilne kiseline IV mogu se kondenzirati s heteroaromatskim aminima V, od kojih su mnogi komercijalno dostupni, korištenjem raznih uvjeta sparivanja, npr. karbodiimid-1-hidroksibenzotriazola u N,N-dimetilformamidu uz polimere na 20°C (za reprezentativne procedure, v. http://www.argotech.com/PDF/resin/ps_carbodiimide.pdf i dostupne od Argonaut Technologies, Inc. Foster City, California), da bi dali (Ia).
Spojevi formule (Ib) mogu se dobiti putem prikazanim na Shemi 2 u nastavku:
[image]
gdje su Q, T, R1-R6 i m kao što je opisano ranije, V je CO2R11 ili CO2CH2Ph, a X je kloro, bromo, jodo ili -OSO2R12; pri čemu je R11 kao što je opisano ranije, a R12 je C1-4 alkil, eventualno supstituiran jednim ili više fluora, ili po želji supstituirani aril.
Halidi i sulfonatni esteri VI komercijalno su dostupni ili se lako pripremaju upotrebom poznatih tehnika. Ova alkilirajuća sredstva mogu reagirati s dianionima feniloctenih kiselina VII, dobivenih pri -78°C u tetrahidrofuranu s ≥ 2 ekvivalenta jake baze, kao što je litijev diizopropilamid, da bi izravno dali VIII (F.T. Bizzarro i sur., WO 00/58293). Alternativno, α-karbanion feniloctenog estera VII, dobivenog pri -78°C u tetrahidrofuranu djelovanjem jake baze, kao što je litijev bis(trimetilsilil)amid (L. Snyder i sur. J. Org. Chem. 1994, 59, 7033-7037), može se alkilirati djelovanjem VI da bi dao α-supstituirane estere. Saponifikacija ovih estera uz upotrebu, na primjer, natrijevog hidroksida u vodenom metanolu pri 20°C do refluksa, vodi do karboksilnih kiselina VIII.
Karboksilne kiseline VIII mogu se kondenzirati s heteroaromatskim aminima V uz upotrebu raznih uvjeta sparivanja, npr., karbodiimid-1-hidroksibenzotriazola u N,N-dimetilformamidu uz polimere na 20°C (za reprezentativne procedure, v. http://www.argotech.com/PDF/resin/ps_carbodiimide.pdf i dostupne od Argonaut Technologies, Inc. Foster City, California), da bi dali amide (Ib).
Spoj formule (Ib) ima asimetrični ugljikov atom koji povezuje amidni karbonilni ugljik, arilni prsten i bočni ogranak koji sadrži Q. U skladu s ovim izumom, poželjna stereokonfiguracija na asimetričnom centru je (R).
Ukoliko želimo izolirati čisti (R)- ili (S)-stereoizomer spoja formule (Ib), moguće je razdvojiti racemičnu smjesu kiralnog prekursora karboksilne kiseline VIII bilo kojim uobičajenim kemijskim postupkom i zatim kondenzirati enantiočiste karboksilne kiseline s aminom formule V uz upotrebu reagensa koji uzrokuje zanemarivu racemizaciju. Za ilustraciju, racemični VIII može se kondenzirati kiralnim derivatom oksazolidinona (v., na primjer, F.T. Bizzarro i sur., WO 00/58293) da bi dao smjesu dijastereoizomernih imida koji se mogu razdvojiti bilo kojim uobičajenim postupkom, npr. kromatografijom na koloni. Hidroliza čistih imida daje stereočiste (R)- i (S)-karboksilne kiseline koje se mogu kondenzirati s heterocikličkim aminima V, uz upotrebu reagensa koji svodi racemizaciju kiralnog centra na minimum, npr. benzotriazol-1-il-oksitris(pirolidino)fosfonijevog heksafluorofosfata (J. Coste i sur. Tetrahedron Lett. 1990, 31, 205-208), da bi se dobili enantiočisti (R)- ili (S)-amidi formule (Ib). Alternativno, racemična smjesa amida formule (Ib) može se razdvojiti putem kiralne tekućinske kromatografije visokog učinka, uz upotrebu kiralne stacionarne faze koja se može naručiti od, na primjer, Daicel Chemical Industries, Ltd, Tokyo, Japan.
Dodatni detalji pripreme spojeva formule (I) navedeni su u primjerima.
Spojevi formule (I) mogu se pripremiti pojedinačno ili kao biblioteka spojeva koja sadrži barem 2, na primjer, od 5 do 1000, spojeva, a bolje 10 do 100 spojeva formule (I). Biblioteke spojeva mogu se pripremiti kombinacijskim "podijeli i pomiješaj" pristupom ili višestrukom paralelnom sintezom uz upotrebu otopina ili kemije na čvrstoj fazi, uz upotrebu postupaka poznatih u struci.
Tijekom sinteze spojeva formule (I), labilne funkcionalne grupe međuprodukata, npr. hidroksi, karboksi i amino-grupe mogu se zaštititi. Zaštitne grupe mogu se ukloniti u bilo kojem koraku sinteze spojeva formule (I), ili mogu biti prisutne na konačnom spoju formule (I). Opsežna rasprava o načinima na koje je moguće zaštititi labilne funkcionalne grupe, kao i o postupcima za cijepanje nastalih zaštićenih derivata nalazi se u, na primjer, Protective Groups in Organic Chemistry, T.W. Greene i P.G.M. Wuts, (1991) Wiley-Interscience, New York, 2nd ed.
Bilo koji novi međuprodukt definiran kao ranije također je uključen u opseg ovog izuma.
U skladu sa sljedećim aspektom ovog izuma, dan je spoj formule (IV) i upotreba takvim spojeva u sintezi aktivatora GK:
[image]
gdje su Q, R1, R2, R5, R6, m i Δ kao što je definirano za formulu (I).
Poželjni su spojevi formule (IV) u kojima:
Q je 4-tetrahidropiranil;
R1 i R2 su vodik;
R5 je SO2R8 ili SO2NR9R10;
R6 je vodik;
R8 je C1-3 alkilna grupa, C3-5 cikloalkilna grupa ili 4-6-člana heterociklička grupa;
R9 i R10 su neovisno jedan o drugome C0-4 alkil, uz uvjet da R9 i R10 nisu oba vodik;
m je 0; a
Δ znači da dvostruka veza ima (E)-konfiguraciju.
U skladu sa sljedećim aspektom ovog izuma, dan je spoj formule (VIII) i upotreba takvim spojeva u sintezi aktivatora GK:
[image]
gdje su Q, R1, R2, R5, R6, m i Δ kao što je definirano za formulu (I).
Poželjni su spojevi formule (VIII) u kojima:
Q je 4-tetrahidropiranil;
R1 i R2 su vodik;
R5 je SO2R8 ili SO2NR9R10;
R6 je vodik;
R8 je C3-5 cikloalkilna grupa ili 4-6-člana heterociklička grupa;
R9 i R10 su neovisno jedan o drugome C0-4 alkil, uz uvjet da R9 i R10 nisu oba vodik;
m je 0.
Poželjna rješenja za različite grupe supstituenata u spojevima formule (IV) i (VIII) opisana su ranije za spojeve formule (I).
Specifični spojevi formula (IV) i (VIII) uključuju i one opisane u Pripremama.
U skladu sa sljedećim aspektom ovog izuma također je dan 5-fluorotiazol-2-ilamin ili njegov amid ili kisela adicijska sol. Ovaj izum posebno daje amide i kisele adicijske soli ovog spoja. Prikladne kisele adicijske soli uključuju one nastale s anorganskim i organskim kiselinama. Takve kiseline su, na primjer, octena, trifluorooctena, benzensulfonska, benzojeva, kamforsulfonska, limunska, etansulfonska, fumarna, glukonska, glutaminska, bromovodična, klorovodična, fluorovodična, izetionska, mliječna, maleinska, malična, mandelična, metansulfonska, mucična, dušična, pamoična, pantotenska, fosforna, sukcinska, sumporna, tartarna, p-toluensulfonska, triflična i slične kiseline. Naročito su poželjne hidrohaline soli, posebno hidroklorid. Amidi i kisele adicijske soli 5-fluorotiazol-2-ilamina korisni su kao međuprodukti u sintezi spojeva formule (I) ili mogu sami po sebi djelovati kao aktivatori GK i kao takvi mogu biti korisni u profilaktičkom ili terapijskom tretmanu hiperglikemije i dijabetesa tipa II.
Sve publikacije, uključujući, ali bez ograničenja, patente i patentne prijave citirane u ovoj specifikaciji, ovdje su uključene citatom, kao što bi to bilo naznačeno za svaku pojedinačnu publikaciju.
Materijali i metode
Mikrovalne reakcije provedene su u CEM Explorer sustavu pri 100W. Kromatografija na koloni provedena je na SiO2 (veličina mreže 40-63 mesh), ukoliko nije drugačije naznačeno. LCMS podaci dobiveni su upotrebom jedne od dviju metoda: Postupak A: Waters Symmetry 3,5 μ C18 kolona (2,1 × 30 mm, brzina protoka = 0,8 mL/min), uz eluciju otopinom (5% MeCN u H2O)-MeCN koja sadrži 0,1% HCO2H kroz 6 min i UV detekcija na 220 nm. Podaci o gradijentu: 0,0-1,2 min: 100% (5% MeCN u H2O); 1,2-3,8 min: uspon do 10% (5% MeCN u H2O)-90% MeCN; 3,8-4,4 min: držati na 10% (5% MeCN u H2O)-90% MeCN; 4,4-5,5 min: uspon do 100% MeCN; 5,5-6,0 min: povratak na 100% (5% MeCN u H2O). Postupak B: Phenomenex Mercury Luna 3 μ C18 kolona (2,0 × 10,0 mm, brzina protoka = 1,5 mL/min), uz eluciju otopinom (5% MeCN u H2O)-MeCN (4:1 do 1:4) koja sadrži 0,1% HCO2H kroz 2,95 min; & upotreba diode-array detekcije. Maseni spektri za postupke A i B dobiveni su upotrebom elektrosprej ionizacije u pozitivnom (ES+) ili negativnom (ES-) ionskom načinu. Spektri kemijske ionizacije pod atmosferskim tlakom (APCI) dobiveni su na instrumentu FinniganMat SSQ 7000C. Sinteza sljedećih spojeva objavljena je ranije: 2-amino-5-kloro-4-metiltiazol: S. Kyoichi i sur. EP 412404; 2-amino-5-formiltiazol: M.D. Frishberg US Patent br. 4 225 719; 5-amino-[1,2,4]tiadiazol-hidroklorid: Y. Yoshida i sur. Bioorg. Med. Chem. 2000, 8, 2317-2335; 2-klorometiltiofen: G. Norcini i sur. US Patent br. 5 716 943; etil-(4-merkaptofenil)acetat: F. Gadient Ger. Offen. 2442979; etil-4-(metilsulfanilfenil)acetat: M.Kiuchi i sur. J. Med. Chem. 2000, 43, 2946-2961; etil-(4-propilsulfanilfenil)acetat: N.P. Buu-Hoi i sur. Chim. Ther. 1967, 2, 39-48; etil-(4-[1,2,3]triazol-1-ilfenil)acetat: G. Biagi i sur. Farmaco Ed. Sci. 1988, 43, 597-611; etil-(4-[1,2,4]triazol1-1-ilfenil)acetat: M. Artico i sur. Eur. J. Med. Chem. 1992, 27, 219-228; (3-fluoro-4-metilsulfanilfenil)octena kiselina: L.B. Snyder i Z. Zheng WO 00/10566; 4-jodometiltetrahidropiran: D.J. Anderson i sur. WO 95/30670; 4-jodotetrahidropiran: Heuberger i Owen J. Chem. Soc. 1952, 910-913; metil-(3-bromo-4-metilsulfanilfenil)acetat: F.T. Bizzarro i sur. WO 00/58293; metil-4-terc-butoksikarbonilmetilbenzoat: F. Agnelli i G.A. Sulikowski Tetrahedron Lett. 1998, 39, 8807-8810; (4-metilsulfanilmetilfenil)octena kiselina: T. Tanaka i sur. JP 54079247; (3R)-3-(tosiloksi)tetrahidrofuran: A. Bouzide i sur. Tetrahedron Lett. 2001, 42, 8781-8783; (3S)-3-(tosiloksi)tetrahidrofuran: F.J.A. Hundscheid i sur. Tetrahedron 1987, 43, 5073-5088; 3-(tosiloksi)oksetan: K. Baum i sur. J. Org. Chem. 1983, 48, 2953-2956. (E)-2-fenil-3-tiofen-2-il akrilna kiselina nabavljena je od Maybridge (Tintagel, UK).
Kratice i akronimi: Ac: acetil, i-Am: izopentil; ATP: adenozin-5'-trifosfat; BOP: benzotriazol-1-iloksitris(dimetilamino)fosfonij-heksafluorofosfat; n-Bu: n-butil; t-Bu: terc-butil; Bz: benzoil: dba: dibenzilidenaceton; DIPEA: N,N-diizopropiletilamin; DMAc: N,N-dimetilacetamid; DME: 1,2-dimetoksietan; DMF: N,N-dimetilformamid; DMPU: 1,3-dimetil-3,4,5,6-tetrahidro-2(1H)-pirimidinon; DMSO: dimetilsulfoksid; DPEPhos: bis(2-difenilfosfinofenil)eter; EDCI: 1-(3-dimetilaminopropil)-3-etilkarbodiimid hidroklorid; Et: etil: FA: aktivacija sklapanjem (fold aktivacija); GK: glukokinaza; Glc: glukoza; G6P: glukoza-6-fosfat; G6PDH: glukoza-6-fosfat dehidrogenaza; GST-GK: glutation-S-transferaza - glukokinazni fuzijski protein; HATU: O-(7-azabenzotriazol-1-il)-N,N,N',N'-tetrametiluronij-heksafluorofosfat; HOBt: 1-hidroksibenzotriazol; IH: izoheksan; i-Pr: izopropil; LDA: litijev diizopropilamid; LHMDS: litijev bis(trimetilsilil)amid; mCPBA: 3-kloroperoksibenzojeva kiselina; Me: metil; NADP(H): β-nikotinamid-adenin-dinukleotid-fosfat (reducirani); NBS: N-bromosukcinimid; Ph: fenil; PS: polimerna podloga; RF: retencijski faktor; RT: retencijsko vrijeme; RTA: retencijsko vrijeme postupkom A; RTB: retencijsko vrijeme postupkom B; RP-HPLC: tekućinska kromatografija visokog učinka - obrnutih faza; t.t.: točka tališta; TFA: trifluorooctena kiselina; TFAA: trifluoroocteni anhidrid; TFFH: fluoro-N,N,N',N',-tetrametilformamidinij-heksafluorofosfat; THF: tetrahidrofuran.
Priprema 1: (E)-2-(4-metansulfonilfenil)-3-tiofen-3-il-akrilna kiselina
[image]
Smjesa 3-tiofenkarboksaldehida (1,40 mL, 15,0 mmol), (4-metansulfonilfenil)octene kiseline (3,23 g, 15,0 mmol) i piperidina (0,45 mL, 4,5 mmol) u PhMe (21 mL) zagrijavana je pri refluksu uz miješanje tijekom 16 h. Nakon hlađenja, PhMe je dekantiran od uljne krutine koja se stvorila na dnu reakcijske posude. Ta je krutina razdijeljena između 1M HCl (60 mL) i EtOAc (400 mL), a zatim je vodena faza dodatno ekstrahirana EtOAc (60 mL). Spojeni organski slojevi isprani su s H2O (60 mL), a zatim protreseni uz zasićenu vodenu otopinu Na2CO3 (100 mL). Nastala emulzija filtrirana je kroz Celite. Organski sloj dodatno je ekstrahiran zasićenom vodenom otopinom Na2CO3 (2 × 100 mL). Spojeni vodeni slojevi isprani su Et2O (80 mL), a zatim filtrirani kroz Celite i pažljivo zakiseljeni AcOH da bi se pH podesio na 4. Nastali prljavo bijeli talog je prikupljen, pažljivo ispran H2O i osušen na zraku da bi dao spoj iz naslova: m/z (ES+) = 634,2 [2M + NH4]+.
Pripremljeno je nekoliko drugih akrilnih kiselina (Tablica 1) kondenziranjem (4-metansulfonilfenil)octene kiseline s prikladnim heteroaromatskim aldehidom i uz katalizu piperidinom, kako je opisano u Pripremi 1.
Tablica 1
[image]
Priprema 9: (E)-2-(4-bromofenil)-3-furan-2-il-akrilna kiselina
[image]
Smjesa 4-bromofeniloctene kiseline (12,90 g, 60,0 mmol), 3-furankarboksaldehida (6,0 mL, 72,0 mmol), NEt3 (12,0 mL, 86,4 mmol) i Ac2O (12,0 mL, 127,2 mmol) zagrijavana je na 140°C (kupelj) uz miješanje tijekom 1 3/4 h. Reakcijska smjesa ohlađena je u ledenoj kupelji, a zatim tretirana 2M HCl (30 mL) da bi se pH prilagodio na 1. Iz otopine je istaložena krutina. Ta je krutina ekstrahirana u Et2O (500 mL). Et2O sloj ispran je H2O (100 mL), a zatim je ekstrahiran 5% w/v vodenom otopinom Na2CO3 (5 × 100 mL). Vodeni ekstrakti isprani su Et2O (2 × 50 mL), a zatim su pažljivo zakiseljeni AcOH do pH 6. Nastala kremasta krutina je prikupljena, isprana H2O i rekristalizirana iz MeOH-H2O da bi dala spoj iz naslova: m/z (ES+) = 604,0 [2M + NH4]+.
Perkinova kondenzacija, uz upotrebu NEt3 i Ac2O, korištena je za dobivanje drugih akrilnih kiselina (Tablica 2) od odgovarajuće ariloctene kiseline i (hetero)aromatskog aldehida, kako je opisano u Pripremi 9.
Tablica 2
[image]
Priprema 15: Etil-(4-metansulfonilfenil)acetat
[image]
SOCl2 (8,2 mL, 112,0 mmol) dodan je u suspenziju (4-metansulfonilfenil)octene kiseline (20,00 g, 93,3 mmol) u EtOH (80 mL) pri -10°C uz miješanje. Smjesa je ostavljena da se zagrije na 20°C tijekom 16 h, a otapala su zatim uklonjena pod sniženim tlakom. Ostatak je otopljen u EtOAc, a nastala otopina isprana je H2O dok pH vodene faze nije postao neutralan. EtOAc otopina isprana je zatim zasićenom vodenom otopinom Na2CO3, a potom je osušena (MgSO4). Filtriranje i uparavanje otapala dalo je spoj iz naslova: m/z (ES+) = 284,1 [M + MeCN + H]+.
Priprema 16: Etil-(4-metilsulfanilmetilfenil)acetat
[image]
(4-metilsulfanilmetilfenil) octena kiselina (2,00 g, 10,2 mmol) esterificirana je kako je opisano ranije u Pripremi 15 da bi dala spoj iz naslova: m/z (ES+) = 242,2 [M + NH4]+.
Priprema 17: Etil-(3-fluoro-4-metilsulfanilfenil)acetat
[image]
(3-fluoro-4-metilsulfanilfenil) octena kiselina (7,54 g, 37,7 mmol) esterificirana je kako je opisano ranije u Pripremi 15 da bi dala spoj iz naslova: RTA = 3,62 min.
Priprema 18: Etil-(4-metansulfinilfenil)acetat
[image]
mCPBA (3,8s g 65% čistoće, 22,2 mmol) dodana je dio po dio otopini etil-(4-metilsulfanilfenil)acetata (4,66 g, 22,2 mmol) u CH2Cl2 (70 mL) uz miješanje, tijekom kojeg je ohlađena u led-H2O kupelji. Smjesa je miješana 4 dana na 20°C, a zatim je reakcija ugašena zasićenom vodenom otopinom Na2CO3. Organski sloj je odvojen, ispran zasićenom vodenom otopinom NaHCO3 i osušen (MgSO4). Filtriranje, uparavanje otapala i "flash" kromatografija (IH-EtOAc, 1:1 do 0:1) dali su spoj iz naslova: m/z (ES+) = 227,0 [M+H]+.
Priprema 19: Etil-(4-etansulfonilfenil)-acetat
[image]
Alkilacija etil-(4-merkaptofenil)acetata (20 g, 102 mmol) EtI (9,8 mL, 122 mmol), uz upotrebu postupka sličnog onom opisanom u Pripremi 39, dala je etil-(4-etilsulfanilfenil)acetata: m/z (ES+) = 225,2 [M+H]+.
Oksidacija ovog spoja (22,6 g, 101 mmol) mCPBA (222 mmol), uz protokol sličan onom opisanom u Pripremi 22, dala je spoj iz naslova: m/z (ES+) = 298,2 [M + MeCN + H]+.
Priprema 20: Etil-[4-(propan-1-sulfonil)fenil]acetat
[image]
Etil-(4-propilsulfanilfenil)acetat (20,0 g, 83,9 mmol) oksidiran je mCPBA (172,0 mmol), uz protokol sličan onom opisanom u Pripremi 22, da bi dao spoj iz naslova: m/z (ES+) = 312,2 [M + MeCN + H]+.
Priprema 21: Trifenil-(tetrahidropiran-4-il-metil)fosfonij-jodid
[image]
Otopina 4-jodometiltetrahidropirana (3,43 g, 15,2 mmol) i PPh3 (3,98 g, 15,2 mmol) u bezvodnom MeCN (10 mL) uz miješanje je zagrijavana do refluksa tijekom 19 h. Nakon hlađenja na 20°C, dodan je Et2O (50 mL). Nastali talog je prikupljen, ispran Et2O (150 mL) i rekristaliziran (MeCN) da bi dao spoj iz naslova: m/z (ES+) = 361,2 [M]+.
Priprema 22: 2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-propionska kiselina
[image]
Suspenzija AlCl3 (12,90 g, 96,8 mmol) u bezvodnom CH2Cl2 (135 mL) uz miješanje je tretirana, dio po dio, pri 0°C, etil-klorooksoacetatom (8,5 mL, 76,0 mmol). Smjesi je kap po kap, tijekom 1 h, dodavan ciklopropil-fenil-sulfid (10,0 mL, 70,0 mmol), uz održavanje reakcijske temperature ispod 10 °C. Smjesa je ostavljena da se zagrije na 20°C, a zatim je miješana još 70 min. Nakon hlađenja na 0°C, dodana je ledeno-hladna H2O i smjesa je miješana još 10 min. CH2Cl2 sloj je odvojen, a vodeni sloj je zatim ekstrahiran s još CH2Cl2 (2 × 50 mL). Spojeni organski slojevi su osušeni (MgSO4), filtrirani i koncentrirani da bi dali etil-(4-ciklopropilsulfanilfenil)-oksoacetat: RTB = 1,74 min. LHMDS (3,7 mL 1,0 M otopine u THF, 3,7 mmol) je uz miješanje dodan suspenziji trifenil(tetrahidropiran-4-il-metil)-fosfonij-jodida (Priprema 21, 1,82 g, 3,7 mmol) u bezvodnom THF (5,6 mL) pri 0°C. Nakon 1 h, tijekom 5 min dodavana je otopina etil-(4-ciklopropilsulfanilfenil)oksoacetata (0,78 g, 3,1 mmol) u bezvodnom THF (4 mL). Smjesa je miješana pri 0°C tijekom 1 h, a zatim je ostavljena da se zagrije na 20°C tijekom 16 h. Nakon hlađenja na 0°C dodana je H2O (7 mL). Dodana je 1M HCl da podesi pH na 6, a zatim je smjesa miješana 1 h na 20°C. THF je uklonjen u vakuumu, a zatim je dodan Et2O (35 mL). Smjesa je miješana 30 min i zatim je filtrirana, uz ispiranje Et2O. Vodeni sloj je odvojen i ekstrahiran Et2O (3 × 10 mL). Spojeni organski ekstrakti isprani su slanom vodom (20 mL), osušeni, filtrirani i koncentrirani. "Flash" kromatografija (IH-CH2Cl2, 2:1 do 1:1, nakon toga THF-CH2Cl2, 1:99) dala je etil-2-(4-ciklopropilsulfanilfenil)-3-(tetrahidropiran-4-il)akrilat: m/z (ES+) = 333,2 [M + H]+. Otopini tog tioetera (609 mg, 1,83 mmol) u CH2Cl2 (35 mL) uz miješanje je dodana otopina mCPBA (992 mg 65% čistoće, 3,74 mmol) u CH2Cl2 (15 mL). Nakon 16 h, dodana je zasićena vodena otopina NaHCO3 (25 mL), a miješanje je nastavljeno još 5 min. Slojevi su odvojeni, a vodena faza zatim je ekstrahirana CH2Cl2 (20 mL). Spojeni organski slojevi isprani su zasićenom vodenom otopinom NaHCO3 (25 mL), H2O (25 mL) i slanom vodom (25 mL), a zatim su osušeni (MgSO4). Filtriranje i uparavanje otapala dalo je etil-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)akrilat: m/z (ES+) = 382,2 [M + NH4]+. Otopina tog spoja (667 mg, 1,83 mmol) u EtOAc (60 mL) tretirana je Pd (10% na C, 424 mg, 0,39 mmol). Reakcijska smjesa miješana je u atmosferi H2 tijekom 3 dana, a zatim je filtrirana kroz Celite. Celite je ispran EtOAc (100 mL), a spojeni filtrati koncentrirani su da bi dali etil-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)propionat: RF (CH2Cl2-THF, 30:1) = 0,56. Otopina ovog estera (664 mg, 1,81 mmol) u THF-H2O (3:1, 20 mL) miješana je uz LiOH⋅H2O (168 mg, 4,00 mmol) tijekom 23 h. THF je uparen pod sniženim tlakom, a ostatak je razrijeđen H2O (10 mL). Smjesa je isprana Et2O (2 × 20 mL) i zakiseljena 2M HCl (5 mL) do pH 1. Ostatak je ekstrahiran EtOAc (3 × 20 mL). Spojeni organski ekstrakti isprani su slanom vodom (20 mL), osušeni (MgSO4), filtrirani i upareni da bi dali spoj iz naslova: m/z (ES+) = 694,4 [2M + NH4]+.
Priprema 23: (E)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il) akrilna kiselina
[image]
Etil-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il) akrilat (v. Priprema 22, 3,44 g, 9,44 mmol) saponificiran je postupkom opisanim u Pripremi 25, da bi dao spoj iz naslova: m/z (ES+) = 673,5 [2M + H]+.
Priprema 24: (E)-2-(4-ciklopropansulfinilfenil)-3-(tetrahidropiran-4-il) akrilna kiselina
[image]
Djelomična oksidacija etil-2-(4-ciklopropilsulfanilfenil)-3-(tetrahidropiran-4-il) akrilata (v. Priprema 22, 3,14 g, 9,44 mmol) mCPBA, upotrebom protokola opisanog ranije u Pripremi 18, dala je etil-2-(4-ciklopropansulfinilfenil)-3-(tetrahidropiran-4-il) akrilat: m/z (ES+) = 349,2 [M+H]+. Saponifikacija ovog estera (1,15 g, 3,3 mmol), postupkom opisanim u Pripremi 25, dala je spoj iz naslova: m/z (ES+) = 641,4 [2M + H]+.
Priprema 25: (E)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) akrilna kiselina
[image]
LDA (24 mL 1,8M otopine u n-C7H16-THF-PhEt, 43,3 mmol) dodana je kap po kap uz miješanje u otopinu DMPU (19 mL, 153,0 mmol) u bezvodnom THF (100 mL) pri -78°C. Nakon 30 min, kap po kap je dodana otopina etil-(4-metansulfonilfenil)-acetata (Priprema 15, 5,00 g, 20,6 mmol) u bezvodnom THF (42 mL). Smjesa je miješana 1 h, a zatim je kap po kap tretirana otopinom tetrahidropiran-4-karboksaldehida (2,36 g, 20,6 mmol) u bezvodnom THF (25 mL). Nakon što je ostavljena da se zagrije do 20°C tijekom 16 h, reakcija je ugašena dodatkom zasićene vodene otopine NH4Cl (210 mL). THF je uklonjen pod sniženim tlakom, a ostatak je ekstrahiran EtOAc (3 × 250 mL). Spojeni EtOAc ekstrakti su osušeni (MgSO4), filtrirani i koncentrirani. Kromatografija na koloni (IH-EtOAc, 7:3) dala je (E)-etil-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) akrilat: m/z (ES+) = 356,2 [M + NH4]+. Otopina tog estera (6,46 g, 19,1 mmol) u MeOH (30 mL) i 1M NaOH (40 mL, 40,0 mmol) zagrijavana je pri refluksu 1 h. Nakon hlađenja, smjesa je isprana EtOAc. Vodena faza zakiseljena je 1M HCl, a zatim je ekstrahirana EtOAc. Spojeni organski ekstrakti su osušeni (MgSO4). Filtriranje i uparavanje otapala dalo je spoj iz naslova: m/z (ES+) = 621,3 [2M+H]+.
Akrilne kiseline nabrojane u Tablici 3 sintetizirane su sličnim postupcima kao što je upravo opisano u Pripremi 25.
Tablica 3
[image]
Priprema 30: (E)-3-(tetrahidropiran-4-il)-2-(4-[1,2,3]triazol-1-ilfenil) akrilna kiselina
[image]
NaOEt (0,63 mL 0,5M otopine u EtOH, 0,32 mmol) je dodan kap po kap otopini etil-(4-[1,2,3]triazol-1-ilfenil)acetata (730 mg, 3,16 mmol) i tetrahidropiran-4-karboksaldehida (396 mg, 3,47 mmol) u bezvodnom DMSO (3 mL), uz miješanje. Smjesa je zagrijavana na 80°C tijekom 16 h, a zatim je tretirana AcOH da se pH prilagodi na 7. Dodan je EtOAc (30 mL), a zatim je otopina isprana H2O (2 × 10 mL) i slanom vodom (10 mL), te je osušena (MgSO4). Filtriranje, uparavanje otapala i kromatografija na koloni (IH-EtOAc, 1:1) dala je etil-3-(tetrahidropiran-4-il)-2-(4-[1,2,3]triazol-1-ilfenil)akrilat: m/z (ES+) = 328,2 [M+H]+. Taj ester (404 mg, 1,23 mmol) je saponificiran kako je gore opisano u Pripremi 25 da bi dao spoj iz naslova: m/z (ES+) = 300,2 [M+H]+.
Postupak opisan u Pripremi 30, uključujući kondenzaciju fenilacetatnog estera s odgovarajućim aldehidom, nakon čega slijedi saponifikacija intermedijarnog α,β-nezasićenog estera, korišten je u pripremi akrilnih kiselina nabrojanih u Tablici 4.
Tablica 4
[image]
Priprema 38: 2-(4-metansulfonilfenil)-3-tiofen-2-il propionska kiselina
[image]
DMPU (50 mL, 413 mmol) je dodan u otopinu LDA (65 mL 1,8M otopine u n-C7H16-THF-PhEt, 117 mmol) u bezvodnom THF (250 mL) pri -78°C. Smjesa je miješana 1 h da bi nastao kremasti talog. Otopina (4-metansulfonilfenil) octene kiseline (12,00 g, 56 mmol) u bezvodnom THF (120 mL) dodavana je tijekom 20 min. Dodano je još bezvodnog THF (30 mL) i gusta žuta otopina miješana je 1 h. Smjesa je tretirana otopinom 2-klorometiltiofena (7,50 g, 57 mmol) i PhMe (5,20 g, 57 mmol) u bezvodnom THF (20 mL), te je miješanje nastavljeno na -78°C kroz 20 min. Reakcijska smjesa ostavljena je da se zagrije na 20°C tijekom 16 h, a zatim je reakcija ugašena dodatkom H2O (500 mL). THF je uklonjen pod sniženim tlakom, a zatim je dodana 12M HCl da dovede pH na 2. Smjesa je ekstrahirana EtOAc (2 × 300 mL), zatim su ekstrakti isprani H2O (2 × 200 mL) i slanom vodom (2 × 100 mL), a potom su osušeni (MgSO4). Filtriranje, uparavanje otapala i kromatografija na koloni (IH-EtOAc, 3:2 s dodatkom 0,5% AcOH) dali su spoj iz naslova: m/z (ES+) = 638,3 [2M + NH4]+.
Priprema 39: Etil-[4-(tetrahidropiran-4-il-sulfanil)fenil]acetat
[image]
NEt3 (1,3 mL, 9,0 mmol) i 4-jodotetrahidropiran (1,93 g, 9,0 mmol) dodani su uz miješanje otopini etil-(4-merkaptofenil)acetata (1,21 g, 6,0 mmol) u bezvodnom DMF (10 mL) pri 0°C. Smjesa je ostavljena da se zagrije na sobnu temperaturu tijekom 3 dana, a zatim su otapala uklonjena pod sniženim tlakom. Ostatak je razdijeljen između Et2O (100 mL) i zasićene vodene otopine NH4Cl (50 mL), te je vodena faza dodatno ekstrahirana Et2O (45 mL). Spojeni eterski ekstrakti isprani su H2O (50 mL), H2O-zasićenom vodenom otopinom Na2CO3 (1:1, 50 mL) i slanom vodom (50 mL), te su osušeni (MgSO4). FIltriranje, uparavanje otapala i "flash" kromatografija (IH-Et2O, 10:1 do 2:1) dali su spoj iz naslova: RF (IH-H2O, 2:1) = 0,31.
Priprema 40: Etil-(4-metoksimetilsulfanilfenil)acetat
[image]
Ovaj spoj pripremljen je postupkom upravo opisanim u Pripremi 39: RF (IH-Et2O, 10:1) = 0,19.
Priprema 41: 2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
LDA (38,9 mL 1,8M otopine u n-C7H16-THF-PhEt, 70,0 mmol) dodana je otopini DMPU (59,3 mL, 490,3 mmol) u bezvodnom THF (150 mL) pri -78°C. Smjesa je miješana 30 min, a zatim je, kap po kap, tretirana otopinom etil-(4-metansulfonilfenil)acetata (Priprema 15, 16,97 g, 70,0 mmol) u bezvodnom THF (50 mL). Miješanje je nastavljeno pri -78°C tijekom 45 min, a zatim je dodana otopina 4-jodometiltetrahidropirana (19,00 g, 84,0 mmol) u bezvodnom THF (40 mL). Smjesa je ostavljena da se zagrije na 20°C tijekom 16 h, a zatim je reakcija ugašena 1M HCl (70 mL). THF je uklonjen pod sniženim tlakoom, a zatim je dodano još H2O (40 mL) i ostatak je ekstrahiran EtOAc (2 × 250 mL). EtOAc ekstrakti su osušeni (MgSO4). Filtriranje, uparavanje otapala i "flash" kromatografija (IH-EtOAc, 9:1 do 1:1) dali su etil-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionat: m/z (ES+) = 698,3 [2M + NH4]+. Otopina tog spoja (20,27 g, 59,6 mmol) u MeOH (100 mL) i 2M NaOH (62,5 mL, 125,0 mmol) zagrijavana je pri refluksu 1 h. Otapala su uklonjena pod sniženim tlakom, a preostala krutina smrvljena je s Et2O (5 × 100 mL), te je otopljena u H2O (100 mL). Vodena otopina isprana je EtOAc (50 mL), zakiseljena 2M HCl do pH 1 i ekstrahirana s EtOAc (2 × 1 L). Nakon sušenja (MgSO4), filtriranje i uparavanje otapala dali su spoj iz naslova: m/z (ES+) = 642,3 [2M + NH4]+.
Pristupi slični ovom opisanim u Pripremi 41, uključujući alkilaciju odgovarajućeg estera 4-jodometiltetrahidropiranom, nakon čega slijedi hidroliza produkta, korišteni su u pripremi karboksilnih kiselina prikazanih u Tablici 5.
Tablica 5
[image]
Priprema 50: 2-(3-fluoro-4-metansulfonilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
Otopina 2-(3-fluoro-4-metilsulfanilfenil)-3-(tetrahidropiran-4-il) propionske kiseline (Priprema 47, 598 mg, 2,0 mmol) u CH2Cl2 (20 mL) uz miješanje je tretirana mCPBA (1,15 g 60% čistoće, 4,0 mmol). Nakon 16 h, otopina je filtrirana, a filtrat je pročišćen kromatografijom na koloni (IH-EtOAc-AcOH, 320:80:1 do 80:320:1) da bi dao spoj iz naslova: m/z (ES+) = 678,3 [2M + NH4]+.
Priprema 51: 2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
Etil-(4-nitrofenil)acetat (25,0 g, 119,5 mmol) alkiliran je 4-jodometiltetrahidropiranom (32,4 g, 143,4 mmol), prema protokolu opisanom u Pripremi 41, da bi dao etil-2-(4-nitrofenil)-3-(tetrahidropiran-4-il) propionat: δH (CDCl3): 1,21 (3H, t); 1,25-1,45 (3H, m); 1,55-1,65 (2H, m); 1,70-1,8 0(1H, m); 2,05-2,15 (1H, m); 3,25-3,35 (2H, m); 3,79 (1H, t); 3,90-3,95 (2H, m); 4,10-4,20 (2H, m); 7,49 (2H, d); 8,19 (2H, d). Nitro-grupa ovog spoja (6,55 g, 18,1 mmol) reducirana je postupkom opisanim u Primjeru 145 da bi se dobio 2-(4-aminofenil)-3-(tetrahidropiran-4-il) propionat: m/z (ES+) = 278,2 [M + H]+. Taj je spoj (30,5 g, 110 mmol) transformiran u etil-2-(4-klorosulfonilfenil)-3-(tetrahidropiran-4-il) propionat pomoću protokola opisanog u Pripremi 59. Otopina tog sulfonil-klorida (33,6 g, 93,2 mmol) u bezvodnom THF (100 mL) dodavana je tijekom 30 min pri 0°C u EtNH2 (116,5 mL 2,0M otopine u THF, 233,0 mmol). Smjesa je zagrijana do 20°C, a zatim je miješana 16 h. Suspenzija je filtrirana kroz Celitni jastučić, koji je potom ispran THF (3 × 50 mL). Spojene THF otopine koncentrirane su da bi dale grubi etil-2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il) propionat: m/z (ES+) = 370,2 [M + H]+. Hidroliza ovog estera (33,7 g, 91,2 mmol), upotrebom postupka naznačenog u Pripremi 41, te pročišćavanje putem RP-HPLC, dali su spoj iz naslova: m/z (ES+) = 342,2 [M + H]+.
Priprema 52: 2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
Alkilacija etil-(4-merkaptofenil)acetata (9,5 g, 48,4 mmol) c-BuBr (7,84 g, 58,1 mmol), upotrebom postupka sličnog onom opisanom u Primjeru 161, dala je etil-(4-ciklobutilsulfanilfenil)acetat: RTA = 4,17 min. Oksidacija tog spoja (18,5 g, 73,9 mmol) mCPBA (222 mmol), po protokolu sličnom onome opisanom u Pripremi 22, dala je etil-(4-ciklobutansulfonilfenil)acetat: m/z (ES+) = 283,2 [M + H]+. Kondenzacija tog spoja (18,84 g, 66,7 mmol) tetrahidropiran-4-karboksaldehidom (8,38 g, 73,4 mmol), postupkom opisanim u Pripremi 30, dala je etil-2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il) akrilat: m/z (ES+) = 396,2 [M + NH4]+. Redukcija ovog α,β-nezasićenog estera (13,00 g, 34,4 mmol), postupkom opisanim u Pripremi 22, dala je etil-2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il) propionat: m/z (ES+) = 381,2 [M + H]+. Taj je ester hidroliziran postupkom naznačenim u Pripremi 22 da bi dao spoj iz naslova: m/z (ES+) = 370,2 [M + NH4]+.
Priprema 53: (2R)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
NEt3 (15,4 mL, 110 mmol) dodan je u suspenziju 2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) propionske kiseline (Priprema 41, 30,0 g, 96,0 mmol) u bezvodnom THF (300 mL) pri 0°C uz miješanje. Nakon 10 min, kap po kap je dodan pivaloil-klorid (13,6 mL, 110 mmol) tijekom 20 min i smjesa je miješana pri 0°C 2 h. U međuvremenu, n-BuLi (45,3 mL 2,5M otopine u heksanima, 115 mmol) dodan je u otopinu (R)-(+)-4-benuzil-2-oksazuolidinona (20,4 g, 115 mmol) u bezvodnom THF (300 mL) pri -78°C. Ta je smjesa miješana od -78°C do 20°C tijekom 2 h. Tako dobivena otopina dodana je kap po kap u prethodno spomenutu otopinu miješanih anhidrida pri -78°C. Reakcija je miješana pri -78°C 1 h, zatim na 20°C 4 h, i zatim je tretirana H2O (300 mL). THF je uklonjen u vakuumu, a ostatak je ekstrahiran EtOAc (3 × 300 mL). Spojeni organski slojevi isprani su H2O, osušeni (Na2SO4), filtrirani i koncentrirani u vakuumu. Kromatografsko odvajanje (EtOAc-n-C6H14, 1:2 do 1:1) dalo je dva produkta: (1) (4R)-4-benzil-3-[(2R)-2-[4-(metilsulfonil)fenil]-3-(tetrahidro-2H-piran-4-il)propanoil]-1,3-oksazolidin-2-on: t.t. 139-141°C (iz Et2O-THF); (2) (4R)-4-benzil-3-[(2S)-2-[4-(metilsulfonil)fenil]-3-(tetrahidro-2H-piran-4-il)propanoil]-1,3-oksazolidin-2-on: m/z (APCI+) = 472 [M + H]+. Otopina LiOH (1,5 g, 64 mmol) i 35%-tnog H2O2 (14,5 g, 128 mmol) u H2O (400 mL) dodana je kap po kap tijekom 40 min u otopinu (4R)-4-benzil-3-[(2R)-2-[4-(metilsulfonil)fenil]-3-(tetrahidro-2H-piran-4-il)propanoil]-1,3-oksazolidin-2-ona (15,1 g, 10,9 mmol) u THF-H2O (3:1, 1,6 L) pri 0°C uz miješanje. Reakcijska smjesa miješana je pri 0°C 1,5 h, a zatim je preostali oksidans uklonjen 10%-tnom vodenom otopinom Na2SO3. Smjesa je isprana Et2O (4 × 300 mL), zakiseljena 10%-tnom vodenom otopinom HCl i ekstrahirana EtOAc (3 × 200 mL). Spojeni organski slojevi isprani su slanom vodom, osušeni (Na2SO4), filtrirani i koncentrirani u vakuumu. Mrvljenje uz Et2O-heksane daje spoj iz naslova: t.t. 217 °C; apsolutna konfiguracija određena je kristalografskom analizom X-zraka.
Priprema 54: (2R)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
Spoj iz naslova ([α]D -48,8 (c = 1,02, CHCl3)) dobiven je iz 2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il) propionske kiseline (Priprema 22) slijedeći protokole opisane u Pripremi 53.
Priprema 55: (2R)-2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
Spoj iz naslova dobiven je iz 2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il) propionske kiseline (Priprema 51) slijedeći protokole opisane u Pripremi 53. Analiziran je kiralnom HPLC: CHIRAL CEL OJ-R® (Daicel Chemical Industries, Ltd., Tokyo, Japan), 4,6 mm ∅ × 15 cm, CH3-CN-0,5 M NaClO4 (pH 2,0), 17:83, 0,5 mL/min, UV 235 nm, 25°C; RT (R) = 43,89 min; RT (S) = 38,84 min).
Priprema 56: (2R)-2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
Enantiomerno čist spoj iz naslova dobiven je iz 2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il) propionske kiseline (Priprema 52) upotrebom protokola opisanih u Pripremi 53. Analiziran je kiralnom HPLC: CHIRAL CEL OJ-R® (Daicel Chemical Industries, Ltd., Tokyo, Japan), 4,6 mm ∅ × 15 cm, CH3-CN-0,5 M NaClO4 (pH 2,0), 17:83, 0,5 mL/min, UV 235 nm, 25 °C; RT (R) = 82,69 min (RT (S) = 78,63 min).
Priprema 57: 2-(4-metilsulfanil-3-nitrofenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
(4-kloro-3-nitrofenil) octena kiselina (10,00 g, 46,4 mmol) esterificirana je kako je opisano ranije u Pripremi 15, da bi dala etil-(4-kloro-3-nitrofenil) acetat: m/z (ES+) = 285,2 [M + MeCN + H]+. Alkilacija ovog estera (10,50 g, 43,1 mmol), po protokolu opisanom u Pripremi 41, dala je etil-2-(4-kloro-3-nitrofenil)-3-(tetrahidropiran-4-il) propionat: m/z (ES+) = 342,1 [M + H]+. Otopina tog spoja (7,42 g, 19,7 mmol) u DMSO (50 mL) tretirana je NaSMe (1,52 g, 21,6 mmol). Smjesa je miješana pri 20°C 5,5 h, a zatim pri 50°C 2 h, te je izlivena na smrvljeni led (500 mL). Nakon što se led posve otopio, smjesa je razdijeljena između EtOAc (250 mL) i H2O (100 mL). Vodena faza dodatno je ekstrahirana EtOAc (4 × 200 mL), a zatim su spojeni organski ekstrakti isprani slanom vodom i osušeni (MgSO4). Filtriranje, uparavanje otapala i kromatografija na koloni (IH-EtOAc, 7:3) dali su etil-2-(4-metilsulfanil-3-nitrofenil)-3-(tetrahidropiran-4-il) propionat: m/z (ES+) = 371,0 [M + NH4]+. Taj je ester (7,48 g, 19,2 mmol) hidroliziran s LiOH⋅H2O, kako je opisano ranije u Pripremi 22, da bi dao spoj iz naslova: m/z (ES+) = 343,3 [M + NH4]+.
Priprema 58: 2-(3-metilsulfanilfenil)-3-(tetrahidropiran-4-il) propionska kiselina
[image]
Etil-(3-nitrofenil) acetat (11,60 g, 55,5 mmol) je kondenziran s tetrahidropiran-4-karboksaldehidom prema postupku opisanom u Pripremi 30 da bi dao etil-2-(3-nitrofenil)-3-(tetrahidropiran-4-il) akrilat: m/z (ES+) = 628,3 [2M + NH4]+. Otopina tog spoja (4,65 g, 15,2 mmol) u EtOH (80 mL) tretirana je gustom otopinom Pd (10% na C, 49 mg, 0,46 mmol) u EtOH (10 mL) i H2O (1 mL). Smjesa je miješana u atmosferi H2 24 h, a zatim je filtrirana kroz Celite. Celite je ispran EtOAc (5 × 50 mL), a zatim su spojeni filtrati upareni da bi dali etil-2-(3-aminofenil)-3-(tetrahidropiran-4-il) propionat: m/z (ES+) = 278,2 [M + H]+. Otopina tog spoja (2,77 g, 10,0 mmol) u DME (10 mL) dodavana je tijekom 30 min u smjesu i-AmONO (2,0 mL, 15,0 mmol) i MeSSMe (9,9 mL, 110,0 mmol) uz miješanje. Temperatura je povišena na 45°C 0,5 h i zatim na 85°C 1,5 h. Nakon hlađenja, otapala su uklonjena pod sniženim tlakom, a ostatak je otopljen u EtOAc (60 mL). Otopina EtOAc isprana je 1M HCl (2 × 20 mL), H2O (20 mL) i slanom vodom (20 mL). Filtriranje, uparavanje otapala i kromatografija na koloni (CH2Cl2- Et2O, 1:0 do 99:1) dali su etil-2-(3-metilsulfanilfenil)-3-(tetrahidropiran-4-il) propionat: m/z (ES+) = 309,2 [M + H]+. Saponifikacija ovog estera LiOH⋅H2O, po protokolu naznačenom u Pripremi 22, dala je spoj iz naslova: m/z (ES+) = 561,3 [2M + H]+.
Priprema 59: 4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]-benzensulfonil-klorid
[image]
2-(4-nitrofenil)-3-(tetrahidropiran-4-il) propionska kiselina (Priprema 46, 10,40 g, 37,2 mmol) kondenzirana je s tiazol-2-ilaminom pomoću postupka opisanog u Primjeru 65 da bi dali 2-(4-nitrofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid: m/z (ES+) = 362,1 [M + H]+. Nitro-grupa ovog spoja (6,55 g, 18,1 mmol) reducirana je postupkom opisanim u Primjeru 145 da bi dao 2-(4-aminofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid: m/z (ES+) = 332,1 [M + H]+. Otopina NaNO2 (2,11 g, 30,5 mmol) u H2O (20 mL) polako je dodavana u smjesu prethodno navedenog, anilina (9,40 g, 28,4 mmol), 12M HCl (30 mL) i H2O (30 mL) pri 0 °C uz miješanje. Nakon 1 h, nastala otopina diazonijeve soli dodavana je tijekom 15 min u smjesu CuCl2⋅2H2O (1,29 g, 7,6 mmol) u AcOH (64,5 mL) i H2O (3,2 mL) koja je prethodno zasićena SO2. Smjesa je miješana 1,5 h, tretirana H2O (200 mL) i ekstrahirana EtOAc (300 + 150 mL). Spojeni EtOAc ekstrakti isprani su H2O (2 × 200 mL), filtrirani i osušeni (MgSO4). Filtriranje i uparavanje otapala dali su spoj iz naslova: m/z (ES+) = 466,1 [M + MeCN + H]+.
Priprema 60: 4-[1-(5-klorotiazol-2-ilkarbamoil)-2-(tetrahidropiran-4-il)etil]benzensulfonil-klorid
[image]
Korištenjem postupaka sličnih onima opisanima u Pripremi 59, 2-(4-nitrofenil)-3-(tetrahidropiran-4-il) propionska kiselina (Priprema 46, 9,74 g, 34,9 mmol) prevedena je u spoj iz naslova: δH (CDCl3): 1,25-1,50 (3H, m); 1,55-1,70 (2H, br); 1,80-1,85 (1H, m); 2,20-2,30 (1H, m); 3,20-3,35 (2H, m); 3,80-4,00 (3H, m); 7,20 (1H, s); 7,65 (2H, d); 8,00 (2H, d).
Priprema 61: 5-fluorotiazol-2-ilamin-hidroklorid
[image]
NEt3 (63,4 mL, 455 mmol) dodan je uz miješanje suspenziji 5-bromotiazol-2-ilamin-hidrobromida (102,7 g, 379 mmol) u CH2Cl2 (1,5 L). Nakon 1 h, kap po kap je dodana TFAA (64,2 mL, 455 mmol) pri 0°C tijekom 15 min. Smjesa je ostavljena da se zagrije na 20°C tijekom 1 h, a zatim je miješana još 2 h. Dodana je H2O (600 mL), a nastali talog je prikupljen. Vodeni sloj filtrata odvojen je i ekstrahiran CHCl3 (3 × 300 mL). Spojeni organski ekstrakti isprani su slanom vodom, osušeni (Na2SO4), filtrirani i koncentrirani. Prikupljeni talog i preostala krutina spojeni su i smrvljeni s EtOAc-n-C6H14 da bi dali N-(5-bromotiazol-2-il)-2,2,2-trifluoroacetamid: δH (CDCl3): 7,45 (1H, s); 13,05 (1H, br). n-BuLi (253 mL 1,58 M otopine u heksanima, 403 mmol) dodavan je kap po kap tijekom 50 min u otopinu gornjeg amida (50,0 g, 183 mmol) u bezvodnom THF (1,3 L) pri -78°C uz miješanje. Nakon 1,5 h, otopina N-fluorobenzensulfonimida (86,0 g, 275 mmol) u bezvodnom THF (250 mL) dodavana je kap po kap tijekom 30 min. Smjesa je miješana 3 h, a zatim je zagrijana do -30°C. Dodana je H2O (300 mL) i smjesa je filtrirana kroz Celitni jastučić. Prikupljena krutina isprana je Et2O (400 mL) i H2O (400 mL). Organski sloj filtrata odvojen je i ekstrahiran vodom (2 × 400 mL). Spojeni vodeni slojevi isprani su Et2O (400 mL), a zatim su zakiseljeni do pH 6,5 dodatkom 2M HCl i ekstrahirani su EtOAc (2 × 400 mL). Spojeni organski ekstrakti isprani su H2O (2 × 400 mL) i slanom vodom, te su osušeni (MgSO4), filtrirani i koncentrirani. Kromatografija na koloni (EtOAc-n-C6H14, 1:3 do 1:2) dala je N-(5-fluorotiazol-2-il)-2,2,2-trifluoroacetamid: δH (CDCl3): 7,13 (1H, d). Otopini ovog amida (15,7 g, 73 mmol) u MeOH (300 mL) pri 0°C uz miješanje je dodan AcCl (12,6 mL, 175 mmol). Smjesa je miješana pri 20°C 30 min, zagrijavana pod refluksom 1 h i napokon koncentrirana u vakuuku. Preostala krutina smrvljena je s THF da bi dala spoj iz naslova: δH (D2O): 7,00 (1H, d).
Priprema 62: 4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil] benzojeva kiselina
[image]
Metil-3-terc-butoksikarbonilmetilbenzoat (1,71 g, 6,84 mmol) alkiliran je 4-jodometiltetrahidropiranom (1,86 g, 8,21 mmol), prema postupku opisanom u Pripremi 41, da bi dao metil-4-[1-terc-butoksikarbonil-2-(tetrahidropiran-4-il)etil]benzoat: RTA = 3,86 min. Otopina tog spoja (1,37 g, 3,94 mmol) u CH2Cl2 (5 mL) tretirana je TFA-CH2Cl2 (2:1, 15 mL) pri 0°C 10 min. Smjesa je miješana pri 20°C 3 h, a zatim je koncentrirana u vakuumu. Ostatak je tretiran PhMe i otapala su uparena pod sniženim tlakom. Taj je postupak dvaput ponovljen da bi dao grubi metil-4-[1-karboksi-2-(tetrahidropiran-4-il)etil]benzoat. Ta je karboksilna kiselina kondenzirana s tiazol-2-ilaminom, slijedeći protokol naznačen u Primjeru 65, da bi dala metil-4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzoat: m/z (ES+) = 375,2 [M + H]+. Taj je ester saponificiran LiOH⋅H2O, slijedeći postupak opisan u Pripremi 22, da bi dao spoj iz naslova: m/z (ES-) = 359,2 [M - H]-.
Primjer 1
(E)-2-(4-metansulfonilfenil)-N-tiazol-2-il-3-tiofen-3-ilakrilamid
[image]
Suspenzija PS-karbodiimida (688 mg, naneseno 1,34 μmol mg-1, 922 μmol), (E)-2-(4-metansulfonilfenil)-3-tiofen-3-ilakrilne kiseline (Priprema 1, 139 mg, 450 μmol) i HOBt (84 mg, 622 μmol) u bezvodnom DMF miješana je 15 min pri 20°C. Dodan je tiazol-2-ilamin (32 mg, 320 μmol), a zatim je smjesa miješana 40 h pri 20°C, te je filtrirana kroz Celite. Filterski kolač ispran je DMF (10 mL); EtOAc (20 mL) i CH2Cl2 (20 mL). Otopine su spojene, otapala uklonjena pod sniženim tlakom, a ostatak je otopljen u EtOAc (50 mL). Otopina EtOAc isprana je zasićenom vodenom otopinom Na2CO3 (3 × 20 mL), H2O (20 mL) i slanom vodom), te je osušena (Na2SO4). Filtriranje, uparavanje otapala i "flash" kromatografija (IH-EtOAc, 3:1 do 1:3) dali su spoj iz naslova: RTA = 3,43 min; m/z (ES+) = 391,0 [M + H]+.
Kondenzacija odgovarajuće karboksilne kiseline s tiazol-2-aminom, posredovana PS-karbodiimid-HOBt, kako je naznačeno u Primjeru 1, također je korištena u sintezi amida nabrojanih u Tablici 6 u nastavku.
Tablica 6
[image] [image] [image] [image]
[A] RT pomoću postupka A. [B] RT pomoću postupka B.
Primjer 36
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-tiofen-2-ilakrilamid
[image]
Otopina (E)-2-(4-metansulfonilfenil)-3-tiofen-2-ilakrilne kiseline (Priprema 2, 309 mg, 1,0 mmol), HATU (813 mg, 2,1 mmol), 5-klorotiazol-2-ilamin-hidroklorida (258 mg, 1,5 mmol) i DIPEA (0,71 mL, 4,0 mmol) u bezvodnom DMF (5 mL) zagrijavana je pod mikrovalnim zračenjem uz miješanje pri 60°C 2 min. Otapala su uparena pod sniženim tlakom, a ostatak je razdijeljen između CH2Cl2 (60 mL) i 1M HCl (60 mL). Organski sloj je odvojen i ispran 1M HCl (60 mL), H2O (60 mL), zasićenom vodenom otopinom Na2CO3 (2 × 60 mL), H2O (60 mL) i slanom vodom (60 mL), te je osušen (Na2SO4). Filtriranje, uparavanje otapala i "flash" kromatografija (IH-EtOAc, 4:1 do 2:3) dali su spoj iz naslova: RTA = 3,77 min; m/z (ES+) = 466,1 [M + MeCN + H]+.
Kondenzacija odgovarajuće karboksilne kiseline s tiazol-2-ilaminima posredovana mikrovalovima, naznačena u Primjeru 36 korištena je i u pripremi amida nabrojanih u Tablici 7 u nastavku.
Tablica 7
[image]
Primjer 44
(E)-2-(4-bromofenil)-N-(5-klorotiazol-2-il)-3-furan-2-ilakrilamid
[image]
Suspenzija (E)-2-(4-bromofenil)-3-furan-2-ilakrilne kiseline (Priprema 9, 4,10 g, 14,0 mmol) i oksalil-klorida (2,5 mL, 28,0 mmol) u bezvodnom CH2Cl2 (100 mL) tretirana je katalitičkom količinom bezvodnog DMF (25 μL). Nastala otopina miješana je pri 20°C kroz 4 h, a zatim su otapala uklonjena pod sniženim tlakom. Ostatku je dodan CH2Cl2 (50 mL), a zatim su otapala uparena pod sniženim tlakom da bi se dobio 2-(4-bromofenil)-3-furan-2-ilakriloil-klorid kao smeđa krutina. Otopina tog kiselog klorida (343 mg, 1,1 mmol) u bezvodnom THF (1 mL) dodana je otopini 5-klorotiazol-2-ilamin-hidroklorida (171 mg, 1,0 mmol) i NEt3 (0,56 mL, 4,0 mmol) u bezvodnom THF (1 mL). Suspenzija je miješana 16 h na 20°C, a zatim su otapala uklonjena pod sniženim tlakom. Ostatak je razdijeljen između CH2Cl2 (10 mL) i zasićenog vodenog NaHCO3 (5 mL). Organski sloj ispran je H2O (5 mL) i slanom vodom (5 mL) te je koncentriran. Nastala krutina rekristalizirana je iz MeOH da bi dala spoj iz naslova: RTA = 4,39 min; m/z (ES+) = 410,9 [M + H]+.
Kondenzacijom odgovarajućeg kiselog klorida s heteroaromatskim aminima pripremljeno je nekoliko drugih enamida, slično Primjeru 44. Ti spojevi nabrojani su u Tablici 8 u nastavku.
Tablica 8
[image] [image]
Primjer 65
2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid
[image]
EDCI (80 mg, 420 μmol) i HOBt (56 mg, 420 μmol) dodani su uz miješanje otopini 2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) propionske kiseline (Priprema 41, 100 mg, 320 μmol) u bezvodnom DMF (6 mL). Nakon 15 min, otopina je tretirana tiazol-2-ilaminom (38 mg, 380 μmol). Smjesa je miješana pri 20°C tijekom 16 h, a zatim je koncentrirana pod sniženim tlakom. Ostatak je razdijeljen između CH2Cl2 i zasićene vodene otopine Na2CO3. Organski sloj ispran je 1M HCl i osušen (MgSO4). Filtriranje i uparavanje otapala dali su spoj iz naslova: RTA = 3,16 min; m/z (ES+) = 436,2 [M + MeCN + H]+.
Postupak iz Primjera 65 također je korišten u pripremi nekoliko drugih amida (Tablica 9).
Tablica 9
[image] [image] [image]
[A] RT pomoću postupka A. [B] RT pomoću postupka B.
Primjer 93
(2R)-3-(tetrahidropiran-4-il)-2-(4-metansulfonilfenil)-N-tiazol-2-ilpropionamid
[image]
Postupak A: Otopini PPh3 (3,53 g, 13,4 mmol) u CH2Cl2 (70 mL) uz miješanje je dodan NBS (882 mg, 10,6 mmol) pri 0 °C. Nakon 10 min, dodana je (2R)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) propionska kiselina (Priprema 53, 2,80 g, 9,0 mmol) i smjesa je miješana pri 0°C 20 min, a zatim pri 20°C 30 min. Pri 0 °C dodani su tiazol-2-ilamin (933 mg, 9,3 mm0l) i piridin (2,2 mL, 18,8 mmol), te je smjesa miješana pri 20 °C 20 h. Nakon uparavanja otapala, ostatak je razdijeljen između 5%-tne vodene otopine limunske kiseline (100 mL) i EtOAc (500 mL). Vodeni sloj dodatno je ekstrahiran EtOAc (200 mL), a spojeni organski slojevi zatim su isprani H2O i slanom vodom, te su osušeni (Na2SO4), filtrirani i koncentrirani u vakuumu. Kromatografsko pročišćavanje (CHCl3-MeOH, 99:1) ostataka na Chromatorex® NH-DM1020 (Fuji Silysia Chemical, Ltd., Aichi-ken, Japan; v. također http://www.fuji-silysia.co.jp/e-fl100dx.htm) dalo je spoj iz naslova: t.t. 217°C; [α]D20 = -51,5 (c = 1,00, CHCl3).
Postupak B: Racemični 2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid (Primjer 65) razdvojen je kiralnom HPLC stacionarne faze. Postupak: CHIRAL CEL OJ® (Daicel Chemical Industries, Ltd., Tokyo, Japan), 10 cm ∅ × 25 cm, MeOH (100%), 189 mL/min, UV 285 nm, 25°C; RT (S) = 21,7 min; RT (R) = 25,4 min. Analiza: CHIRAL CEL OJ® (Daicel Chemical Industries, Ltd., Tokyo, Japan), 4,6 mm ∅ × 15 cm, CH3-CN-0,5 M NaClO4 (pH 2,0), 20:80, 0,5 mL/min, UV 225 nm, 25°C; RT (S) = 11,53 min; RT (R) = 19,30 min).
Postupak A Primjera 93 korišten je za dobivanje spojeva nabrojanih u Tablici 10 iz odgovarajućih heteroaromatskih amina i enantiočiste kiseline.
Tablica 10
[image]
Postupak A Primjera 93 također je korišten u pripremi spojeva nabrojanih u Tablici 11, iz odgovarajućeg heteroaromatskog amina i enantiočiste kiseline.
Tablica 11
[image]
Primjer 114
(E)-2-(4-ciklopropansulfonilfenil)-N-(5-fluoropiridin-2-il)-3-(tetrahidropiran-4-il)akrilamid
[image]
TFFH (283 mg, 1,07 mmol) i DIPEA (373 μmol, 2,14 mmol) dodani su otopini (E)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)akrilne kiseline (Priprema 23, 300 mg, 0,89 mmol) u bezvodnom CH2Cl2 (18 mL) uz miješanje. Nakon 30 min, otopina je tretirana, dio po dio, 2-amino-5-fluoropiridinom (200 mg, 1,78 mmol) tijekom 30 min, a zatim je miješana još 16 h. Uparavanje otapala i pročišćavanje RP-HPLC dali su spoj iz naslova: RTA = 3,34 min; m/z (ES+) = 431,2 [M + H]+.
Postupak opisan u Primjeru 114 također je korišten u pripremi nekoliko drugih amida (Tablica 12).
Tablica 12
[image]
Primjer 124, Primjer 125, Primjer 126
(E)-2-fenil-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid, (E)-2-(4-formilfenil)-N-(5-formiltiazol-2-il)-3-(tetrahidropiran-4-il)akrilamid i (E)-N-(5-formiltiazol-2-il)-2-fenil-3-(tetrahidropiran-4-il)akrilamid
[image]
n-BuLi (17 mL 1,6 M otopine u heksanima, 27,2 mmol) uz miješanje je dodan otopini (E)-2-(4-bromofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamida (Primjer 12, 4,00 g, 10,2 mmol) u bezvodnom THF (100 mL) pri -78°C. Nakon 110 min, smjesa je tretirana bezvodnim DMF (5 mL, 64,6 mmol), a zatim je ostavljena da se zagrije na 20°C tijekom 30 min. Reakcija je ugašena 1M HCl, a zatim je THF uparen pod sniženim tlakom. Vodena faza ekstrahirana je CH2Cl2, a zatim su CH2Cl2 ekstrakti osušeni (MgSO4), filtrirani i koncentrirani. Ostatak je pomiješan s otopinom Na2S2O5. Nastala krutina prikupljena je i smrvljena s EtOAc. Taj je materijal potom suspendiran u EtOAc, te je uz miješanje dodana zasićena vodena otopina NaHCO3. Slojevi su odvojeni, a vodena faza ekstrahirana je EtOAc i CH2Cl2. Spojeni organski slojevi su osušeni, filtrirani, koncentrirani i propušteni kroz kromatografsku kolonu (CH2Cl2-THF, 93:7), da bi dali Primjer 125 (RTB = 1,30 min; m/z (ES+) = 371,2 [M + H]+ i Primjer 126 (RTB = 1,38 min; m/z (ES+) = 343,3 [M + H]+. EtOAc ispirci od bisulfitnog adicijskog kompleksa su koncentrirani, a ostatak je propušten kroz "flash" kromatografiju (CH2Cl2-THF, 24:1 do 93:7) da bi dali Primjer 124 (RTB = 1,39 min; m/z (ES+) = 315,3 [M + H]+) i dodatnu količinu Primjera 126.
Primjer 127
2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]tiazol-5-karboksilna kiselina
[image]
Etil-2-aminotiazol-5-karboksilat (2,21 g, 12,8 mmol) kondenziran je s 2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) propionskom kiselinom (Priprema 41, 1,00 g, 3,2 mmol), prema postupku opisanom u Primjeru 65, da bi se dobio etil-2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]tiazol-5-karboksilat: m/z (ES+) = 508,3 [M + MeCN + H]+. Otopini ovog estera (1,44 g, 3,1 mmol) u THF-H2O (3:1, 30 mL) dodan je LiOH⋅H2O (410 mg, 9,8 mmol). Smjesa je miješana pri 20°C 16 h i zatim na 55°C 24 h. Otapala su uklonjena u vakuumu, a ostatak je otopljen u H2O (50 mL). Vodena otopina isprana je EtOAc (20 mL), a zatim je zakiseljena 2M HCl do pH 1 i eksrahirana EtOAc (2 × 100 mL). Spojeni organski ekstrakti su osušeni (MgSO4), filtrirani i koncentrirani da bi dali krutinu koja je rekristalizirana (EtOAc-MeOH) da bi dala spoj iz naslova: RTA = 2,95 min; m/z (ES+) = 480,2 [M + MeCN + H]+.
Primjer 128
2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]tiazol-5-karboksilna kiselina metoksi-metil-amid
[image]
NEt3 (647 μL, 4,64 mmol) i BOP (976 mg, 2,21 mmol) dodani su uz miješanje otopini 2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]tiazol-5-karboksilne kiseline (Primjer 127, 968 mg, 2,21 mmol) u bezvodnom DMF (30 mL). Nakon 5 min, dodan je N,O-dimetilhidroksilamin-hidroklorid (237 mg, 2,43 mmol) i smjesa je miješana pri 20°C 18 h. Otapala su uklonjena u vakuumu, a ostatak je otopljen u EtOAc (75 mL). EtOAc otopina isprana je zasićenom vodenom otopinom Na2CO3 (40 mL), 2M HCl (40 mL) i slanom vodom (40 mL), te je osušena (MgSO4). Filtriranje i uparavanje otapala dali su spoj iz naslova: RTB = 1,27 min; m/z (ES+) = 482,0 [M + H]+.
Primjer 129
2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]tiazol-5-karboksilna kiselina metilamid
[image]
2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]tiazol-5-karboksilna kiselina (Primjer 127, 399 mg, 0,91 mmol) kondenzirana je s MeNH2⋅HCl u prisutnosti NEt3, prema postupku opisanom u Primjeru 65, da bi dala spoj iz naslova: RTA = 2,82 min; m/z (ES+) = 452,3 [M + H]+.
Primjer 130
(E)-2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akriloilamino]tiazol-5-karboksilna kiselina metilamid
[image]
Etil-2-aminotiazol-5-karboksilat (0,73 g, 4,26 mmol) kondenziran je s (E)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il) akrilnom kiselinom (Priprema 25, 0,33 g, 1,07 mmol), prema postupku opisanom u Primjeru 65, da bi dao (E)-etil-2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akriloilamino]tiazol-5-karboksilat: m/z (ES+) = 465,3 [M + H]+. Taj je ester (0,50 g, 1,07 mmol) je saponificiran, korištenjem postupka opisanog u Primjeru 127, da bi dao (E)-2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akriloilamino]tiazol-5-karboksilnu kiselinu: m/z (ES-) = 435,2 [M - H]-. Korištenjem pristupa opisanog u Primjeru 129, ta je kiselina (0,16 g, 0,37 mmol) transformirana u spoj iz naslova: RTA = 2,87 min; m/z (ES+) = 450,2 [M + H]+.
Primjer 131 i Primjer 132
N-(5-formiltiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid i N-(5-hidroksimetiltiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid
[image]
DIBAL (2,45 mL 1,5 M otopine u PhMe, 3,68 mmol) je kap po kap uz miješanje dodan u otopinu etil-2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]tiazol-5-karboksilata (v. Primjer 127, 1,72 g, 3,68 mmol) u bezvodnom CH2Cl2 (50 mL) pri -78°C. Nakon 50 min, dodano je još DIBAL (2,0 mL 1,5 M otopine u PhMe, 3,00 mmol). Smjesa je miješana još 70 min, a zatim je reakcija ugašena MeOH (3 mL) i 1M HCl (3 mL). Nakon zagrijavanja na 20°C dodano je još 1M HCl (20 mL). Organska faza je odvojena, osušena (MgSO4), filtrirana i koncentrirana te je pročišćena kromatografijom na koloni (IH-EtOAc, 1:9 do 0:1, zatim MeOH:EtOAc, 1:9) da bi dala aldehid iz naslova (RTA = 2,97 min; m/z (ES+) = 464,2 [M + MeCN + H]+)i alkohol iz naslova (RTA = 2,56 min; m/z (ES+) = 425,3 [M + H]+).
Primjer 133
N-(5-cijanotiazol-2-il)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-propionamid
[image]
Otopina 2-(4-ciklopropansulfonilfenil)-N-(5-formiltiazol-2-il)-3-(tetrahidropiran-4-il)propionamida (Primjer 86, 369 mg, 0,82 mmol) u piridinu (1,53 mL) tretirana je uz miješanje H2NOH⋅HCl (63 mg, 0,91 mmol) pri 0°C. Smjesa je miješana pri 20°C 3 h, a zatim je zagrijana na 60°C i tretirana Ac2O (155 μL, 1,65 mmol). Nakon 3 h, smjesa je ohlađena na 20°C i koncentrirana u vakuumu i tretirana CH2Cl2 (6 mL) i H2O (6 mL). Vodena faza zakiseljena je do pH 3 10%-tnom vodenom otopinom limunske kiseline. Organski sloj je odvojen, a vodeni sloj je dodatno ekstrahiran CH2Cl2 (2 × 10 mL). Spojeni organski ekstrakti su osušeni (MgSO4), filtrirani i koncentrirani da bi dali ostatak koji je pročišćen kromatografijom na koloni (IH-EtOAc, 1:3), što daje spoj iz naslova: RTA = 3,40 min; m/z (ES+) = 487,4 [M + MeCN + H]+.
Primjer 134
N-(5-cijanotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid
[image]
Postupak opisan u Primjeru 133 korišten je za prevođenje N-(5-formiltiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamida (Primjer 131, 200 mg, 0,47 mmol) u spoj iz naslova: RTA = 3,14 min; m/z (ES+) = 461,3 [M + MeCN + H]+.
Primjer 135
Metil-{2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]-tiazol-5-ilmetil}karbamat
[image]
(NH4)2CO3 (2,25 g, 34,1 mmol) uz miješanje je dodan otopini N-(5-formiltiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamida (Primjer 131, 125 mg, 0,3 mmol) u MeOH (15 mL). Nakon 16 h pri 20°C, smjesa je koncentrirana, a ostatak je razdijeljen između CH2Cl2 i H2O. Organski sloj ispran je Na2CO3 i 2M HCl, a zatim je osušen (MgSO4). Filtriranje, uparavanje otapala i kromatografija na koloni (EtOAc) dali su spoj iz naslova: RTA = 1,07 min; m/z (ES+) = 482,3 [M + H]+.
Primjer 136
(E)-3-(1-formilpiperidin-4-il)-2-(4-metansulfonilfenil)-N-tiazol-2-ilakrilamid
[image]
(E)-terc-butil-4-[2-karboksi-2-(4-metansulfonilfenil)vinil]piperidin-1-karboksilat (Priprema 35, 3,17 g, 7,7 mmol) kondenziran je s tiazol-2-ilaminom (2,32 g, 23,2 mmol), postupkom opisanim u Primjeru 65, da bi se dobio (E)-terc-butil-4-[2-(4-metansulfonilfenil)-2-(tiazol-2-ilkarbamoil)vinil]piperidin-1-karboksilat: m/z (ES+) = 492,2 [M + H]+. Otopini ovog karbamata (1,40 g, 2,8 mmol) u CH2Cl2 (20 mL) uz miješanje je dodana TFA (20 mL). Nakon 2 h, otopina je koncentrirana u vakuumu. Ostatak je otopljen u H2O, a zatim je otopina isprana EtOAc. Vodeni sloj koncentriran je da bi dao trifluoroacetatnu sol (E)-2-(4-metansulfonilfenil)-3-piperidin-4-il-N-tiazol-2-ilakrilamida: m/z (ES+) = 392,1 [M + H]+. Otopina imidazola (102 mg, 1,5 mmol) u bezvodnom DMF (1 mL) uz miješanje je tretirana Me3SiCl (114 μL, 0,9 mmol). Nakon 20 min, dodana je upravo dobivena trifluoroacetatna sol (150 mg, 0,3 mmol). Smjesa je miješana 16 h, a zatim je razdijeljena između CH2Cl2 i 1M HCl. Organski sloj je osušen (MgSO4), filtriran, koncentriran i propušten kroz "flash" kromatografiju (EtOAc-MeOH, 97:3 do 19:1). Rekristalizacija (EtOAc) ostatka dala je spoj iz naslova: RTA = 3,05 min; m/z (ES+) = 420,2 [M + H]+.
Primjer 137 i Primjer 138
(E)-2-(4-metansulfonilfenil)-3-(1-oksoheksahidro-1λ4-tiopiran-4-il)-N-tiazol-2-ilakrilamid i (E)-3-(1,1-dioksoheksahidro-1λ6-tiopiran-4-il)-2-(4-metansulfonilfenil)-N-tiazol-2-ilakrilamid
[image]
mCPBA (71 mg 86% čistoće, 410 μmol) dodana je uz miješanje otopini (E)-2-(4-metansulfonilfenil)-3-(tetrahidrotiopiran-4-il)-N-tiazol-2-ilakrilamida (Primjer 71, 96 mg, 230 μmol) u CH2Cl2 (5 mL). Nakon 2 h, reakcija je ugašena zasićenom vodenom otopinom Na2CO3. Organski sloj ispran je zasićenom vodenom otopinom NaHCO3 i osušen je (MgSO4). Filtriranje, uparavanje otapala i "flash" kromatografija (EtOAc, zatim CH2Cl2-MeOH, 19:1) dali su Primjer 138 (RTA = 3,12 min; m/z (ES+) = 482,2 [M + MeCN + H]+) i Primjer 137 (RTA = 2,95 min; m/z (ES+) = 425,1 [M + H]+).
Primjer 139 i Primjer 140
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(1-oksoheksahidro-1λ4-tiopiran-4-il)akrilamid i (E)-N-(5-klorotiazol-2-il)-3-(1,1-dioksoheksahidro-1λ6-tiopiran-4-il)-2-(4-metansulfonilfenil)akrilamid
[image]
Nepotpuna oksidacija (E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidrotiopiran-4-il)akrilamida (Primjer 72), prema postupku upravo opisanom za Primjer 137 i Primjer 138, dali su Primjer 139 (RTB = 1,36 min; m/z (ES+) = 458,9 [M + H]+) i Primjer 140 (RTB = 1,48 min; m/z (ES+) = 515,9 [M + MeCN + H]+).
Primjer 141 i Primjer 142
2-(3-fluoro-4-metansulfinilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid i 2-(3-fluoro-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid
[image]
Nepotpuna oksidacija 2-(3-fluoro-4-metilsulfanilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamida (Primjer 85, 350 mg, 0,92 mmol) s 1,5 ekv. mCPBA, prema postupku opisanom ranije za Primjer 137 i Primjer 138, dala je Primjer 141 (RTA = 3,06 min; m/z (ES+) = 397,1 [M + H]+) i Primjer 142 (RTA = 3,12 min; m/z (ES+) = 413,1 [M + H]+).
Primjer 143
N-(5-bromotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid
[image]
Otopina 2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamida (Primjer 65, 202 mg, 510 μmol), NBS (91 mg, 510 μmol) i Br2O2 (6 mg, 26 μmol) u CCl4 (2 mL) zagrijavana je do refluksa tijekom 16 h. Nakon uklanjanja otapala, ostatak je razdijeljen između EtOAc (30 mL) i H2O (30 mL). Organski ekstrakti isprani su zasićenom vodenom otopinom NH4Cl (30 mL), a zatim su osušeni (MgSO4). Filtriranje, uparavanje otapala i "flash" kromatografija (CH2Cl2-EtOAc, 2:3) dali su spoj iz naslova: RTA = 3,50 min; m/z (ES+) = 516,2 [M + MeCN + H]+.
Primjer 144
(E)-2-(4-hidroksifenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid
[image]
BBr3 (2,5 mL 1,0 M otopine u CH2Cl2, 2,5 mmol) dodan je uz miješanje otopini (E)-2-(4-metoksifenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamida (Primjer 13, 340 mg, 984 μmol) u bezvodnom CH2Cl2 (20 mL) pri -78°C. Nakon 1 h, smjesa je ostavljena da se zagrije na 20°C kroz 24 h. Dodan je CH2Cl2 (100 mL) i smjesa je isprana H2O (20 mL) i slanom vodom (20 mL) te je osušena (MgSO4). Filtriranje, uparavanje otapala i kromatografija na koloni (CH2Cl2-MeOH, 50:1) dali su spoj iz naslova: RTB = 1,27 min; m/z (ES+) = 331,0 [M + H]+.
Primjer 145
(E)-2-(4-metansulfonilaminofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid
[image]
Suspenzija (E)-2-(4-nitrofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamida (Primjer 81, 1,54 g, 4,0 mmol) u EtOH (54 mL) i THF (31 mL) uz miješanje je tretirana H2O (13 mL), zasićenom vodenom otopinom NH4Cl (13 mL) i Fe prahom (1,49 g, 26,7 mmol). Nakon 4,5 h pri 20°C, reakcijska smjesa filtrirana je kroz Celite, uz ispiranje CH2Cl2. Spojeni filtrati koncentrirani su, a ostatak je otopljen u CH2Cl2. CH2Cl2 otopina isprana je H2O i osušena je (MgSO4). Filtriranje, uparavanje otapala i kromatografija na koloni (EtOAc-MeOH, 19:1) dali su (E)-2-(4-aminofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid: m/z (ES+) = 330,1 [M + H]+. Otopina tog spoja (104 mg, 291 μmol) u bezvodnom CH2Cl2 (4 mL) uz miješanje je tretirana MeSO2Cl (90 μL, 1165 μmol) i piridinom (94 μL, 1165 μmol). Nakon 16 h, smjesa je razrijeđena CH2Cl2 (25 mL), i dvaput ekstrahirana 2M NaOH. Spojeni vodeni ekstrakti isprani su Et2O i zakiseljeni 12M HCl do pH 1, te su dvaput ekstrahirani CH2Cl2. Spojeni organski ekstrakti isprani su slanom vodom i osušeni (MgSO4). Filtriranje i uparavanje otapala dali su spoj iz naslova: RTB = 1,26 min; m/z (ES+) = 408,0 [M + H]+.
Primjer 146
3-(tetrahidropiran-4-il)-2-[4-(tetrahidropiran-4-ilmetilsulfanil)fenil]-N-tiazol-2-ilpropionamid
[image]
Otopina 2-(4-metoksimetilsulfanilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamida (Primjer 77, 1,29 g, 3,28 mmol) u THF (50 mL) dodana je otopini AgNO3 (0,59 g, 3,28 mmol) u EtOH (85 mL) pri 40°C uz miješanje. Smjesa je zaštićena od svjetla i miješana pri 40°C 21 h. Otapala su uparena pod sniženim tlakom, a preostala krutina smrvljena je s i-PrOH (60 mL), THF (60 mL) i Et2O (60 mL). Nakon sušenja na zraku, krutina je žestoko promiješana s CH2Cl2 (200 mL) i 6M HCl (82 mL) kroz 4 h pod Ar. Slojevi su odvojeni, a vodena faza je ekstrahirana s CH2Cl2 (2 × 100 mL). Spojeni organski ekstrakti filtrirani su kroz Celite, isprani slanom vodom (100 mL) i osušeni (MgSO4). Filtriranje i uparavanje otapala dali su 2-(4-merkaptofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid: m/z (ES+) = 394,2 [M + H]+. Otopini ovog benzentiola (197 mg, 565 μmol) u bezvodnom DMF (7 mL) uz miješanje pri 0°C dodani su NEt3 (0,14 mL, 1006 μmol) i otopina 4-jodometiltetrahidropirana (151 mg, 668 μmol) u bezvodnom DMF (3 mL). Smjesa je zagrijana do 20°C i miješana je 16 h. Otapala su uparena pod sniženim tlakom, a ostatak je razdijeljen između CH2Cl2 (25 mL) i 2%-tne vodene otopine limunske kiseline (10 mL). Vodeni sloj ekstrahiran je CH2Cl2 (10 mL), a spojeni organski slojevi isprani su H2O (10 mL), zasićenom vodenom otopinom Na2CO3 (10 mL), H2O (10 mL) i slanom vodom (10 mL). Nakon sušenja (MgSO4), filtriranje i uparavanje otapala dali su ostatak koji je propušten kroz "flash" kromatografiju (IH-EtOAc, 3:1 do 0:1) da bi dao spoj iz naslova: RTA = 3,61 min; m/z (ES+) = 447,3 [M + H]+.
Primjer 147
2-[4-(piridin-3-ilsulfanil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid
[image]
Otopina Pd2dba3 (18 mg, 20 μmol) i DPEPhos (24 mg, 45 μmol) u bezvodnom PhMe (4 mL) miješana je pri 20°C 3 min. Dodani su 3-jodopiridin (107 mg, 522 μmol), 2-(4-merkaptofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid (v. Primjer 146, 173 mg, 500 μmol) i t-BuOK (65 mg, 579 μmol) te je smjesa zagrijana na 105°C (kupelj) kroz 2,5 h. Nakon hlađenja na 20°C, smjesa je razrijeđena CH2Cl2 (10 mL) i filtrirana kroz Celite, uz ispiranje CH2Cl2 (5 mL) i EtOAc (10 mL). Uparavanje otapala i "flash" kromatografija (IH-EtOAc, 3:1 do 0:1) dali su spoj iz naslova: RTB = 1,37 min; m/z (ES+) = 426,0 [M + H]+.
Primjer 148
3-(tetrahidropiran-4-il)-2-[4-(tetrahidropiran-4-ilmetansulfonil)fenil]-N-tiazol-2-ilpropionamid
[image]
Otopina 3-(tetrahidropiran-4-il)-2-[4-(tetrahidropiran-4-ilmetilsulfanil)fenil]-N-tiazol-2-ilpropionamida (Primjer 146, 146 mg, 327 μmol) u CH2Cl2 (7 mL) uz miješanje je tretirana otopinom mCPBA (186 mg 65%-tne čistoće, 690 μmol) u CH2Cl2 (7 mL). Nakon 4 dana, dodana je zasićena vodena otopina Na2CO3 (10 mL) i smjesa je žestoko miješana 5 min. Vodena faza ekstrahirana je CH2Cl2 (10 mL), a spojeni organski ekstrakti isprani su zasićenom vodenom otopinom Na2CO3 (10 mL), H2O (10 mL) i slanom vodom (10 mL), te su osušeni (MgSO4). Filtriranje, uparavanje otapala i "flash" kromatografija (EtOAc) dali su spoj iz naslova: RTA = 3,26 min; m/z (ES+) = 479,3 [M + H]+.
Oksidacijom odgovarajućeg tioetera pripremljeno je nekoliko drugih sulfona (Tablica 13) slijedeći postupak opisan u Primjeru 148.
Tablica 13
[image]
[A] RT pomoću postupka A. [B] RT pomoću postupka B.
Spojevi nabrojani u Tablici 14 pripremljeni su iz 2-(4-merkaptofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamidam (v. Primjer 146) kombiniranjem postupaka korištenih u pripremi Primjera 146 i 148.
Tablica 14
[image]
[A] RT pomoću postupka A. [B] RT pomoću postupka B.
Primjer 161
2-[4-(oksetan-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid
[image]
Smjesa 2-(4-merkaptofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamida (v. Primjer 146, 349 mg, 1,0 mmol), K2CO3 (152 mg, 1,1 mmol), NaI (150 mg, 1,0 mmol) i 3-(tosiloksi)oksetana (274 mg, 1,2 mmol) u bezvodnom DMAc (20 mL) zagrijavana je 2 h na 130°C. Otapalo je upareno pod sniženim tlakom, a ostatak je zatim razdijeljen između CH2Cl2 (75 mL) i 2%-tne vodene otopine limunske kiseline (20 mL). Organski sloj ispran je H2O (20 mL), zasićenom vodenom otopinom Na2CO3 (20 mL) i slanom vodom (20 mL), te je osušen (MgSO4). Filtriranje i uparavanje otapala dali su 2-[4-(oksetan-3-ilsulfanil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid: m/z (ES+) = 405,2 [M + H]+. Taj je tioeter oksidiran prema protokolu naznačenom u Primjeru 148 da bi se dobio spoj iz naslova: RTA = 3,04 min; m/z (ES+) = 437,2 [M + H]+.
Spojevi nabrojani u Tablici 15 sintetizirani su prema protokolima opisanim u Primjeru 161.
Tablica 15
[image]
Primjer 165
2-[4-(2-oksopropan-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid
[image]
Reakcija 2-(4-merkaptofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamida (v. Primjer 146, 363 mg, 1,04 mmol) s kloroacetonom (90 μL, 1,10 mmol), prema postupku sličnom onome opisanom u Primjeru 146, dala je 2-[4-(2-oksopropilsulfanil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid: m/z (ES+) = 405,3 [M + H]+. Otopini tog tioetera (399 mg, 0,99 mmol) u CH2Cl2 (20 mL) uz miješanje je dodan TBA-OX (2,46 g, 2,44 mmol). Nakon 19 h, reakcijska smjesa tretirana je s još TBA-OX (0,97 g, 0,96 mmol). 20 h kasnije dodano je još TBA-OX (1,09 g, 1,07 mmol) i smjesa je miješana još 3 dana. Uparavanje otapala i "flash" kromatografija (IH-EtOAc, 3:2 do 0:1) dali su spoj iz naslova: RTA = 3,12 min; m/z (ES+) = 437,2 [M + H]+.
Spojevi nabrojani u Tablici 16 dobiveni su iz 2-(4-merkaptofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamida (v. Primjer 146) kombiniranjem postupaka za pripremu Primjera 147 i onih za pripremu Primjera 141 i 142.
Tablica 16
[image]
Primjer 171
2-(3-amino-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid
[image]
2-(4-metilsulfanil-3-nitrofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid (Primjer 80, 5,84 g, 13,2 mmol) oksidiran je mCPBA slijedeći postupak opisan u Primjeru 148 da bi dao 2-(4-metansulfonil-3-nitrofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid: m/z (ES+) = 481,1 [M + MeCN + H]+. Ovaj spoj (520 mg, 1,2 mmol) je reduciran prema postupku opisanom u Primjeru 145, da bi dao spoj iz naslova: RTA = 2,95 min; m/z (ES+) = 426,1 [M + NH4]+.
Primjer 172
2-(3-kloro-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid
[image]
Otopina NaNO2 (34 mg, 498 μmol) u H2O (0,8 mL) dodana je otopini 2-(3-amino-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamida (Primjer 171, 200 mg, 488 μmol) u 6M HCl (1,6 mL) pri 0°C. Reakcija je miješana pri 0°C 35 min, a zatim je polako dodana smjesi Cu praha (80 mg, 1,26 mmol) i 12M HCl (0,8 mL) pri 0°C uz miješanje. Temperatura je podignuta na 20°C, a miješanje je nastavljeno još 1 h. Smjesa je zatim zagrijavana na 60°C tijekom 1 h, a zatim je ponovno ohlađena na 20°C i ekstrahirana CH2Cl2 (3 × 15 mL). Organski ekstrakti su osušeni (MgSO4), filtrirani i koncentrirani da bi dali ostatak koji je pročišćen RP-HPLC da bi dao spoj iz naslova: RTA = 3,17 min; m/z (ES+) = 429,2 [M + H]+.
Primjer 173
2-[4-(morfolin-4-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid
[image]
NEt3 (120 μL, 868 μmol) i morfolin (76 μL, 868 μmol) dodani su otopini 4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzensulfonil-klorida (Priprema 59, 300 mg, 723 μmol) u bezvodnom DMF (4 mL). Nakon 10 min, otapala su uklonjena u vakuumu, a ostatak je prenesen u CH2Cl2 (50 mL). CH2Cl2 otopina isprana je H2O (20 mL), 1M HCl (20 mL), H2O (20 mL), zasićenom vodenom otopinom Na2CO3 (20 mL9 i slanom vodom (20 mL), te je osušena (MgSO4). FIltriranje, uparavanje otapala i rekristalizacija CH2Cl2-IH) dali su spoj iz naslova: RTA = 3,15 min; m/z (ES+) = 466,1 [M + H]+.
Sulfonamidi nabrojani u Tablici 17 sintetizirani su prema postupcima sličnima ovom opisanom u Primjeru 173.
Tablica 17
[image] [image] [image] Primjer 198
N-(5-klorotiazol-2-il)-2-[4-(piperazin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)propionamid
[image]
NEt3 (278 μL, 2,0 mmol) i terc-butil-piperazin-1-karboksilat (373 mg, 2,0 mmol) dodani su uz miješanje otopini 4-[1-(5-klorotiazol-2-ilkarbamoil)-2-(tetrahidropiran-4-il)etil]benzensulfonil-klorida (Priprema 60, 449 mg, 1,0 mmol) u bezvodnom DMAc (4 mL). Smjesa je miješana 16 h, a zatim su otapala uklonjena u vakuumu. Ostatak je otopljen u EtOAc (50 mL) da bi dao otopinu koja je isprana H2O (15 mL), zasićenom vodenom otopinom Na2CO3 (15 mL) i slanom vodom (15 mL), te je osušena (MgSO4). Filtriranje, uparavanje otapala i kromatografija na koloni (IH-EtOAc, 7:3 do 1:1) dali su terc-butil 4-{4-[1-(5-klorotiazol-2-ilkarbamoil)-2-(tetrahidropiran-4-il)etil]benzensulfonil}piperazin-1-karboksilat: m/z (ES+) = 599,5 [M + H]+. Otopina tog spoja (189 mg, 316 μmol) u CH2Cl2-TFA (1:1, 7 mL) miješana je 1 h. Otapala su uparena pod sniženim tlakom, a ostatak je smrvljen u Et2O. Produkt je skupljen, ispran Et2O i osušen na zraku da bi dao trifluoroacetatnu sol spoja iz naslova: RTA = 2,64 min; m/z (ES+) = 499,3 [M + H]+.
Spojevi nabrojani u Tablici 18 sintetizirani su kao trifluoroacetatne soli prema postupcima opisanima u Primjeru 198.
Tablica 18
[image]
Primjer 201
N-etil-4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzamid
[image]
4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzojeva kiselina (Priprema 62, 150 mg, 420 μmol) kondenzirana je s EtNH2⋅HCl u prisutnosti DIPEA, prema općem postupku opisanom u Primjeru 65, da bi dala spoj iz naslova: RTA = 2,97 min; m/z (ES+) = 388,3 [M + H]+.
1H NMR podaci za neke od Primjera prikazani su u Tablici 19.
Tablica 19
[image]
Sljedeći spojevi također se mogu sintetizirati prema opisanim postupcima:
2-(3-kloro-4-metansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonil-3-trifluorometilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-ilpropionamid i
2-(3,4-diklorofenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid.
Testovi
Aktivnost GK in vitro
Prema protokolu sličnom onome opisanom u WO 00/58293, aktivnost GK ispitana je povezivanjem stvaranja G6P putem GST-GK, do stvaranja NADPH, uz G6PDH kao enzim.
Ispitivanje GK provedeno je na 30°C na pločama od 96 jažica s ravnim dnom (Costar), a konačan inkubacijski volumen bio je 100 μL. Reakcijski pufer sadržao je: 25 mM Hepes pufer (pH 7,4), 12,5 mM KCl, 5 mM D-Glc, 5 mM ATP, 6,25 mM NADP, 25 mM MgCl2, 1 mM ditiotreitol, ispitivani spoj ili 5% DMSO, 3,0 jedinice/mL G6PDH i 0,4 μL/mL GST-GK, dobivene iz GK ljudske jetre. ATP, G6PDH i NADP nabavljeni su od Roche Diagnostics. Ostali reagensi bili su ≥ 98% čistoće i nabavljeni su od Kanto Chemicals. Ispitivani spojeiv otopljeni su u DMSO prije dodavanja u reakcijski pufer bez ATP. Ta smjesa prethodno je inkubirana u komori s kontroliranom temperaturom SPECTRAmax 250 spektrofotometra za mikroploče (Molecular Devices Corporation, Sunnyvale, CA) 10 min, a zatim je reakcija započela dodatkom 10 μL otopine ATP.
Nakon početka reakcije, porast optičke gustoće (OD) pri 340 nM mjereno je kroz 10-minutni period inkubacije kao mjera aktivnosti GK. Dodano je dovoljno GST-GK da nastane porast OD340 kroz 10 minuta inkubacije u jažicama koje su sadržale 5% DMSO, ali ne i ispitivani spoj. Preliminarni pokusi ustanovili su da je reakcija GK linearna u tom vremenskom periodu, čak i u prisutnosti aktivatora koji su doveli do 8 puta veće aktivnost GK. Aktivnost GK u kontrolnim jažicama uspoređena je s aktivnošću u jažicama koje su sadržale ispitivane aktivatore GK. Izračunate su koncentracije spojeva koje su uzrokovale 50% porast aktivnosti GK (tj. FA1.5). Aktivatori GK postižu FA1.5 pri ≤ 30 μM.
Gore opisani Primjeri 1-201 proizveli su EC50 u rasponu od 0,1 do 32,6 μM s maksimalnim FAs od 1,6 do 8,7.
Sljedeći spojevi nisu postigli FA1.5 pri ≤ 30 μM i prema tome nisu poželjni spojevi ovog izuma:
2-(4-bromofenil)-3-furan-2-il-N-[1,3,4]tiadiazol-2-il-akrilamid;
3-furan-2-il-2-(4-metoksifenil)-N-(4-trifluorometil-tiazol-2-il)akrilamid;
N-(5-bromotiazol-2-il)-3-furan-2-il-2-(3-metoksifenil)akrilamid;
N-(5-klorotiazol-2-il)-3-furan-2-il-2-(3-metoksifenil)akrilamid;
4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzojeva kiselina;
N-metil-4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzamid;
N,N-dimetil-4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzamid;
2-(4-aminofenil)-N-(5-klorotiazol-2-il)-3-(tetrahidropiran-4-il)-propionamid;
N-(5-dimetilaminometiltiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
N-(5-klorobenzooksazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonilfenil)-N-(1-metil-1H-benzoimidazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
N-(1H-benzoimidazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-propionamid;
N-izokinolin-1-il-2-(4-metansulfonilfenil)-3 -(tetrahidropiran-4-il)-propionamid;
N-izokinolin-3-il-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
3-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzojeva kiselina;
3-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]-N-tiazol-2-il-benzamid;
3-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzojeva kiselina metil-ester;
2-(4-merkaptofenil)-3-(tetrahidro-piran-4-il)-N-tiazol-2-il-propionamid;
2-(4-aminofenil)-3-(tetrahidro-piran-4-il)-N-tiazol-2-il-propionamid;
2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]-tiazol-4-karboksilna kiselina;
4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzamid;
2-(3-ciklopropansulfonilaminofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid;
2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionilamino]-tiazol-4-karboksilna kiselina etil-ester;
2-[2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-propionilamino]-tiazol-5- karboksilna kiselina etil-ester;
2-(3-metansulfonilaminofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid;
2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-(5-trifluorometiltiazol-2-il)-propionamid;
2-(4-cijanofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid;
2-(4-dimetilaminometilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-akrilamid;
2-(4-metilaminometilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-akrilamid;
2-[2-(4-karboksifenil)-3-(tetrahidropiran-4-il)akriloilamino]-tiazole-5-karboksilna kiselina;
N-[5-(4-etilpiperazin-1-karbonil)tiazol-2-il]-2-fenil-3-(tetrahidropiran-4-il)akrilamid;
N-[5-(4-metilpiperazin-I-karbonil)tiazol-2-il]-2-fenil-3-(tetrahidropiran-4-il)akrilamid;
2-[2-fenil-3-(tetrahidropiran-4-il)akriloilamino]tiazol-5-karboksilna kiselina (2-dimetilaminoetil)amid;
2-(4-metansulfonilfenil)-4-(tetrahidropiran-4-il)-N-tiazol-2-ilbutiramid;
2-(4-metansulfonilfenil)-4-(tetrahidropiran-4-il)-but-2-enoična kiselina tiazol-2-ilamid;
2-(4-acetilaminofenil)-N-(5-klorotiazol-2-il)-3-(tetrahidropiran-4-il)akrilamid;
N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-piperidin-4-il-akrilamid;
2-(4-metansulfonilfenil)-3-piperidin-4-il-N-tiazol-2-il-akrilamid;
2-(4-aminofenil)-3-(tetrahidro-piran-4-il)-N-tiazol-2-il-akrilamid;
2-(4-aminofenil)-N-(5-kloro-tiazol-2-il)-3-(tetrahidro-piran-4-il-akrilamid;
2-(4-metansulfonilfenil)-3-piperidin-1-il-N-tiazol-2-il-propionamid;
2-(4-metansulfonilfenil)-3-(3-metiltiofen-2-il)-N-tiazol-2-il-akrilamid;
2-(4-metansulfonilfenil)-3-piridin-3-il-N-tiazol-2-il-akrilamid;
2-(3-bromofenil)-N-(5-klorotiazol-2-il)-3-tiofen-2-il-akrilamid;
2-(3-bromofenil)-N-tiazol-2-il-3-tiofen-2-il-akrilamid;
N-(4,5-dimetiltiazol-2-il)-2-fenil-3-tiofen-2-il-akrilamid;
N-(5-klorotiazol-2-il)-2-fenil-3-tiofen-2-il-akrilamid;
N-(5-metiltiazol-2-il)-2-fenil-3-tiofen-2-il-akrilamid;
2-(4-bromofenil)-N-pyrazin-2-il-3-tiofen-2-il-akrilamid;
3-furan-2-il-2-(3-metoksifenil)-N-tiazol-2-il-akrilamid;
2-(4-bromofenil)-N-(5-bromopiridin-2-il)-3-furan-2-il-akrilamid;
N-(5-bromotiazol-2-il)-2-(4-cijanofenil)-3-fenil-akrilamid;
2-(4-cijanofenil)-3-fenil-N-[1,3,4]tiadiazol-2-il-akrilamid;
2-(4-cijanofenil)-3-furan-2-il-N-[1,3,4]tiadiazol-2-il-akrilamid;
2-(4-cijanofenil)-3-fenil-N-tiazol-2-il-akrilamid;
3-furan-2-il-2-(3-metoksifenil)-N-piridin-2-il-akrilamid;
2-(4-bromofenil)-N-(4,5-dimetiltiazol-2-il)-3-tiofen-2-il-akrilamid;
2-(4-bromofenil)-N-piridin-2-il-3-tiofen-2-il-akrilamid;
2-(4-bromofenil)-N-pirimidin-4-il-3-tiofen-2-il-akrilamid;
2-(4-bromofenil)-3-tiofen-2-il-N-(4-trifluorometil-tiazol-2-il)akrilamid;
N-(5-bromopiridin-2-il)-3-furan-2-il-2-(4-metoksifenil)akrilamid;
3-furan-2-il-2-(4-metoksifenil)-N-pirimidin-4-il-akrilamid;
N-(5-bromotiazol-2-il)-3-furan-2-il-2-(4-metoksifenil)akrilamid;
N-(5-klorotiazol-2-il)-3-furan-2-il-2-(4-metoksifenil)akrilamid;
N-benzotiazol-2-il-3-furan-2-il-2-(4-metoksifenil)akrilamid;
N-benzotiazol-2-il-2-(4-bromofenil)-3-tiofen-2-il-akrilamide;
3-furan-2-il-2-(4-metoksifenil)-N-[1,3,4]tiadiazol-2-il-akrilamid;
2-(4-bromofenil)-N-(5-bromopiridin-2-il)-3-tiofen-2-il-akrilamide; i
N-(4,5-dimetiltiazol-2-il)-3-furan-2-il-2-(4-metoksifenil)akrilamid.
Aktivnost GK in vivo
Nakon 18 h gladovanja, C57BL/6J miševima je oralno doziran aktivator GK u koncentraciji 50 mg/kg tjelesne težine. Određivanje Glc u krvi provedeno je 5 puta tijekom 6 h nakon doziranja.
Miševi (n = 5) su izvagani i gladovali su 18 h prije oralnog tretmana. Aktivatori GK otopljeni su u nisaču Gelucire opisanom u WO 00/58293 (EtOH:Gelucire 44/14:PEG400 q.s. 4:66:30 v/v/v) u koncentraciji 13,3 mg/mL. Miševima je oralno dozirano 7,5 mL formulacije po kg tjelesne težine tako da doza bude 50 mg/kg. Neposredno prije doziranja, provedeno je prethodno očitavanje Glc (vrijeme nula) rezanjem malog dijela životinjskog repa (< 1 mm) i prikupljanjem 15 μL krvi za analizu. Nakon tretiranja aktivatorom GK, provedena su daljnja očitavanja Glc u krvi u periodima od 1, 2, 4 i 6 h nakon doziranja iz iste repne rane. Rezultati su interpretirani uspoređivanjem srednjih vrijednosti Glc u krvi za 5 miševa tretiranih samo nosačem, s vrijednostima 5 miševa tretiranih aktivatorom GK tijekom 6 h trajanja testa. Spojevi se smatraju aktivnima kad pokazuju statistički značajno smanjenje Glc u krvi u usporedbi s nosačem za dvije uzastopne vremenske točke u testu.
Nekoliko od gore opisanih primjera aktivatora GK pokazalo je izraženi učinak aktivacije GK in vivo oralnom primjenom u spomenutom periodu.
Claims (35)
1. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da je:
Q je aril, 5- ili 6-člani heteroaril ili 4-8 člani heterociklički prsten;
T, zajedno s -N=C- na koji je vezan, tvori heteroarilni prsten, ili heterociklički prsten, gdje je N=C veza jedino nezasićeno mjesto;
R1 i R2 su, neovisno jedan o drugome, vodik, hidroksi, halogen, cijano, nitro, vinil, etinil, metoksi, OCFnH3-n, -N(C0-4 alkil)(C0-4 alkil), CHO, ili C1-2 alkil po želji supstituiran s 1-5 neovisnih halogenih, hidroksi, cijano, metoksi, -N(C0-2 alkil)(C0-2 alkil), SOCH3 ili SO2CH3 supstituenata; ili R1 i R2 zajedno tvore karbociklički ili heterociklički prsten; ili R1 i R2 mogu zajedno predstavljati kisikov atom vezan na prsten dvostrukom vezom;
R3 i R4 su, neovisno jedan o drugome, vodik, halogen, OCFnH3-n, metoksi, CO2R77, cijano, nitro, CHO, CONR99R100, CON(OCH3)CH3, ili C1-2 alkil, heteroaril, ili C3-7 cikloalkil, po želji supstituiran s 1-5 neovisnih halogenih, hidroksi, cijano, metoksi, -NHCO2CH3 ili -N(C0-2 alkil)(C0-2 alkil) supstituenata; ili R3 i R4 zajedno tvore 5-8-člani aromatski, heteroaromatski, karbociklički ili heterociklički prsten;
R5 i R6 su, neovisno jedan o drugome, vodik, hidroksi, halogen, cijano, nitro, CO2R7, CHO, COR8, C(OH)R7R8, C(=NOR7)R8, CONR9R10, SR7, SOR8, SO2R8, SO2NR9R10, CH2NR9R10, NR9R10, N(C0-4 alkil)SO2R8, NHCOR7, ili C1-4 alkilna grupa, C2-4 alkenilna grupa, C2-4 alkinilna grupa, C1-4 alkoksi grupa, arilna grupa ili heteroarilna grupa, gdje je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, CFnH3-n, aril, heteroaril, -COC1-2 alkil, -CON(C0-2 alkil)(C0-2 alkil), SCH3, SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata; ili R5 i R6 zajedno tvore 5-8-člani karbociklički ili heterociklički prsten;
R7 i R77 su, neovisno jedan o drugome, vodik, ili C1-4 alkilna grupa, C2-4 alkenilna grupa, C2-4 alkinilna grupa, C3-7 cikloalkilna grupa, arilna grupa, heteroarilna grupa, ili 4-7 člana heterociklička grupa, pri čemu je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, C3-7 cikloalkil, 4-7-članih heterocikličkih prstenova, CFnH3-n, arila, heteroarila, CO2H, -COC1-2 alkila, -CON(C0-2 alkil)(C0-2 alkil), SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata;
R8 je C1-4 alkilna grupa, C2-4 alkenilna grupa, C2-4 alkinilna grupa, C3-7 cikloalkilna grupa, arilna grupa, heteroarilna grupa, ili 4-7 člana heterociklička grupa, pri čemu je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, C3-7 cikloalkil, 4-7-članih heterocikličkih prstenova, CFnH3-n, arila, heteroarila, CO2H, -COC1-2 alkila, -CON(C0-2 alkil)(C0-2 alkil), SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata;
R9, R10, R99 i R100 su, neovisno jedan o drugome, vodik, ili C1-4 alkilna grupa, C3-7 cikloalkilna grupa, arilna grupa, heteroarilna grupa, ili 4-7 člana heterociklička grupa, pri čemu je bilo koja od grupa po želji supstituirana s 1-6 neovisnih halogena, cijano, nitro, hidroksi, C1-2 alkoksi, -N(C0-2 alkil)(C0-2 alkil), C1-2 alkil, C3-7 cikloalkil, 4-7 članih heterocikličkih prstenova, CFnH3-n, arila, heteroarila, -COC1-2 alkila, -CON(C0-2 alkil)(C0-2 alkil), SOCH3, SO2CH3 ili -SO2N(C0-2 alkil)(C0-2 alkil) supstituenata; ili R9 i R10 ili R99 i R100 zajedno tvore 6-8-člani heterobiciklički prstenasti sustav ili 4-8-člani heterociklički prsten koji je po želji supstituiran s 1-2 neovisna C1-2 alkila, CH2OCH3, COC0-2 alkila, hidroksi ili SO2CH3 supstituenta;
n je 1, 2 ili 3;
m je 0 ili 1; a
iscrtkana linija zajedno s punom linijom tvori eventualnu dvostruku vezu, a Δ znači da dvostruka veza ima (E)-konfiguraciju.
2. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da iscrtkana linija zajedno s punom linijom tvori dvostruku vezu.
3. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da iscrtkana linija zajedno s punom linijom tvori jednostruku vezu.
4. Spoj prema zahtjevu 3, ili njegova farmaceutski prihvatljiva sol, naznačen time da iscrtkana linija zajedno s punom linijom tvori jednostruku vezu, a apsolutna konfiguracija na asimetričnom centru α u odnosu na amidni karbonilni ugljik je (R).
5. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da je m 0.
6. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time da je Q tienil, furil, tiazolil, piridil, tetrahidropiranil, piperidinil, tetrahidrotiopiranil, 1-okso-tetrahidrotiopiranil ili 1,1-diokso-tetrahidrotiopiranil.
7. Spoj prema zahtjevu 6, ili njegova farmaceutski prihvatljiva sol, naznačen time da je Q 4-tetrahidropiranil.
8. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time da je grupa formule
[image]
tiazolil, tiadiazolil, oksazolil, izoksazolil, pirimidinil, pirazinil ili piridil.
9. Spoj prema zahtjevu 8, ili njegova farmaceutski prihvatljiva sol, naznačen time da je grupa formule
[image]
2-pirazinil ili 2-tiazolil.
10. Spoj prema zahtjevu 9, ili njegova farmaceutski prihvatljiva sol, naznačen time da je grupa formule
[image]
2-tiazolil, R3 je 5-fluoro, a R4 je vodik.
11. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time da su R3 i R4 neovisno izabrani između vodika, halogena i metila.
12. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time da je R5 SOR8, SO2R8 ili SO2NR9R10.
13. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time da je R8 C1-4 alkil ili C3-7 cikloalkil.
14. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time da je R5 SO2C3-4 cikloalkil.
15. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time da je R6 vodik.
16. Spoj, naznačen time da je izabran između sljedećih:
(E)-2-(4-metansulfonilfenil)-N-tiazol-2-il-3-tiofen-3-ilakrilamid;
(E)-2-(4-metansulfonilfenil)-N-tiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-3-furan-2-il-2-(4-metansulfonilfenil)-N-tiazol-2-ilakrilamid;
(E)-2-(4-metansulfonilfenil)-3,N bistiazol-2-ilakrilamid;
(E)-2-(4-metansulfonilfenil)-3-(5-metiltiofen-2-il)-N tiazol-2-ilakrilamid;
(E)-3-(5-klorotiofen-2-il)-2-(4-metansulfonilfenil)-N tiazol-2-ilakrilamid;
(E)-2-(4-metansulfonilfenil)-3-tiazol-5-il-N tiazol-2-ilakrilamid;
2-(4-metansulfonilfenil)-N tiazol-2-il-3-tiofen-2-ilpropionamid;
2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
2-(4-ciklopropansulfonilfenil)-N (5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
N (5-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
(E)-2-(4-bromofenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilakrilamid;
(E)-2-(4-metoksifenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilakrilamid;
(E)-3-(tetrahidropiran-4-il)-N tiazol-2-il-2-(4-[1,2,4]triazol-1-ilfenil)akrilamid;
(E)-3-(tetrahidrotiopiran-4-il)-N tiazol-2-il-2-(4-[1,2,4]triazol-1-ilfenil)akrilamid;
(E)-3-(tetrahidropiran-4-il)-N tiazol-2-il-2-(4-[1,2,3]triazol-1-ilfenil)akrilamid;
3-(tetrahidropiran-4-il)-N tiazol-2-il-2-(4-trifluorometilsulfanilfenil)propionamid;
2-(4-metilsulfanilmetilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
2-(4-metansulfonilfenil)-N (1H pirazol-3-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonilfenil)-N piridin-2-il-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonilfenil)-N pirimidin-4-il-3-(tetrahidropiran-4-il)propionamid;
N (4,5-dihidrotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
N-(1H-imidazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
N-benzotiazol-2-il-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N [1,3,4]tiadiazol-2-ilpropionamid;
2-(4-metansulfonilfenil)-N (3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
N-(5-fluoropiridin-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonilfenil)-N (5-metiltiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonilfenil)-N (4-metiltiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-ciklopropansulfonilfenil)-N (3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-ciklopropansulfonilfenil)-N pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N-[1,2,4]tiadiazol-5-ilpropionamid;
(E)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilakrilamid;
2-(4-metansulfonilfenil)-N (5-nitrotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-N (5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-tiofen-2-ilakrilamid;
(E)-N (5-kloro-4-metiltiazol-2-il)-2-(4-metansulfonilfenil)-3-tiofen-2-ilakrilamid;
(E)-N (5-klorotiazol-2-il)-3-furan-2-il-2-(4-metansulfonilfenil)akrilamid;
(E)-N (5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-tiofen-3-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-piridin-3-ilakrilamid;
N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-tiofen-2-ilpropionamid;
N-(5-kloro-4-metiltiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-tiazol-5-ilakrilamid;
(E)-2-(4-bromofenil)-N (5-klorotiazol-2-il)-3-furan-2-ilakrilamid;
(E)-2-(4-bromofenil)-3-furan-2-il-N-pirimidin-4-ilakrilamid;
(E)-2-(4-bromofenil)-N (5-bromotiazol-2-il)-3-furan-2-ilakrilamid;
(E)-2-(4-bromofenil)-3-furan-2-il-N-tiazol-2-ilakrilamid;
(E)-2-(4-bromofenil)-3-furan-2-il-N-(5-metiltiazol-2-il)akrilamid;
(E)-N benzotiazol-2-il-2-(4-bromofenil)-3-furan-2-ilakrilamid;
(E)-2-(4-bromofenil)-N-(4,5-dimetiltiazol-2-il)-3-furan-2-ilakrilamid;
(E)-2-(4-bromofenil)-N-(5-bromotiazol-2-il)-3-tiofen-2-ilakrilamid;
(E)-2-(4-bromofenil)-N-tiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-2-(4-bromofenil)-N-[1,3,4]tiadiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-2-(4-bromofenil)-N-(5-metiltiazol-2-il)-3-tiofen-2-ilakrilamid;
(E)-2-(4-bromofenil)-N-(5-klorotiazol-2-il)-3-tiofen-2-ilakrilamid;
(E)-3-furan-2-il-2-(4-metoksifenil)-N-tiazol-2-ilakrilamid;
(E)-3-furan-2-il-2-(4-metoksifenil)-N-(5-metiltiazol-2-il)akrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-nitrofenil)-3-tiofen-2-ilakrilamid;
(E)-N-(5-bromotiazol-2-il)-2-(4-nitrofenil)-3-tiofen-2-ilakrilamid;
(E)-2-(4-nitrofenil)-N-tiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-N-(5-bromotiazol-2-il)-2-(4-metansulfonilfenil)-3-tiofen-2-ilakrilamid;
(E)-2-(4-cijanofenil)-N-tiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-cijanofenil)-3-tiofen-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-cijanofenil)-3-fenilakrilamid;
2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-il-propionamid;
(E)-2-fenil-N-tiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-2-fenil-N-[1,3,4]tiadiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-N-(5-bromotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-metansulfonilfenil)-3-(tetrahidrotiopiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidrotiopiran-4-il)akrilamid;
(E)-N-(5-kloro-4-metiltiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidrotiopiran-4-il)akrilamid;
(E)-2-(4-metansulfinilfenil)-3-(tetrahidrotiopiran-E-il)-N tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfinilfenil)-3-(tetrahidrotiopiran-4-il)akrilamid;
N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-yI)propionamid;
2-(4-metoksimetilsulfanilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
3-(tetrahidropiran-4-il)-2-[4-(tetrahidropiran-4-ilsulfanil)fenil]-N-tiazol-2-ilpropionamid;
2-(3-metilsulfanilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
2-(4-metilsulfanil-3-nitrofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
(E)-2-(4-Nitrofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-nitrofenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-metilsulfanilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metilsulfanilfenil)-3-(tetrahidropiran-4-il)akrilamid;
2-(3-fluoro-4-metilsulfanilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-ciklopropansulfonilfenil)-N (5-formiltiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-ciklopropansulfinilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-ciklopropansulfinilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
2-(3-bromo-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-etansulfonilfenil)-N-(3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-etilsulfamoilfenil)-N-pyrimidin-4-il-3-(tetrahidropiran-4-il)propionamid;
2-(4-etilsulfamoilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid
(2R)-3-(tetrahidropiran-4-il)-2-(4-metansulfonilfenil)-N tiazol-2-ilpropionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N (5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
(2R)-N-(5-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N-[1,2,4]tiadiazol-5-ilpropionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-N-(5-fluoropiridin-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N (5-fluoropiridin-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N (3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-pirimidin-4-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-izoksazol-3-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-(1-metil-1H-pirazol-3-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-pirimidin-4-il-3-(tetrahidropiran-4-il)-propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-piridin-2-il-3-(tetrahidropiran-4-il)-propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-(1-metil-1H pirazol-3-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-(3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-(6-metoksipirimidin-4-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-2-(4-ciklopropansulfonilfenil)-N-(5-fluoropiridin-2-il)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-ciklopropansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)akrilamid;
2-(3-fluoro-4-metansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-N-(S-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-etansulfonilfenil)-N-pirimidin-4-il-3-(tetrahidropiran-4-il)akrilamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-(3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-pirimidin-4-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-izoksazol-3-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-(1-metil-1H-pirazol-3-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-pirimidin-4-il-3-(tetrahidropiran-4-il)-propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-piridin-2-il-3-(tetrahidropiran-4-il)-propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-(1-metil-1H pirazol-3-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-(3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-etilsulfamoilfenil)-N-(6-metoksipirimidin-4-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-2-(4-ciklopropansulfonilfenil)-N-(5-fluoropiridin-2-il)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-ciklopropansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)akrilamid;
2-(3-fluoro-4-metansulfonilfenil) N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-N-(S-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-etansulfonilfenil)-N-pirimidin-4-il-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-metansulfonilfenil)-3-(1-oksoheksahidro-1λ4-4-tiopiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-3-( l,1-dioksoheksahidro-1λ6-6-tiopiran-4-il)-2-(4-metansulfonilfenil)-N tiazol-2-ilakrilamid;
(E)-N (5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(1-oksoheksahidro-1λ4-4-tiopiran-4-il)akrilamid;
(E)-N-(S-klorotiazol-2-il)-3-(1,1-dioksoheksahidro-1λ4-6-tiopiran-4-il)-2-(4-metansulfonilfenil)akrilamid;
2-(3-fluoro-4-metansulfinilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(3-fluoro-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
N (5-bromotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
(E)-2-(4-hidroksifenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-2-(4-metansulfonilaminofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
3-(tetrahidropiran-4-il)-2-[4-(tetrahidropiran-4-ilmetilsulfanil)fenil]-N-tiazol-2-ilpropionamid;
2-[4-(piridin-3-ilsulfanil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
3-(tetrahidropiran-4-il)-2-[4-(tetrahidropiran-4-ilmetansulfonil)fenil]-N-tiazol-2-ilpropionamid;
2-(4-metoksimetansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(tetrahidropiran-4-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(piridin-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(3-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-ciklopropilmetansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(piridin-3-ilmetansulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(propan-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-etansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-cijanometansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-([1,2,4] oksadiazol-3-ilmetansulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-([1,3]dioksolan-2-ilmetansulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(propan-2-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(oksetane-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-((3S)-tetrahidrofuran-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-((3R)-tetrahidrofuran-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(2-oksopropan-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(piridin-2-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(piridin-2-sulfinil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(pirazin-2-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(pirazin-2-sulfinil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(pirimidin-5-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(3-amino-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(3-kloro-4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(morfolin-4-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-sulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-metilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-dimetilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(4-metilpiperazin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-{ 4-[(piridin-2-ilmetil)sulfamoil]fenil}-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-{4-[(piridin-3-ilmetil)sulfamoil]fenil}-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
3-(tetrahidropiran-4-il)-2- (4-[(tetrahidropiran-4-ilmetil)sulfamoil]fenil)-N-tiazol-2-ilpropionamid;
2- {4-[(tetrahidrofuran-2-ilmetil)sulfamoil]fenil}-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
3-(tetrahidropiran-4-il)-N-tiazol-2-il-2-[4-(tiomorfolin-4-sulfonil)fenil]propionamid;
2-[4-(azetidin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-([1,4]oksazepan-4-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-ciklopropilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(ciklopropilmetilsulfamoil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
3-(tetrahidropiran-4-il)-N-tiazol-2-il-2-{4-[(tiofen-2-ilmetil)sulfamoil]fenil}propionamid;
2-[4-((1S,4S)-2-oksa-5-azabiciklo [2.2.1 ]heptan-5-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(4-metil-[1,4]diazepan-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-((2R)-2-metoksimetilpirolidin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
3-(tetrahidropiran-4-il)-2-[4-(tetrahidropiran-4-ilsulfamoil)fenil]-N-tiazol-2-ilpropionarnide;
2-[4-(imidazol-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
N-(5-klorotiazol-2-il)-2-[4-(2-dimetilaminoetilsulfalnoil)fenil]-3-(tetrahidropiran-4-il)propionamid;
N-(5-klorotiazol-2-il)-2-[4-(3-hidroksiazetidin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)propionamid;
N-(5-klorotiazol-2-il)-2-[4-((3S)-3-hidroksipirolidin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)propionamid;
N-(5-klorotiazol-2-il)-2-[4-(4-metilpiperazin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)propionamid;
N-(5-klorotiazol-2-il)-2-[4-(piperazin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)propionamid;
N-(5-klorotiazol-2-il)-2-[4-(2-metilaminoetilsulfamoil)fenil]-3-(tetrahidropiran-4-il)propionamid;
2-[4-(2-aminoetilsulfamoil)fenil]-N-(5-klorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
N-etil-4-[2-(tetrahidropiran-4-il)-1-(tiazol-2-ilkarbamoil)etil]benzamid;
2-(3-kloro-4-metansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-metansulfonil-3-trifluorometilfenil)-N-(S-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid; i
2-(3,4-diklorofenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
ili njihove farmaceutski prihvatljive soli.
17. Spoj, naznačen time da je izabran između sljedećih:
(E)-2-(4-metansulfonilfenil)-N-tiazol-2-il-3-tiofen-2-ilakrilamid;
(E)-3-furan-2-il-2-(4-metansulfonilfenil)-N tiazol-2-ilakrilamid;
2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
2-(4-ciklopropansulfonilfenil)-N (5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-3-(tetrahidropiran-4-il)-N tiazol-2-il-2-(4-[1,2,4]triazol-1-ilfenil)akrilamid;
(E)-3-(tetrahidrotiopiran-4-il)-N-tiazol-2-il-2-(4-[1,2,4]triazol-1-ilfenil)akrilamid;
(E)-3-(tetrahidropiran-4-il)-N tiazol-2-il-2-(4-[1,2,3]triazol-1-ilfenil)akrilamid;
N-benzotiazol-2-il-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)propionamid;
2-(4-ciklopropansulfonilfenil)-N-(3-methil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
2-(4-ciklopropansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N-[1,2,4]tiadiazol-5-ilpropionamid;
(E)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-N-(5-kloro-4-metiltiazol-2-il)-2-(4-metansulfonilfenil)-3-tiofen-2-ilakrilamid;
(E)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-N-(5-bromotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-metansulfonilfenil)-3-(tetrahidrotiopiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidrotiopiran-4-il)akrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metansulfinilfenil)-3-(tetrahidrotiopiran-4-il)akrilamid;
2-(4-metoksimetilsulfanilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
(E)-2-(4-nitrofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-nitrofenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-metilsulfanilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-metilsulfanilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-N-(5-klorotiazol-2-il)-2-(4-ciclopropansulfinilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-ciklopropansulfinilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N-[1,2,4]tiadiazol-5-ilpropionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-(5-fluoropiridin-2-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
(2R)-2-(4-ciklopropansulfonilfenil)-N-(3-metil-[1,2,4]tiadiazol-5-il)-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-pirazin-2-iI-3-(tetrahidropiran-4-il)propionamid;
(2R)-2-(4-ciklobutansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
(E)-2-(4-ciklopropansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)akrilamid;
(E)-N-(5-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid;
(E)-2-(4-metansulfonilaminofenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilakrilamid;
2-[4-(piridin-3-ilsulfanil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-metoksimetansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(tetrahidropiran-4-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(piridin-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-ciklopropilmetansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-([1,2,4] oksadiazol-3-ihnethansulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-([1,3]dioksolan-2-ilmetansulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(oksetan-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
2-[4-((3S)-tetrahidrofuran-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-((3R)-tetrahidrofuran-3-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(2-oksopropan-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-metilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-dimetilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N tiazol-2-ilpropionamid;
2-[4-(4-metilpiperazin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-{4-[(piridin-2-ilmetil)sulfamoil]fenil}-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-{4-[(piridin-3-ilmetil)sulfamoil]fenil}-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(azetidin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-ciklopropilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(ciklopropilmetilsulfamoil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
3-(tetrahidropiran-4-il)-N tiazol-2-il-2-{4-[(tiofen-2-ilmetil)sulfamoil]fenil}propionamid;
2-[4-((1S,4S)-2-oksa-5-azabiciklo[2.2.1]heptan-5-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(4-metil-[1,4] diazepane-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
2-[4-(imidazol-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)-N-tiazol-2-ilpropionamid;
N-(5-klorotiazol-2-il)-2-[4-(2-dimetilaminoetilsulfamoil)fenil]-3-(tetrahidropiran-4-il)propionamid; i
N-(5-klorotiazol-2-il)-2-[4-(piperazin-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)propionamid;
ili njihove farmaceutski prihvatljive soli.
18. Spoj, naznačen time da je izabran između sljedećih:
(2R)-2-(4-ciklobutansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid; i
(2R)-2-(4-ciklobutansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid;
ili njihove farmaceutski prihvatljive soli.
19. Spoj, naznačen time da je (2R)-2-(4-ciklopropansulfonilfenil)-N-(5-fluorotiazol-2-il)-3-(tetrahidropiran-4-il)propionamid, ili njegova farmaceutski prihvatljiva sol.
20. Spoj, naznačen time da je (2R)-2-(4-ciklopropansulfonilfenil)-N-pirazin-2-il-3-(tetrahidropiran-4-il)propionamid, ili njegova farmaceutski prihvatljiva sol.
21. Spoj, naznačen time da je (E)-N-(5-fluorotiazol-2-il)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilamid, ili njegova farmaceutski prihvatljiva sol.
22. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da:
Q je 4-tetrahidropiranil;
T, zajedno s -N=C- na koji je vezan tvori 2-pirazinilni ili 2-tiazolilni prsten.
R1 i R2 su vodik;
R3 i R4 su, neovisno jedan o drugome, vodik ili fluor;
R5 je SO2R8;
R6 je vodik;
R8 je C3-5 cikloalkilna grupa, ili 4-6-člana heterociklička grupa, i, nadalje, kad iscrtkana linija zajedno s punom linijom tvori dvostruku vezu, R8 može biti C1-3 alkilna grupa.
R9 i R10 su neovisno C0-4 alkil, uz uvjet da R9 i R10 nisu oba vodik;
m je 0, a
iscrtkana linija, zajedno s punom linijom tvori eventualnu dvostruku vezu, a Δ upućuje da dvostruka veza ima (E)-konfiguraciju.
23. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da:
Q je 4-tetrahidropiranil;
T, zajedno s -N=C- na koji je vezan tvori 2-pirazinilni ili 2-tiazolilni prsten.
R1 i R2 su vodik;
R3 i R4 su, neovisno jedan o drugome, vodik ili fluor;
R5 je SO2R8;
R6 je vodik;
R8 je C3-4 cikloalkilna grupa, a kad iscrtkana linija zajedno s punom linijom tvori dvostruku vezu, R8 može biti C1-3 alkilna grupa.
m je 0, a
iscrtkana linija, zajedno s punom linijom tvori eventualnu dvostruku vezu, a Δ upućuje da dvostruka veza ima (E)-konfiguraciju.
24. Farmaceutski pripravak, naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 23, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač.
25. Postupak profilaktičkog ili terapijskog tretmana stanja u kojem je poželjna aktivacija GK, naznačen time da obuhvaća korak primjene učinkovite količine spoja prema bilo kojem od zahtjeva 1 do 23, ili njegove farmaceutski prihvatljive soli.
26. Postupak profilaktičkog ili terapijskog tretmana hiperglikemije ili dijabetesa, naznačen time da obuhvaća korak primjene učinkovite količine spoja prema bilo kojem od zahtjeva 1 do 23, ili njegove farmaceutski prihvatljive soli.
27. Postupak prema zahtjevu 26, naznačen time da se spoj prema bilo kojem od zahtjeva 1 do 23 primjenjuje u kobinaciji s jednim ili više antihiperglikemičnih ili antidijabetičkih sredstava.
28. Postupak prevencije dijabetesa u ljudi koji pokazuju predijabetičku hiperglikemiju ili smanjenu toleranciju na glukozu, naznačen time da obuhvaća korak primjene učinkovite profilaktičke količine spoja prema bilo kojem od zahtjeva 1 do 23, ili njegove farmaceutski prihvatljive soli.
29. Postupak pripreme spoja formule (Ia):
[image]
naznačen time da obuhvaća postupak kondenzacije spoja formule (IV):
[image]
sa spojem formule (V):
[image]
pri čemu su Q, T, R1 do R6, m i Δ kako je definirano u zahtjevu 1.
30. Postupak pripreme spoja formule (Ib):
[image]
naznačen time da obuhvaća korak kondenzacije spoja formule (VIII):
[image]
sa spojem formule (V):
[image]
pri čemu su Q, T, R1 do R6, m i Δ kako je definirano u zahtjevu 1.
31. Spoj formule (IV):
[image]
naznačen time da:
Q je 4-tetrahidropiranil;
R1 i R2 su vodik;
R5 je SO2R8 ili SO2NR9R10;
R6 je vodik;
R8 je C1-3 alkilna grupa, C3-5 cikloalkilna grupa ili 4-6-člana heterociklička grupa;
R9 i R10 su neovisno jedan o drugome C0-4 alkil, uz uvjet da R9 i R10 nisu oba vodik;
m je 0; a
Δ znači da dvostruka veza ima (E)-konfiguraciju.
32. Spoj formule (IV), naznačen time da je izabran između sljedećih:
(E)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)akrilna kiselina;
(E)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)akrilna kiselina;
(E)-2-(4-metansulfonilfenil)-3-(tetrahidropiran-4-il)akrilna kiselina;
(E)-2-(4-etansulfonilfenil)-3-(tetrahidropiran-4-il)akrilna kiselina; i
(E)-2-[4-(propan-1-sulfonil)fenil]-3-(tetrahidropiran-4-il)akrilna kiselina.
33. Spoj formule (VIII):
[image]
naznačen time da:
Q je 4-tetrahidropiranil;
R1 i R2 su vodik;
R5 je SO2R8 ili SO2NR9R10;
R6 je vodik;
R8 je C3-5 cikloalkilna grupa ili 4-6-člana heterociklička grupa;
R9 i R10 su neovisno jedan o drugome C0-4 alkil, uz uvjet da R9 i R10 nisu oba vodik; a
m je 0.
34. Spoj formule (VIII), naznačen time da je izabran između sljedećih:
2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)-propionska kiselina;
2-(4-metoksimetansulfanilfenil)-3-(tetrahidropiran-4-il)-propionska kiselina;
2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il)propionska kiselina;
2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il)propionska kiselina;
(2R)-2-(4-ciklopropansulfonilfenil)-3-(tetrahidropiran-4-il)propionska kiselina;
(2R)-2-(4-etilsulfamoilfenil)-3-(tetrahidropiran-4-il)propionska kiselina; i
(2R)-2-(4-ciklobutansulfonilfenil)-3-(tetrahidropiran-4-il)propionska kiselina.
35. Spoj, naznačen time da je 5-fluorotiazol-2-ilamin ili njegov amid ili kisela adicijska sol.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44668303P | 2003-02-11 | 2003-02-11 | |
US49443403P | 2003-08-11 | 2003-08-11 | |
US51280003P | 2003-10-20 | 2003-10-20 | |
PCT/US2004/003968 WO2004072031A2 (en) | 2003-02-11 | 2004-02-10 | Phenylacetamides and their use as glucokinase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20050687A2 true HRP20050687A2 (en) | 2006-02-28 |
Family
ID=32872762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20050687A HRP20050687A2 (en) | 2003-02-11 | 2005-08-01 | Tri(ciclo) substituted amide compounds |
Country Status (26)
Country | Link |
---|---|
US (2) | US7214681B2 (hr) |
EP (2) | EP2168962A3 (hr) |
JP (1) | JP4757188B2 (hr) |
KR (1) | KR101120916B1 (hr) |
AR (1) | AR043157A1 (hr) |
AT (1) | ATE391718T1 (hr) |
AU (1) | AU2004212500B2 (hr) |
BR (1) | BRPI0407139A (hr) |
CA (1) | CA2515670A1 (hr) |
CY (1) | CY1110254T1 (hr) |
DE (1) | DE602004012969T2 (hr) |
DK (1) | DK1594867T3 (hr) |
EA (1) | EA012700B1 (hr) |
ES (1) | ES2303628T3 (hr) |
HR (1) | HRP20050687A2 (hr) |
IL (1) | IL169954A (hr) |
MA (1) | MA27708A1 (hr) |
MX (1) | MXPA05008406A (hr) |
MY (1) | MY145590A (hr) |
NO (1) | NO20053742L (hr) |
NZ (1) | NZ541759A (hr) |
PL (1) | PL378117A1 (hr) |
PT (1) | PT1594867E (hr) |
SI (1) | SI1594867T1 (hr) |
TW (1) | TWI314553B (hr) |
WO (1) | WO2004072031A2 (hr) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
KR20050074959A (ko) * | 2002-10-03 | 2005-07-19 | 노파르티스 아게 | 제ii형 당뇨병 치료에 유용한 글루코키나아제 활성인자로서의 치환된 (티아졸-2-일)-아미드 또는 술폰아미드 |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
BRPI0509573A (pt) | 2004-04-02 | 2007-09-25 | Novartis Ag | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 |
US7781451B2 (en) * | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
EA012204B1 (ru) * | 2004-04-21 | 2009-08-28 | Прозидион Лимитед | Три(цикло)замещённые амидные соединения |
GB0418058D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
MX2007001650A (es) * | 2004-08-12 | 2007-07-13 | Prosidion Ltd | Fenilacetamidas substituidas y su uso como activadores de glucocinasa. |
US20100063081A1 (en) | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
NZ564743A (en) | 2005-07-11 | 2010-03-26 | Mitsubishi Tanabe Pharma Corp | An oxime derivative as a glucokinase activating agent and preparations thereof |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
CN101272784A (zh) | 2005-09-29 | 2008-09-24 | 塞诺菲-安万特股份有限公司 | 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途 |
GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
EP1948644A1 (en) * | 2005-11-03 | 2008-07-30 | Prosidion Limited | Tricyclo substituted amides |
JP2009514836A (ja) * | 2005-11-03 | 2009-04-09 | プロシディオン・リミテッド | トリシクロ置換型アミド |
US20080293741A1 (en) * | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
WO2007061923A2 (en) * | 2005-11-18 | 2007-05-31 | Takeda San Diego, Inc. | Glucokinase activators |
US8022222B2 (en) * | 2006-01-27 | 2011-09-20 | Array Biopharma, Inc. | Glucokinase activators |
US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
US7888504B2 (en) * | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
BRPI0715531A2 (pt) * | 2006-07-24 | 2014-06-24 | Hoffmann La Roche | Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
MX2009003850A (es) | 2006-10-09 | 2009-04-23 | Clariant Finance Bvi Ltd | Metodo para producir alcanol amidas de acido graso. |
DE102006047618B3 (de) | 2006-10-09 | 2007-11-15 | Clariant International Limited | Verfahren zur Herstellung von Bisbenzoxazolen |
DE102006047617B4 (de) * | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
DE102006047620B4 (de) | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung tertiärer Amide von Alkylphenylcarbonsäuren |
US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
EP2091947A2 (en) * | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
JP5207981B2 (ja) * | 2007-01-10 | 2013-06-12 | 田辺三菱製薬株式会社 | ヒドラゾン誘導体 |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP5248477B2 (ja) * | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PE20091313A1 (es) * | 2008-01-15 | 2009-09-03 | Lilly Co Eli | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina |
MX2010007853A (es) | 2008-01-18 | 2010-10-06 | Astellas Pharma Inc | Derivado de fenilacetamida. |
DE102008017216B4 (de) | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
SI2275414T1 (sl) | 2008-04-28 | 2015-10-30 | Kyorin Pharmaceutical Co., Ltd., | Ciklopentilakrilamidni derivat |
WO2009139438A1 (ja) * | 2008-05-15 | 2009-11-19 | 田辺三菱製薬株式会社 | 光学活性カルボン酸の製造方法 |
CL2009001203A1 (es) | 2008-05-16 | 2009-10-23 | Takeda San Diego Inc | Compuestos derivados de indazol y pirazol sustituidos; composicion farmaceutica de dichos compuestos; kit farmaceutico; y su uso como activadores de la glucoquinasa para tratar enfermedades metabolicas tales como hiperglicemia, diabetes, dislipidemias, obesidad, sindrome metabolico x y enfermedades cardiovasculares. |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UA104742C2 (uk) | 2008-12-19 | 2014-03-11 | Эли Лилли Энд Компани | Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази |
DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
US8765728B2 (en) | 2009-11-16 | 2014-07-01 | Mellitech | [1,5]-diazocin derivatives |
US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US8877794B2 (en) * | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
CA2819381A1 (en) | 2010-10-13 | 2012-04-19 | Takeda California, Inc. | Method of making azaindazole derivatives |
DE102010056564A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Limited | Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung |
DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112015005631A2 (pt) * | 2012-09-26 | 2017-07-04 | Kowa Co | composto, composição farmacêutica, agente de ativação de glucoquinase, agente hipoglicêmico, agente para prevenir e/ou tratar pelo menos uma doença, métodos para ativar glucoquinase, para diminuir o nível de glicose no sangue e para prevenir e/ou tratar pelo menos uma doença, e, uso de um composto |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US320050A (en) * | 1885-06-16 | Geoege t | ||
US219887A (en) * | 1879-09-23 | Improvement in wooden printing-types | ||
US4046768A (en) * | 1976-06-17 | 1977-09-06 | Velsicol Chemical Corporation | 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones |
ATE278680T1 (de) * | 1999-03-29 | 2004-10-15 | Hoffmann La Roche | Glukokinase aktivatoren |
US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
EE200200065A (et) * | 1999-08-12 | 2003-04-15 | Pharmacia Italia S.P.A. | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon |
US6353111B1 (en) * | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
ATE304011T1 (de) | 2000-05-03 | 2005-09-15 | Hoffmann La Roche | Hydantoin-enthaltende glucokinase aktivatoren |
JP3788935B2 (ja) | 2000-05-03 | 2006-06-21 | エフ.ホフマン−ラ ロシュ アーゲー | アルキニルフェニルヘテロ芳香族グルコキナーゼ活性化物質 |
DE60106599T2 (de) * | 2000-05-08 | 2006-02-09 | F. Hoffmann-La Roche Ag | Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren |
DK1283830T3 (da) * | 2000-05-08 | 2008-08-25 | Hoffmann La Roche | Para-amin-substituerede phenylamidglucokinase-aktivatorer |
US6489485B2 (en) * | 2000-05-08 | 2002-12-03 | Hoffmann-La Roche Inc. | Para-amine substituted phenylamide glucokinase activators |
ES2243547T3 (es) * | 2000-07-20 | 2005-12-01 | F. Hoffmann-La Roche Ag | Bencenacetamida sustituida para alfa-acilo y alfa heteroatomos como activador de glucokinasa. |
US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
US6433188B1 (en) * | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
AU2002221902B2 (en) * | 2000-12-06 | 2006-11-23 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
WO2003047626A1 (en) | 2001-12-03 | 2003-06-12 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
US6911545B2 (en) * | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
JP2005518391A (ja) | 2001-12-21 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | Gk活性化剤としてのアミド誘導体 |
EP1496052B1 (en) | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
PT1501815E (pt) | 2002-04-26 | 2007-01-31 | Hoffmann La Roche | Fenilacetamidas substituídas e a sua utilização como activadores de glicocinase |
US20070231874A1 (en) | 2002-05-16 | 2007-10-04 | Kenji Kamata | Crystal of glucokinase protein, and method for drug design using the crystal |
JP4881559B2 (ja) | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | 治療薬としてのアリールカルボニル誘導体 |
KR20050074959A (ko) | 2002-10-03 | 2005-07-19 | 노파르티스 아게 | 제ii형 당뇨병 치료에 유용한 글루코키나아제 활성인자로서의 치환된 (티아졸-2-일)-아미드 또는 술폰아미드 |
ATE506354T1 (de) * | 2003-01-06 | 2011-05-15 | Lilly Co Eli | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren |
-
2004
- 2004-02-03 PL PL378117A patent/PL378117A1/pl not_active Application Discontinuation
- 2004-02-10 DE DE602004012969T patent/DE602004012969T2/de not_active Expired - Lifetime
- 2004-02-10 AT AT04707845T patent/ATE391718T1/de active
- 2004-02-10 ES ES04707845T patent/ES2303628T3/es not_active Expired - Lifetime
- 2004-02-10 JP JP2006503482A patent/JP4757188B2/ja not_active Expired - Fee Related
- 2004-02-10 WO PCT/US2004/003968 patent/WO2004072031A2/en active Application Filing
- 2004-02-10 AU AU2004212500A patent/AU2004212500B2/en not_active Ceased
- 2004-02-10 US US10/776,584 patent/US7214681B2/en not_active Expired - Fee Related
- 2004-02-10 NZ NZ541759A patent/NZ541759A/en not_active IP Right Cessation
- 2004-02-10 BR BR0407139-5A patent/BRPI0407139A/pt not_active Application Discontinuation
- 2004-02-10 EA EA200501095A patent/EA012700B1/ru not_active IP Right Cessation
- 2004-02-10 EP EP08150303A patent/EP2168962A3/en not_active Withdrawn
- 2004-02-10 SI SI200430768T patent/SI1594867T1/sl unknown
- 2004-02-10 EP EP04707845A patent/EP1594867B1/en not_active Expired - Lifetime
- 2004-02-10 DK DK04707845T patent/DK1594867T3/da active
- 2004-02-10 PT PT04707845T patent/PT1594867E/pt unknown
- 2004-02-10 MX MXPA05008406A patent/MXPA05008406A/es active IP Right Grant
- 2004-02-10 KR KR1020057014855A patent/KR101120916B1/ko not_active IP Right Cessation
- 2004-02-10 CA CA002515670A patent/CA2515670A1/en not_active Abandoned
- 2004-02-11 MY MYPI20040408A patent/MY145590A/en unknown
- 2004-02-11 TW TW093103369A patent/TWI314553B/zh not_active IP Right Cessation
- 2004-02-11 AR ARP040100429A patent/AR043157A1/es not_active Application Discontinuation
-
2005
- 2005-07-28 IL IL169954A patent/IL169954A/en not_active IP Right Cessation
- 2005-08-01 HR HR20050687A patent/HRP20050687A2/hr not_active Application Discontinuation
- 2005-08-04 NO NO20053742A patent/NO20053742L/no not_active Application Discontinuation
- 2005-08-11 MA MA28433A patent/MA27708A1/fr unknown
-
2007
- 2007-04-16 US US11/735,685 patent/US7582632B2/en not_active Expired - Fee Related
-
2008
- 2008-06-03 CY CY20081100579T patent/CY1110254T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050687A2 (en) | Tri(ciclo) substituted amide compounds | |
JP2006517590A5 (hr) | ||
JP4621198B2 (ja) | トリ(シクロ)置換アミドグルコキナーゼ活性化化合物 | |
JP2007533722A (ja) | トリ(シクロ)置換アミド化合物 | |
KR100890695B1 (ko) | 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도 | |
JP3971189B2 (ja) | p−アミノ置換フェニルアミドグルコキナーゼ活性化物質 | |
AU2003232204B8 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
AU2003292229A1 (en) | 5-substituted-pyrazine or pyridine glucokinase activators | |
MXPA02010745A (es) | Activadores de glucocinasa heteroaromaticos de alquinil-fenilo. | |
US8580779B2 (en) | 1,2-bis-sulfonamide derivatives as chemokine receptor modulators | |
CN1809561B (zh) | 苯基乙酰胺及它们作为葡糖激酶调节剂的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
A1OB | Publication of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20110207 Year of fee payment: 8 |
|
OBST | Application withdrawn |